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Résumé 
Candida albicans est une levure pathogène qui, à l’état commensal, colonise les 
muqueuses de la cavité orale et du tractus gastro-intestinal. De nature opportuniste, C. 
albicans cause de nombreuses infections, allant des candidoses superficielles (muguet 
buccal, vulvo-vaginite) aux candidoses systémiques sévères. C. albicans a la capacité de se 
développer sous diverses morphologies, telles que les formes levures, pseudohyphes et 
hyphes. Des stimuli environnementaux mimant les conditions retrouvées chez l’hôte 
(température de 37°C, pH neutre, présence de sérum) induisent la transition levure-à-hyphe 
(i.e. morphogenèse ou filamentation). Cette transition morphologique contribue à la 
pathogénicité de C. albicans, du fait que des souches présentant un défaut de filamentation 
sont avirulentes. Non seulement la morphogenèse est un facteur de virulence, mais elle 
constituerait aussi une cible pour le développement d’antifongiques. En effet, il a déjà été 
démontré que l’inhibition de la transition levure-à-hyphe atténuait la virulence de C. 
albicans lors d’infections systémiques. Par ailleurs, des études ont démontré que de 
nombreuses molécules pouvaient moduler la morphogenèse. Parmi ces molécules, certains 
acides gras, dont l’acide linoléique conjugué (CLA), inhibent la formation d’hyphes. Ainsi, 
le CLA posséderait des propriétés thérapeutiques, du fait qu’il interfère avec un 
déterminant de pathogénicité de C. albicans. Par contre, avant d’évaluer son potentiel 
thérapeutique dans un contexte clinique, il est essentiel d’étudier son mode d’action.      
 
Ce projet vise à caractériser l’activité anti-filamentation des acides gras et du CLA 
et à déterminer le mécanisme par lequel ces molécules inhibent la morphogenèse chez C. 
albicans. Des analyses transcriptomiques globales ont été effectuées afin d’obtenir le profil 
transcriptionnel de la réponse de C. albicans au CLA. L’acide gras a entraîné une baisse 
des niveaux d’expression de gènes encodant des protéines hyphes-spécifiques et des 
régulateurs de morphogenèse, dont RAS1. Ce gène code pour la GTPase Ras1p, une 
protéine membranaire de signalisation qui joue un rôle important dans la transition levure-
à-hyphe. Des analyses de PCR quantitatif ont confirmé que le CLA inhibait l’induction de 
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RAS1. De plus, le CLA a non seulement causé une baisse des niveaux cellulaires de Ras1p, 
mais a aussi entraîné sa délocalisation de la membrane plasmique. En affectant les niveaux 
et la localisation cellulaire de Ras1p, le CLA nuit à l’activation de la voie de signalisation 
Ras1p-dépendante, inhibant ainsi la morphogenèse. Il est possible que le CLA altère la 
structure de la membrane plasmique et affecte indirectement la localisation membranaire de 
Ras1p. Ces travaux ont permis de mettre en évidence le mode d’action du CLA. Le 
potentiel thérapeutique du CLA pourrait maintenant être évalué dans un contexte 
d’infection, permettant ainsi de vérifier qu’une telle approche constitue véritablement une 
stratégie pour le traitement des candidoses. 
 
 
 
Mots clés: Candida albicans, morphogenèse, transition levure-à-hyphe, acides gras, acide 
conjugué linoléique, Ras1p, voie de signalisation 
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Summary 
The yeast Candida albicans is an inhabitant of the oral cavity, the gastrointestinal 
and genitourinary tracts of humans. Generally encountered as a commensal, it is also an 
opportunistic pathogen that causes a spectrum of infections, ranging from superficial 
mycoses (thrush, vulvovaginitis) to severe and life-threatening systemic infections. A 
striking feature of C. albicans is its ability to grow in different morphological forms, 
including budding yeasts, pseudohyphae, and hyphae. Environmental cues that mimic host 
conditions (elevated temperature, neutral or alkaline pH, and serum) induce the yeast-to-
hypha transition. Morphogenesis is considered to be an attribute of pathogenesis, as 
mutants locked as yeasts or filamentous forms are avirulent. Given that the yeast-to-hypha 
transition is a virulence factor, it may also constitute a target for the development of 
antifungal drugs. Indeed, evidence has shown that impairing morphogenesis is a means to 
treat systemic candidiasis. Concurrently, a number of molecules have been reported to 
modulate morphogenesis in C. albicans. For instance, several fatty acids, including 
conjugated linoleic acid (CLA), inhibited the yeast-to-hypha transition. By interfering with 
an important attribute of C. albicans pathogenesis, CLA may harbor antifungal properties. 
However, before assessing its therapeutic potential in a clinical context, it is mandatory to 
address CLA’s mode of action.  
 
The present study aims to further characterize the hypha-inhibiting properties of 
fatty acids and CLA and to elucidate the mechanism by which these molecules inhibit the 
yeast-to-hypha transition in C. albicans. Gene expression analyses were performed to gain 
insight into the transcriptional response of cells to CLA on a genome-wide scale and to 
probe the fatty acid’s mode of action. CLA downregulated the expression of hypha-specific 
genes and blocked the induction of genes encoding regulators of hyphal growth, including 
that of RAS1, which encodes the small GTPase Ras1p. A membrane-associated signaling 
protein, Ras1p plays a major role in morphogenesis. Quantitative PCR analyses showed 
that CLA prevented the increase in RAS1 mRNA levels which occurred at the onset of the 
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yeast-to-hypha transition. Unexpectedly, CLA reduced the steady-state levels of Ras1p. 
Additionally, CLA caused the delocalization of GFP-Ras1p from the plasma membrane. 
These findings indicate that CLA treatment results in suboptimal Ras1p cellular 
concentrations and localization, which impedes Ras1p signaling and inhibits the yeast-to-
hypha transition. CLA may indirectly affect Ras1p localization by altering the structure of 
the plasma membrane. These studies have provided the mechanism underlying CLA’s 
hypha-inhibiting properties and may serve as the rationale to examine CLA’s therapeutic 
potential in the context of a Candida infection. There is a general lack of clinical evidence 
demonstrating that impairing morphogenesis is a sound approach to treat candidiasis. To 
remedy this situation, the therapeutic potential of molecules that modulate morphogenesis, 
such as CLA, should be clinically assessed.  
 
 
 
Keywords: Candida albicans, yeast-to-hypha transition, morphogenesis, hyphal growth, 
fatty acids, conjugated linoleic acid, Ras1p signaling  
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Introduction 
The growing population of immunocompromised humans has allowed many fungi 
to become pathogens. The most common agents of fungal infections include Candida, 
Aspergillus, and Cryptococcus (Pappas, 2010). In the genus Candida, almost 200 species of 
ascomycetous, asexual yeasts are currently listed, yet only C. albicans, C. dubliniensis, C. 
glabrata, C. krusei, C. tropicalis, C. parapsilosis, and C. lusitaniae are encountered as 
opportunistic pathogens of humans (Odds et al., 2007). C. albicans is the most common 
cause of invasive fungal infections in hospital settings, in addition to being the causative 
agent of superficial mycoses such as oral thrush and vulvovaginitis (Horn et al., 2009; 
Miceli et al., 2011) (discussed in section 1.5).  
 
The first description of (oral) thrush, an infection of the mucous membranes of the 
mouth and throat, dates back to 400 B. C. and was made by Hippocrates who mistook the 
infection for oral ulcers (Adams, 1939). It was not until 1846 that thrush was shown to be 
caused by a contagion rather than by abnormalities of the host (Berg, 1846). Using a 
“scientific approach”, Berg reproduced thrush in healthy newborns by infecting them with 
material from aphthous lesions. While Berg’s experiments demonstrated that thrush was 
caused by an organism (i.e. a fungus), it was not identified correctly. Confusion regarding 
the true identity of the fungus was perpetuated until 1923, when Berkhout proposed that the 
organism causing thrush should bear the generic name Candida (Berkhout, 1923). In 1954, 
the nomen conservandum (C. albicans) was officially approved (Calderone, 2002). The 
name Candida is derived from the Latin phrase “toga candida” which was used to describe 
the special white robe worn by candidates for the Roman Senate; albicans means “to 
whiten”. The name “Candida albicans” may refer to the oral lesions of aphthae or thrush or 
to the characteristic white colonies produced by C. albicans on agar (Calderone, 2002).  
 
C. albicans is now ranked as the third or fourth most common agent of microbial 
septicemia in hospitals, having surpassed many bacterial infections in terms of incidence 
and morbidity (Almirante et al., 2005; Beck-Sague & Jarvis, 1993; Tortorano et al., 2004). 
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These severe, often lethal Candida infections are on the rise due to a growing population of 
hospitalized patients with underlying immune deficiencies stemming from treatment for 
cancer or immunosuppression following a transplantation (Enoch et al., 2006). Treatment 
of such infections is complicated by the limited arsenal of antifungal drugs, the severe side 
effects in patients, the development of antifungal drug resistance, and the emergence of 
species refractory to conventionally used agents (Sanglard & Odds, 2002). There is a need 
for new targets or new strategies in antifungal therapy (discussed in section 1.6).  
 
An Ascomycete, C. albicans belongs to the Saccharomycotina subphylum, to the 
Hemiascomycetes class, and to the Candida albicans clade (Figure 1.1) (Taylor, 2007). 
Baker’s yeast Saccharomyces cerevisiae also belongs to the Hemiascomycetes class, which 
makes it a close relative of C. albicans. Both yeasts diverged approximately 200 million to 
800 million years ago (Hedges, 2002). Yet, about two-thirds of the ~6,500 genes in the C. 
albicans genome have clear homologues in S. cerevisiae, allowing many gene functions to 
be inferred and key aspects of various processes in the pathogenic to be understood 
(discussed in 1.3). Additionally, both yeasts are similar in their cellular morphologies, their 
ability to metabolize fermentable carbon sources, and their capacity to reproduce asexually 
by budding. A parasexual cycle has been identified in C. albicans, but differs from the 
complete sexual cycle described for S. cerevisiae because the pathogenic yeast is diploid, 
does not exist naturally in a haploid form, and does not undergo meiosis (discussed in 
1.1.3).  
 
A striking feature that differentiates C. albicans from S. cerevisiae and other 
Candida species is its ability to grow in a variety of morphological forms, including as 
budding yeasts, as pseudohyphae, and as true hyphae (Sudbery et al., 2004) (discussed in 
section 1.1). The yeast-to-hypha transition, also known as morphogenesis or filamentation, 
is induced by a variety of environmental cues (discussed in section 1.2) which activate a 
complex network of signaling pathways composed of transducers, kinases, and 
transcription factors (Biswas et al., 2007; Brown et al., 2007; Ernst, 2000) (discussed in 
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section 1.3). These signaling pathways are involved in sensing and transmitting inducing 
signals and in regulating the regulatory and structural elements essential for hyphal growth. 
Interestingly, the same pathways regulate the expression of virulence factors of C. albicans 
such as cell surface adhesins, secreted aspartic proteases, lipases, and phospholipases 
(discussed in section 1.4). Because it contributes to the overall pathogenesis of C. albicans, 
morphogenesis also constitutes one of its virulence factors (see section 1.4.3).  
 
 
 
Figure 1. 1 Phylogenetic tree of fungi pathogenic to humans and animals. 
A maximum-likelihood phylogeny based on small-subunit rDNA sequences of diverse fungi. Taxa 
of commonly encountered pathogenic fungi were added to the phylogeny. Adapted from Taylor 
(2007).  
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It has been suggested that virulence factors of C. albicans may be potential targets 
for the development of new antifungal drugs (see section 1.6.2). One such virulence factor 
that could be targeted by antifungal agents is morphogenesis. Interestingly, many small 
molecules have been reported to modulate the yeast-to-hypha transition. For instance, fatty 
acids, including conjugated linoleic acid (CLA), inhibited hyphal growth in C. albicans 
(Clement et al., 2007). Thus, CLA and fatty acids may be candidates for the development 
of novel antifungal agents. However, understanding how fatty acids inhibit morphogenesis 
is a prerequisite before undertaking studies to assess their therapeutic potential. In the 
present study, CLA is used to probe the mechanism by which fatty acids inhibit hyphal 
growth in C. albicans.  
 
This thesis is divided into four major sections. In Chapter 1, morphogenesis in C. 
albicans is described in depth, in terms of the different morphological growth forms, 
inducing signals, and molecular events involved in the morphogenetic transition. The 
association between the yeast-to-hypha transition and virulence is described, demonstrating 
why morphogenesis may constitute a target for the development of antifungal drugs. In 
Chapter 2, findings pertaining to the hypha-inhibiting effects of CLA and to its mode of 
action are presented. These results were published in an article entitled “Conjugated 
linoleic acid inhibits hyphal growth in Candida albicans by modulating Ras1p cellular 
levels and downregulating TEC1 expression” in the scientific journal Eukaryotic Cell. In 
Chapter 3, a review on small molecules that modulate morphogenesis is presented. This 
minireview entitled “Modulation of morphogenesis in Candida albicans by various small 
molecules” was submitted to the scientific journal Eukaryotic Cell and is presently in 
revision. Finally, in Chapter 4, issues that are relevant to this work are discussed and 
perspectives are proposed.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Chapter 1. Literature review 
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In this chapter, the various aspects of morphogenesis, including cell morphologies, 
morphogenetic signals and signaling pathways, and downstream targets of these signaling 
pathways, are reviewed. The different types of Candida infections are described. 
Conventional antifungal drugs available to treat such infections as well as novel treatments 
are also discussed. Most of the notions constituting the backdrop of this study are provided 
in this chapter. 
 
1.1 Cell morphologies of C. albicans 
C. albicans was initially considered to be dimorphic, as it can grow in a budding 
yeast form or as branching, filamentous forms such as pseudohyphae and true hyphae. 
However, the pathogenic yeast also exists in a mating-competent opaque form (Bennett & 
Johnson, 2005; Slutsky et al., 1987) and can be induced to form thick-walled spherical cells 
known as chlamydospores (Staib & Morschhauser, 2007). The term pleiomorphic appears 
to be better suited to describe C. albicans, as it fully reflects the spectrum of its 
morphologies (Figure 1.2).  
 
1.1.1 Pseudohyphae and true hyphae 
 
Even though pseudohyphae superficially resemble hyphae, both morphological 
forms have different cell shapes. A feature that characterizes hyphal cells is the absence of 
constrictions at the mother-daughter junction or at subsequent septal junctions, which 
results in cells with parallel sides along their entire length (Figure 1.2C). In contrast, 
pseudohyphae have constrictions at the mother-daughter junction and between each 
individual cellular compartment (Sudbery et al., 2004) (Figure 1.2B). Sides of 
pseudohyphal cells are not parallel, resulting in compartments being wider in the middle 
than at the two ends (Merson-Davies & Odds, 1989). Additionally, hyphae are narrower 
than pseudohyphae, with a width of ~2 μm compared to ~2.8 μm-5 μm, respectively 
(Sevilla & Odds, 1986). 
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Figure 1. 2 Morphological forms of Candida albicans.  
Yeasts (A), pseudohyphae (B), and hyphae (C). Budding yeast cells are similar to diploid S. 
cerevisiae cells. Pseudohyphal cells have constrictions at the mother-daughter junction and at the 
positions of septa. Hyphae have parallel cell walls and no constrictions. (D) White-opaque 
phenotypic switching of the C. albicans WO-1 strain, grown on salt-dextrose at 23°C for three days. 
White (W) and opaque (O) colonies are seen. The cellular phenotype of white (E) and opaque cells 
(F). The white cell is round with a relatively smooth surface while the opaque cell is twice the size 
of the white cell and has unique wall pimples. (G) Chlamydospores are thick-walled spherical cells 
that are ~3 to 4 times larger than normal yeast cells. Adapted from Brown et al. (2007); Berman & 
Sudbery (2002); Staib & Morschhauser (2007). 
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C. albicans undergoes reversible morphological transitions between unicellular 
budding yeast cells and filamentous growth forms such as pseudohyphae and true hyphae. 
A variety of environmental conditions induce the switch from yeast growth to filamentous 
growth (Sudbery et al., 2004) (see section 1.2). Pseudohyphae develop into elongated buds 
that remain attached to the mother cells, resulting in filaments of elongated cells with 
constrictions at the septa. In contrast, true hyphae grow by continuous apical extension 
followed by septation. Although morphological and cell cycle studies suggest that 
pseudohyphal and hyphal growth forms represent distinct developmental stages (Berman & 
Sudbery, 2002; Sudbery et al., 2004), recent work has demonstrated that the pseudohyphal 
morphology is not an alternate fate, but rather a true intermediate state between the yeast 
and hyphal morphologies (Carlisle et al., 2009).  
 
Several aspects of the cell cycle of hyphae and pseudohyphae also differ (Figure 
1.3). In pseudohyphal cells, the daughter bud emerges from the mother cell at the start of 
the cell cycle. In hyphae, germ tube formation occurs before the start of the cell cycle, and 
is thus cell cycle-independent (Hazan et al., 2002). Polarized growth in yeast and 
pseudohyphal cells involves the polarisome, while apical extension of the germ tube is 
driven by the Spitzenkörper. Specific to hyphal cells, this membranous structure is usually 
found in strictly filamentous fungi and resembles the yeast polarisome (Whiteway & 
Bachewich, 2007). In pseudohyphal cells, the first septum is laid down at the mother-
daughter junction, whereas in hyphae, it is formed within the growing germ tube (Sudbery 
et al., 2004). The position of the septum affects the position of the first mitosis, which 
occurs at the mother-daughter junction in pseudohyphae, but entirely within the germ tube 
in hyphae. The absence of cytokinesis is common to both pseudohyphal and hyphal growth 
modes, which results in cells remaining attached. However, while hyphae appear as long, 
septated filaments, pseudohyphae have constrictions at the septa. 
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Figure 1. 3 Characteristic features of cell division for the yeast, pseudohyphal, and hyphal growth 
forms in C. albicans.  
In the yeast and pseudohyphal growth modes, a bud emerges from the mother cell, defining the 
position of the first septum. Changes in the pattern of actin polarization reflect a switch from 
polarized growth at the tip to isotropic growth throughout the growing bud. In pseudohyphal 
growth, daughter cells become increasingly elongated due to an extended period of polarized 
growth. Mitosis occurs across the plane of the septum at the mother-daughter junction. In yeast 
growth, cytokinesis yields two discrete cells while in pseudohyphal growth, cells remain attached, 
separated by constrictions. In hyphal development, a germ tubes emerges from the mother cell 
before the G1/S transition. The first septum is formed within the germ tube, where mitosis occurs. 
One nucleus migrates back into the mother cell, while the other moves further into the germ tube. 
Actin cortical patches continue to cluster at the growing tip, resulting in an elongated hypha. 
Hyphal cells remain attached, forming septated filaments. Adapted from Sudbery et al. (2004). 
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1.1.2 Biofilms 
C. albicans biofilms are defined as surface-associated microbial communities, 
encased within a matrix of extracellular polymers (Costerton et al., 1995). Although not a 
distinct C. albicans morphology per se, hyphae and pseudohyphae play a determinant role 
in biofilm development. C. albicans biofilms show a complex three-dimensional 
architecture and display extensive spatial heterogeneity, consisting of a dense network of 
yeasts, hyphae, and pseudohyphae encased within a matrix of exopolymeric material 
(Figure 1.4A). Biofilm formation occurs in three distinct stages: (i) attachment and 
colonization of yeast cells to a surface, (ii) germ tube formation and proliferation of yeast 
and filamentous cells, which allows the formation of a basal layer of anchoring cells, and 
(iii) growth of pseudohyphae and hyphae and secretion of a carbohydrate- and protein-rich 
extracellular matrix (Chandra et al., 2001; Douglas, 2003; Ramage et al., 2001) (Figure 
1.4B). While hyphal cells provide the scaffold to build the biofilm, they also express 
adhesin-encoding genes (discussed in section 1.4.1), which contribute to cell surface 
adherence properties required to maintain the structural integrity of the biofilm.  
 
C. albicans biofilms have important clinical consequences. They are involved in 
mucosal candidiasis (thrush, vulvovaginitis), form at the surface of implanted medical 
devices, such as prostheses, stents, shunts, implants, and various types of catheters, and can 
cause their failure (Kojic & Darouiche, 2004), have increased antifungal drug resistance, 
resist host immune defenses, and constitute a sustained reservoir of infecting cells (Lopez-
Ribot, 2005).  
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Figure 1. 4 Candida albicans biofilms. 
(A) Scanning electron microscopy (SEM) image of a mature (48 h) C. albicans biofilm, composed 
of yeast cells, pseudohyphae, and hyphae. Bar = 10 μm. Adapted from Ramage et al. (2005). (B) 
The SEM images show the stages of C. albicans biofilm formation, starting with the initial adhesion 
and attachment of C. albicans yeast cells to a surface, followed by the formation of germ tubes. 
Yeast and filamentous cells proliferate, forming a basal layer of anchoring cells. Further 
proliferation of microcolonies and filamentation contribute to biofilm development. As the biofilm 
matures, it becomes encased within a matrix of extracellular material. Adapted from Ramage et al. 
(2009).  
12 
 
 
1.1.3 Phenotypic switching 
A change in cellular morphology also occurs during colony switching, which is seen 
only in specific strains (Pomes et al., 1985; Slutsky et al., 1985). At low frequency, C. 
albicans strain 3153A can spontaneously and reversibly convert from smooth, white dome-
shaped colonies to variant colony shapes in which cells grow in yeast and filamentous 
forms (star, ring, irregular wrinkle, hat, stipple, and fuzzy) (Berman & Sudbery, 2002). In 
the C. albicans strain WO-1, the white-opaque switch involves the transition from white 
domed colonies containing white cells to opaque, flat colonies containing opaque cells 
(Figure 1.2D). White cells are round with a morphology resembling that of Baker’s yeast 
while opaque cells are oblong, twice the size of white cells, and have pimples on the 
surface of the cell wall (Anderson & Soll, 1987) (Figure 1.2E-F). White and opaque cells 
differ in virulence and in the capacity to colonize and infect different body locations. 
Indeed, white cells appear to be better suited for internal infections, while opaque cells 
thrive in skin infections (Kvaal et al., 1999). 
 
The white-opaque switch has garnered more attention since it was shown to be 
required for mating (Bennett & Johnson, 2005; Miller & Johnson, 2002). In C. albicans, 
there are two mating-type-like (MTL) loci, MTLa and MTLα, which reside on chromosome 
5 and include the MTL genes MTLa1, MTLα1, and MTLα2 (Hull & Johnson, 1999). For 
mating to occur, diploid cells have to undergo loss of heterozygosity at the MTL loci, 
resulting in a or α strains which express only MTLa or MTLα genes. Strains that are 
homozygous or hemizygous at the MTL have a tendency to undergo the white-opaque 
switch (Lan et al., 2002; Slutsky et al., 1987) (Figure 1.5A). Moreover, opaque cells mate 
more efficiently (Miller & Johnson, 2002). Diploid a and α opaque cells mate to create 
tetraploid a/a/α/α cells (Figure 1.5B). Although meiosis has not been observed in C. 
albicans, tetraploid cells undergo chromosome loss under certain laboratory conditions, 
thereby returning to the diploid state and completing a parasexual cycle (Bennett & 
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Johnson, 2003). By making the white-opaque switch a prerequisite for mating, C. albicans 
ensures that mating only occurs under specific conditions. 
 
Figure 1. 5 White-opaque switching in C. albicans.  
(A) A sectored colony on an agar plate, in which most of the cells are in the white phase, but 
containing a minority of cells in the opaque phase. SEM images show white cells, which are round, 
and opaque cells, which appear oblong, twice the size of white cells and have pimples on the 
surface of the cell wall. The transition from the white phase to the opaque phase is blocked by the 
a1 and α2 proteins, ensuring that a/α strains are not permissive for white-opaque switching. Only a 
or α strains can switch to the opaque phase, the state in which they are primed to mate. (B) Mating 
of opaque cells yields a mononuclear tetraploid a/a/α/α cell. Reduction in ploidy can be achieved by 
chromosome loss, thereby regenerating a- and α–mating competent progeny and completing a 
parasexual cycle. Meiosis has not been observed in C. albicans. Adapted from Bennett & Johnson 
(2005).  
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1.1.4 Chlamydospores 
Compared to other morphological growth forms, the chlamydospore growth mode 
remains elusive. Chlamydospores, thick-walled spherical cells that are ~3 to 4 times larger 
than normal yeast cells, appear to be a dormant growth form (Jansons & Nickerson, 1970) 
(Figure 1.2G). They have a high lipid and carbohydrate content, and are known to 
germinate under certain conditions (Fabry et al., 2003; Miller et al., 1974). Chlamydospore 
formation is induced at low temperature and in conditions of oxygen, light, and nutrient 
depletion (Staib & Morschhauser, 2007). Media consisting of rice or cornmeal agar 
supplemented with the detergent Tween 80 have been designed to induce chlamydospore 
production. This growth mode remains obscure as chlamydospores have rarely been 
observed during infection and do not appear to play a role in pathogenicity.  
 
 
1.2 Morphogenetic signals 
The yeast-to-hypha transition in C. albicans is triggered by a large number of 
different treatments which are presumed to reflect host conditions encountered by the 
pathogenic yeast in vivo (Odds, 1988a). Environmental cues that promote hyphal 
development are presented in Figure 1.6, and include a neutral or alkaline pH (6.5-8.0) and 
a growth temperature of 37°C (Buffo et al., 1984; Davis, 2003; Shapiro et al., 2009), 
nitrogen and/or carbon starvation (Csank et al., 1998), embedded growth and/or low 
oxygen concentration (Brown et al., 1999), and a wide range of chemicals (Odds, 1988a). 
The most commonly used chemicals that have morphogenetic potential are serum, amino 
acids (proline, methionine), the amino sugar N-acetylglucosamine, glucose, ammonium, 
and 5% CO2/bicarbonate (Biswas & Morschhauser, 2005; Ernst, 2000; Hudson et al., 2004; 
Klengel et al., 2005; Land et al., 1975b; Maidan et al., 2005b; Mattia et al., 1982; Miwa et 
al., 2004). Phosphate- or alkane-enriched media induce pseudohyphal growth (Hornby et 
al., 2004; Sorkhoh et al., 1990).  
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While serum remains the most potent inducer of hyphal growth, its chemical 
complexity has hampered the quest to identify its hypha-inducing factors. Initially, it was 
believed that serum induced hyphal growth by imposing nitrogen starvation, given that it is 
mainly composed of proteins that constitute an inaccessible source of nutrients until they 
are hydrolyzed (Brown & Gow, 1999). However, serum still stimulates hyphal growth 
when combined with a rich source of nutrients such as YPD, indicating that a factor other  
 
 
 
Figure 1. 6 Environmental cues promote hyphal development via specific signaling pathways in C. 
albicans.  
Hyphal growth is induced by neutral or alkaline pH, serum, glucose, N-acetylglucosamine 
(GlcNAc), amino acids, nitrogen and carbon starvation, low oxygen concentration, and embedding 
in a physical matrix. A high temperature (37°C) is a common requirement for all hypha-inducing 
conditions, except for embedded growth. Specific signaling pathways mediate the responses to 
these signals. There appears to be some functional overlap between some of these pathways. 
Adapted from Brown et al. (2007).  
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than nitrogen starvation is responsible for morphogenesis. Low molecular weight 
compounds (< 1 kDa) were suggested to be the active factors in serum, as a serum filtrate 
induced hyphal growth (Feng et al., 1999). Accordingly, Hudson et al. (2004) demonstrated 
that glucose was responsible for ~80% of the serum activity. However, given that hyphal 
growth is induced using 5-20% serum in media containing glucose at concentrations 10- to 
20-fold higher than those found in serum alone, it appears impossible that glucose is the 
only active agent in serum. Glucose does remain a morphogen, as low concentrations 
ranging between 0.01% and 0.3% were shown to stimulate hyphal development in liquid 
and solid media (Hudson et al., 2004; Maidan et al., 2005b). Recently, muramyl dipeptides 
have been identified as the hypha-inducing factors in serum (Wang & Xu, 2008; Xu et al., 
2008).  
 
Although a variety of environmental signals induce hyphal growth, neutral pH and a 
temperature of 37°C are the two factors that are common to most of the hypha-inducing 
regimes. A shift from acidic (pH 4.5) to alkaline (pH ≥ 6.5) conditions combined to an 
increase in temperature is known to promote hyphal growth (Buffo et al., 1984; Lee et al., 
1975). Additionally, a distinct pH signaling pathway is responsible for mediating the 
effects of alkaline pH (Davis, 2009) (see section 1.3.5). In contrast, although it was known 
that temperature played a pivotal role in triggering morphogenesis, the missing link 
between high temperature and the onset of hyphal induction was uncovered recently. High 
temperatures are required to compromise the function of the heat shock protein Hsp90p, a 
repressor of hyphal growth (Shapiro et al., 2009) (discussed in section 3.8). 
 
Different media are routinely used to induce hyphal growth in C. albicans. In these 
media, hypha-inducing cues are a combination of many individual factors, including a high 
temperature (37°C), a neutral pH, and a low cell density (OD600 < 0.1-0.5). Poor carbon 
sources (e.g. mannitol, N-acetylglucosamine) or low glucose concentrations (e.g. in tissue 
culture media) impose a state of carbon starvation, which promotes hyphal development 
(Brown et al., 2007). Moreover, hypha-inducing media contain a complex mixture of amino 
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acids, including proline and methionine, which have morphogenetic properties (Lee et al., 
1975; Maidan et al., 2005b; Odds, 1988a). Morphogenesis results from the synergistic 
effect of a variety of environmental cues (Brown et al., 2007; Ernst, 2000). 
 
 
1.3 Morphogenetic signaling pathways in C. albicans 
A complex network of signaling pathways regulate the yeast-to-hypha transition 
(Figure 1.8). The mitogen-activated protein (MAP) kinase, cAMP-protein kinase A (PKA), 
Czf1p, Cph2p-Tec1p, and Rim101p pathways stimulate hyphal growth, while the Tup1p 
signaling pathway represses the yeast-to-hypha transition. Although it was initially thought 
that each pathway made a somewhat independent contribution in regulating hyphal 
development, it is now clear that there is cross-talk between pathways. Most of the 
knowledge pertaining to morphogenetic signaling pathways in C. albicans has been gained 
by examining phenotypes of mutant strains lacking one (or more) specific gene(s). Thus, 
before describing the role of signaling pathways in morphogenesis, several aspects of C. 
albicans genetics are discussed.  
 
The study of the molecular mechanisms regulating the yeast-to-hypha transition in 
C. albicans has been hindered by genetic features of the pathogenic yeast, including its 
diploidy, its lack of an exploitable sexual cycle, its alternative codon usage, and the 
unavailability of good molecular tools and transformation protocols. One approach used to 
gain insight into biological aspects and gene functions is to analyze strains in which a 
specific gene is deleted or mutated. Given that C. albicans is an obligate diploid organism, 
a mutation has to become homozygous to observe a pronounced phenotype. In diploid 
organisms, homozygotes are generated by using genetic cross. However, although C. 
albicans carries a mating-type-like locus (Hull & Johnson, 1999) and can be engineered to 
mate (Magee & Magee, 2000; Miller & Johnson, 2002) (discussed in section 1.1.3), its 
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sexual cycle is not exploitable, rendering genetic cross superfluous. Moreover, molecular 
tools to sequentially disrupt both alleles of a gene in C. albicans were initially unavailable.  
 
For these reasons, C. albicans genes (involved in morphogenesis or in other 
biological processes) used to be identified/analyzed based on their ability to complement or 
suppress mutations in the corresponding S. cerevisiae genes (Liu et al., 1994) or to interfere 
with or constitutively activate the corresponding signaling pathways in S. cerevisiae 
(Whiteway et al., 1992). The sequencing and annotation of the C. albicans genome 
revolutionized research in C. albicans: gene functions could be inferred from those 
described for S. cerevisiae genes and functional analyses could be conducted using reverse 
genetics (Braun et al., 2005). However, comparative genome analyses showed that several 
C. albicans genes, such as those encoding lipases, proteases, and cell wall proteins, had no 
homologues in S. cerevisiae. In addition, functions of homologous genes had diverged. 
Moreover, it was becoming clear that while specific components of signaling pathways 
were conserved between both yeasts, molecular mechanisms and environmental cues had 
often diverged, perhaps due to the fact C. albicans had co-evolved with its human host 
(Biswas et al., 2007). 
 
Advances in gene disruption technology have enabled to carry out studies directly in 
the pathogenic yeast. The Ura blaster method, the first to be developed, relies on 
homologous recombination to replace the chromosomal copy of a target gene by the 
disruption cassette whose 5’ and 3’ ends are homologous to DNA sequences that flank the 
target gene (Fonzi & Irwin, 1993) (Figure 1.7A). Direct repeats of the hisG sequence from 
Salmonella thyphimurium flank the C. albicans URA3 gene, enabling intramolecular 
recombination events. The disruption cassette is transformed into a strain of C. albicans 
auxotrophic for uracil; Ura+ heterozygous disruption mutants, in which one allele of the 
target gene is replaced by the URA3 cassette, are selected on medium lacking uridine. The 
URA3 marker is “recycled” by passaging Ura+ transformants on medium containing 5-
fluoroorotic acid (5-FOA) (Alani et al., 1987; Boeke et al., 1984). 5-FOA selects for strains 
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that delete the URA3 gene via intramolecular recombination between the hisG flanks. The 
resulting Ura- heterozygous strain is transformed again using the URA3 cassette to disrupt 
the second allele of the target gene.  
 
Initially, the Ura blaster method was embraced by the C. albicans community. 
Many mutants were created in order to determine the role of genes in virulence. However, 
mutant strains displayed several problems. First, URA3 expression is subject to 
chromosomal positioning (Brand et al., 2004; Cheng et al., 2003b; Lay et al., 1998). 
Second, high URA3 expression levels are required for many processes, including 
morphogenesis, adhesion, and virulence (Brand et al., 2004; Cheng et al., 2003b; 
Sundstrom et al., 2002b). Thus, virulence defects may be linked either to the deletion of a 
target gene or to poor URA3 expression. Moreover, 5-FOA is a significant mutagen that can 
cause major chromosomal abnormalities (Wellington et al., 2006).  
 
To circumvent these problems, several solutions have been proposed, including 
reintegrating a copy of URA3 at a standard locus from which it is consistently expressed 
(Murad et al., 2000; Sundstrom et al., 2002b), using dominant selectable markers 
conferring resistance to mycophenolic acid (Staib et al., 1999; Wirsching et al., 2000) and 
nourseothricin (Reuss et al., 2004; Roemer et al., 2003; Shen et al., 2005), and using 
auxotrophic markers that do not affect virulence, such as HIS1, LEU2, and ARG4 (Noble & 
Johnson, 2005). New and improved gene disruption tools have also been made available 
and have been reviewed elsewhere (Noble & Johnson, 2005) (Figure 1.7B).  
 
Furthermore, regulatable promoters, including the glucose repressible PCK1 and 
MAL2 (Backen et al., 2000; Brown et al., 1996; Leuker et al., 1997), the 
methionine/cysteine-repressible MET3 promoter (Care et al., 1999), and the tetracycline-
repressible promoter system (Nakayama et al., 2000) have been developed to generate 
conditional null mutants and to conduct functional studies of essential genes. A collection 
of gene replacement and conditional expression (GRACE) C. albicans mutants has also 
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been generated, in which one allele of a target gene is replaced by the HIS3 auxotrophic 
marker while the other allele is placed under the control of the tetracycline-repressible 
promoter (Roemer et al., 2003).  
 
 
Figure 1. 7 Selected methods for gene disruption in C. albicans.  
(A) The Ura blaster method consists in transforming a gene disruption cassette into a strain of C. 
albicans auxotrophic for uracil (ura3/ura3). The cassette harbors the URA3 gene, flanked by direct 
repeats of the hisG sequence from Salmonella typhimurium and has 5’ and 3’ ends homologous to 
sequences flanking the target gene. Mutants in which one allele of the target gene is replaced by the 
URA3 cassette are selected on medium lacking uridine. Counterselection on 5-fluoroorotic acid (5-
FOA) identifies mutants that have lost the URA3 sequences through recombination between the 
hisG repeats. Transformation with the disruption cassette is repeated to disrupt the second copy of 
the target gene. (B) A linear gene disruption fragment with long regions of homology (300-500 bp) 
to sequences flanking the target gene is created using a fusion PCR technique. The first allele of a 
target gene is disrupted by transforming the first disruption fragment marked by the HIS1 gene from 
C. dubliniensis, and selecting on medium lacking histidine. The second copy of the target gene is 
disrupted by transforming the second disruption fragment, marked by the C. maltosa LEU2 gene, 
and selecting on medium lacking histidine and leucine.  
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A second issue that has hindered gene function analysis in C. albicans is that it 
displays a noncanonical codon usage: CTG is decoded as a serine instead of a leucine. 
Consequently, many heterologous markers such as Escherichia coli lacZ and jellyfish green 
fluorescent protein (GFP) cannot be functionally expressed in C. albicans unless they are 
modified (Berman & Sudbery, 2002). To overcome these impediments, a number of 
specialized reporter genes have been developed (reviewed in Berman & Sudbery [2002]). 
Convenient cassettes harboring these reporters have been generated, enabling gene 
expression to be monitored at the RNA or protein level and gene products to be localized in 
vivo (Gerami-Nejad et al., 2001; Gerami-Nejad et al., 2004; Gerami-Nejad et al., 2009). 
Thus, the development of molecular tools, combined to the availability of a sequenced 
genome and to improved transformation protocols, have made it fairly straightforward to 
conduct functional analyses of signaling genes in C. albicans.  
 
1.3.1 The mitogen-activated protein kinase signaling pathway 
The first morphogenetic signaling components to be identified in C. albicans were 
members of a MAP kinase pathway, analogous to the filamentous and invasive growth 
pathways in S. cerevisiae (Alonso-Monge et al., 2006; Gimeno et al., 1992; Palecek et al., 
2002). In C. albicans, the MAP kinase pathway is comprised of three kinases, including 
Cst20p, homologous to the PAK Ste20p (Csank et al., 1997; Ushinsky et al., 2002), Hst7p 
homologous to the MAP kinase kinase Ste7p (Leberer et al., 1996), and Cek1p, the 
Candida ERK-like kinase homologous to the MAP kinases Fus3p and Kss1p (Whiteway et 
al., 1992) (Figure 1.8). Although a homologue of the S. cerevisiae MAP kinase kinase 
kinase STE11 has been annotated (Braun et al., 2005), the C. albicans STE11 gene has not 
been functionally dissected (Brown et al., 2007). These kinases function by sequential 
phosphorylation, and ultimately activate the transcription factor Cph1p, a homologue of 
Ste12p which lies downstream of Cek1p (Liu et al., 1994). The tyrosine phosphatase 
Cpp1p is a negative regulator of the MAP kinase, as constitutive hyphal development of a 
cpp1/cpp1 mutant was inhibited by deleting CEK1 (Csank et al., 1997).  
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The MAP kinase signaling cascade plays a minor role in hyphal growth. Strains 
lacking CST20, HST7, CEK1, and CPH1 were unable to form hyphae on solid Spider 
medium, containing the poor carbon source mannitol and on SLAD nitrogen starvation 
medium, but filamented in liquid Spider, Lee, and serum media (Csank et al., 1998; Kohler 
& Fink, 1996; Leberer et al., 1996; Liu et al., 1994). Thus, the MAP kinase induces 
morphogenesis in response to nutrient limitation on solid media only, while other pathways 
promote hyphal development in response to other inducing factors.  
 
Activation of the MAP kinase pathway occurs through the GTPase module 
Cdc42p/Cdc24p (Bassilana et al., 2003) (Figure 1.8). Cdc42p, a Rho-type G protein 
(Bassilana et al., 2003; Hazan & Liu, 2002) and Cdc24p, its exchange factor, have critical 
roles in viability and in hyphal growth (Bassilana et al., 2003; Bassilana et al., 2005; 
Ushinsky et al., 2002; VandenBerg et al., 2004). In response to serum, CDC24 expression 
was transiently induced and Cdc24p was recruited to hyphal tips, where it maintained 
Cdc42p in its GTP-bound active state (Bassilana et al., 2005). Cdc42p was shown to bind 
with high affinity to a Cst20p motif in vitro and to Cla4p, another PAK kinase (Leberer et 
al., 1997; Su et al., 2005). Given that Ras1p regulates the MAP kinase pathway (Leberer et 
al., 2001), Bassilana et al. (2003) proposed that the Cdc42p/Cdc24p GTPase module 
formed a complex with Ras1p to activate Cst20p and the MAP kinase pathway. 
Additionally, in response to nitrogen, the transmembrane ammonium permease Mep2p was 
shown to be involved in activating the MAP kinase and cAMP-PKA pathways in a Ras1p-
dependent manner and in inducing hyphal growth (Biswas & Morschhauser, 2005). 
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Figure 1. 8 Regulation of morphogenesis in C. albicans by multiple signaling pathways.  
The MAP kinase, cAMP-PKA, and pH signaling pathways activate morphogenesis, while the yeast-
to-hypha transition is repressed by Tup1p, Nrg1p, and Rfg1p. A variety of environmental signals 
trigger simultaneously different signaling pathways, resulting in the activation of specific 
transcription factors (boxed) which induce or repress hyphal development. An important regulator 
of hyphal growth, the small GTPase Ras1p, functions upstream of the MAP kinase and the cAMP-
PKA signaling pathways, which operate through the transcription factors Cph1p and Efg1p, 
respectively. Efg1p appears to act as a hub, as it induces hyphal growth in response to different 
environmental cues, including serum, carbon starvation, CO2, and neutral pH. However, Efg1p is a 
repressor of filamentation in embedded conditions. Hyphal development is repressed by Tup1p, 
which functions by recruiting the DNA-binding proteins Nrg1p and Rfg1p. Adapted from Brown et 
al. (2007).  
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Recent data described the mucin-like protein Msb2p and the adaptor protein Sho1p, 
two plasma membrane proteins, as potential sensors of the MAP kinase pathway (Roman et 
al., 2009b). During resumption of growth, Cek1p phosphorylation depended on SHO1 
(Roman et al., 2005; Roman et al., 2009a). In addition, Msb2p and Sho1p played a role in 
hyphal and invasive growth and in the activation of Cek1p in response to cell wall stress 
(Roman et al., 2005; Roman et al., 2009b). In S. cerevisiae, Cdc42p was shown to interact 
with Msb2p (Cullen et al., 2004) and Ste20p (Cst20p homologue) (Peter et al., 1996), while 
in C. albicans, the interaction between Cdc42p and Cst20p was demonstrated (Su et al., 
2005). Based on these findings, Roman et al. (2009b) proposed that a putative 
Msb2p/Sho1p complex may interact with Cdc42p, promoting the recruitment of Cdc24p 
and the sequential phosphorylation of Cst20p and Cek1p. However, an interaction between 
Msb2p and Sho1p has yet to be demonstrated.  
 
The function of the MAP kinase pathway depends on the transcription factor Cph1p, 
the S. cerevisiae Ste12p homologue (Liu et al., 1994). Contrary to Ste12p, Cph1p does not 
regulate the expression of TEC1, a transcription factor involved in morphogenesis 
(discussed in section 1.3.4). CPH1 was required for the expression of several hypha-
specific genes, including ECE1, HWP1, HYR1, RBT1, SAPs5-6, and RBT4, but only in 
conditions in which hyphal growth depended on the MAP kinase pathway (Lane et al., 
2001a). It remains that a cph1/cph1 mutant strain filamented and expressed hypha-specific 
genes in most liquid hypha-inducing conditions, thereby questioning the presumed 
involvement of the MAP kinase pathway in morphogenesis (Braun & Johnson, 2000; 
Brown et al., 2007; Lane et al., 2001a). In fact, findings suggest that the MAP kinase 
pathway plays a clear role in mating, rather than in hyphal development (Bennett et al., 
2003; Chen et al., 2002; Magee et al., 2002; Sahni et al., 2010).  
 
Although the MAP kinase pathway plays a minor role in morphogenesis and hypha-
specific genes expression, it does contribute to a certain extent to C. albicans pathogenesis 
in vivo. Strains lacking CDC42, CDC24, CST20, CEK1, and CPP1 were attenuated in a 
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mouse model of systemic candidiasis (Bassilana et al., 2003; Csank et al., 1997; Csank et 
al., 1998; Leberer et al., 1996). Inactivation of CEK1 and CPP1 also attenuated virulence 
in the mammary glands of lactating mice, preventing tissue colonization (Guhad et al., 
1998a; Guhad et al., 1998b). However, deletion of CDC42, CDC24, and CEK1 impaired 
growth in vitro, which may account for reduced virulence of mutant strains in vivo. In 
contrast, hst7/hst7 and cph1/cph1 mutant strains retained their virulence in the mouse 
model of systemic candidiasis (Leberer et al., 1996; Lo et al., 1997). It remains that CPH1 
contributed to the residual virulence of an efg1/efg1 mutant, suggesting that the MAP 
kinase is involved in virulence in vivo (Lo et al., 1997). 
 
It is noteworthy to mention that like in S. cerevisiae, C. albicans has several other 
MAP kinase signaling pathways, including a cell integrity pathway, the protein kinase C 
(PKC) pathway and a stress-activated kinase pathway (i.e. the HOG pathway), which have 
been reviewed elsewhere (Alonso-Monge et al., 2006).  
 
1.3.2 The cAMP-PKA signaling pathway 
The cAMP-PKA signaling pathway plays an important role in filamentation in S. 
cerevisiae, in C. albicans, and in other fungi (Lengeler et al., 2000). In the pathogenic 
yeast, an increase in cAMP accompanies the yeast-to-hypha transition, thereby linking 
cAMP signaling to filamentation. Components of the cAMP signaling pathway include the 
G protein-coupled receptor Gpr1p, the Gα protein Gpa2p, the GTPase Ras1p, the adenylate 
cyclase Cyr1p, the cAMP-dependent PKA, and the transcriptional factor Efg1p (Figure 
1.8). 
 
cAMP signaling is regulated by Ras1p, Gpr1p-Gpa2p, and the transmembrane 
ammonium permease Mep2p. Each upstream regulator responds to a specific set of 
inducing factors and activates the cAMP signaling pathway. For instance, on solid media or 
in presence of the amino acid methionine, Gpr1p and Gpa2p were required for 
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morphogenesis. Moreover, filamentation defects of gpr1/gpr1 and gpa2/gpa2 strains were 
corrected by the addition of exogenous cAMP or by the overexpression of downstream 
components of the cAMP-PKA pathway, indicating Gpr1p and Gpa2p function upstream of 
cAMP signaling. However, both mutants were only mildly affected in liquid hypha-
inducing media, which suggests that Gpr1p and Gpa2p play minor roles in morphogenesis 
(Maidan et al., 2005a; Miwa et al., 2004; Sanchez-Martinez & Perez-Martin, 2002). 
Additionally, in nitrogen starvation conditions, Mep2p induced hyphal growth by activating 
cAMP signaling in a Ras1p-dependent manner, indicating that the transmembrane 
permease lies upstream of Ras1p (Biswas & Morschhauser, 2005).  
 
Ras1p belongs to the Ras superfamily of small guanosine triphosphatases (GTPases) 
(Wennerberg et al., 2005). Ras proteins regulate cell growth, proliferation, and 
differentiation (Hancock, 2003). In C. albicans, Ras1p is required for morphogenesis in 
most hypha-inducing conditions, suggesting it is a major regulator of the developmental 
process (Feng et al., 1999; Leberer et al., 2001; Zhu et al., 2009). Ras1p regulates 
morphogenesis by activating the cAMP-PKA and MAP kinase signaling pathways, given 
that the addition of exogenous cAMP or the overexpression of components of the MAP 
kinase cascade corrected the filamentation defect of a ras1/ras1 mutant (Leberer et al., 
2001).  
 
As a small GTPase, Ras1p exhibits high-affinity binding for GDP and GTP, and 
possesses low intrinsic GTP hydrolysis and GDP/GTP exchange activities. Ras1p is 
activated upon being loaded with GTP by its guanine nucleotide exchange factor (GEF) 
encoded in C. albicans by CSC25 (CDC25). The GTP-bound form of Ras1p possesses high 
affinity for effector targets, enabling their activation. The GTPase-activating protein (GAP) 
encoded by IRA2 accelerates Ras1p’s intrinsic GTPase activity, thus promoting the 
formation of the inactive GDP-bound form. The activation of Ras1p is essential for hyphal 
growth, as a cdc25/cdc25 mutant exhibited a filamentation defect (Shapiro et al., 2009; Uhl 
et al., 2003). In contrast, a strain deleted for IRA2 was hyperfilamentous (Shapiro et al., 
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2009). Likewise, a dominant-active Ras1p mutation (Ras1pG13V) promoted hyphal growth 
in noninducing conditions (Feng et al., 1999).  
 
Activation of the cAMP signaling pathway occurs upon the synthesis of cAMP, a 
secondary messenger, by adenylate cyclase. CYR1, which encodes the adenylate cyclase in 
C. albicans, contributes to hyphal growth in most solid and liquid hypha-inducing 
conditions, except in conditions of embedded growth (Cao et al., 2006; Rocha et al., 2001). 
The morphogenetic growth defect of the cyr1/cyr1 mutant was corrected by the addition of 
exogenous cAMP, indicating the importance of Cyr1p in activating cAMP signaling. 
Moreover, RAS1 overexpression did not restore filamentation to a cyr1/cyr1 mutant strain, 
which suggests that Ras1p lies upstream of Cyr1p (Rocha et al., 2001). Interestingly, 
activated Ras1p was shown to bind directly to the N-terminal Ras-association (RA) domain 
of Cyr1p and to promote cAMP synthesis (Fang & Wang, 2006).  
 
Cyr1p can also be activated directly by morphogenetic molecules, including CO2 
and the hypha-inducing factors of serum muramyl dipeptides. CO2/bicarbonate and 
muramyl dipeptides induced hyphal growth by stimulating directly the adenylate cyclase 
catalytic domain and by binding to the leucine-rich repeat domain of Cyr1p, respectively, 
resulting in cAMP synthesis (Klengel et al., 2005; Xu et al., 2008). These findings 
demonstrate that factors other than Ras1p contribute to the activation of Cyr1p upon hyphal 
development. Accordingly, transcript profiling of ras1/ras1 and cyr1/cyr1 mutants 
indicated that Cyr1p regulated a subset of genes independently of Ras1p (Harcus et al., 
2004). Thus, Cyr1p is activated by Ras1p, but also by serum components and CO2 (Klengel 
et al., 2005; Leberer et al., 2001; Rocha et al., 2001; Xu et al., 2008). In addition, it may 
also be activated by Gpr1p-Gpa2p (Maidan et al., 2005a) (Figure 1.8). 
 
cAMP signaling is positively regulated by the adenylate cyclase-associated protein 
encoded by SRV2. The high-affinity phosphodiesterase encoded by PDE2 hydrolyzes 
cAMP to AMP and downregulates cAMP signaling. SRV2 contributed to hyphal growth in 
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various solid and liquid inducing conditions and was required for cAMP synthesis (Bahn & 
Sundstrom, 2001; Bahn et al., 2007). In contrast, a pde2/pde2 mutant was constitutively 
filamentous, presumably due to increased intracellular cAMP levels (Bahn et al., 2003). 
Upon the yeast-to-hypha transition, the induction of PDE2 coincides with the gradual 
decline in cAMP levels (Jung & Stateva, 2003). Recently, Ras2p, an atypical Ras protein, 
was also shown to negatively regulate cAMP signaling (Zhu et al., 2009).  
 
Increasing cAMP levels activate the cAMP-dependent PKA. In C. albicans, PKA is 
constituted of a regulatory subunit and two catalytic subunits. BCY1 encodes the enzyme’s 
regulatory domain, while TPK1 (Bockmuhl et al., 2001) and TPK2 (Sonneborn et al., 2000) 
encode the catalytic subunits of PKA (Cassola et al., 2004; Staab et al., 2003). cAMP binds 
to PKA’s regulatory domain Bcy1p, causing a conformational change which results in the 
release and the activation of the catalytic subunits Tpk1p and Tpk2p. Thus, Bcy1p is a 
negative regulator of PKA, keeping it in an inactive state by inhibiting its 
phosphotransferase activity. Accordingly, overexpression of BCY1 blocked hyphal 
development in solid and liquid media, demonstrating that Bcy1p is a negative regulator of 
morphogenesis (Staab et al., 2003). In contrast, Tpk1p and Tpk2p are positive regulators of 
the yeast-to-hypha transition, albeit they function in different inducing conditions. For 
instance, while Tpk1p was required for hyphal growth on solid media only, Tpk2p was 
necessary for hyphal growth in liquid media and for invasive growth (Bockmuhl et al., 
2001; Sonneborn et al., 2000). Additionally, epistasis analysis placed both Tpk1p and 
Tpk2p downstream of Ras1p, but upstream of the transcription factor Efg1p (Bockmuhl et 
al., 2001).  
 
The cAMP signaling pathway mainly operates through the basic helix-loop-helix 
(bHLH) transcription factor Efg1p, a member of the APSES family of fungus-specific 
transcriptional regulators. Hyphal development induced by various signals such as serum, 
N-acetylglucosamine, proline, Spider medium, neutral pH, and CO2, depends on Efg1p (El 
Barkani et al., 2000; Lo et al., 1997; Stoldt et al., 1997). Thus, Efg1p appears to be a hub 
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that receives input from many environmental cues and signaling pathways (Figure 1.8). 
Additionally, Efg1p is also involved in chlamydospore formation and phenotypic switching 
(Sonneborn et al., 1999a; Sonneborn et al., 1999b; Srikantha et al., 2000), while it is a 
repressor of filamentation induced in microaerophilic or embedded conditions (Giusani et 
al., 2002) (see section 1.3.3). EFG1 overexpression corrected filamentation defects of 
tpk1/tpk1 and tpk2/tpk2 mutants, placing it downstream of PKA. Yet, this suppressive 
activity depended on a potential phosphorylation site for PKA (threonine 206) in Efg1p, 
suggesting that PKA may phosphorylate and activate Efg1p (Bockmuhl et al., 2001). So 
far, the phosphorylation of Efg1p by PKA has not been demonstrated.  
 
Efg1p regulates the expression of genes involved in hyphal growth, cell wall 
dynamics, virulence, and metabolism (Doedt et al., 2004; Lane et al., 2001a; Sohn et al., 
2003). Transcriptional profiling showed that Efg1p regulated the expression of over 200 
genes during the yeast-to-hypha transition. Interestingly, approximately 75% of those 
transcripts were repressed, suggesting Efg1p functions primarily as a transcriptional 
repressor. Efg1p was shown to bind directly to the promoters of several Efg1p-repressed 
genes and to its own promoter (Tebarth et al., 2003; Wang et al., 2009). Indeed, EFG1 is an 
autoregulated gene, as a decline in EFG1 transcript levels correlated with the binding of 
Efg1p to its own promoter (Stoldt et al., 1997; Tebarth et al., 2003). The Sin3p-Rpd3p-
containing histone deacetylase complex is involved in the negative autoregulation of EFG1 
(Tebarth et al., 2003).  
 
Additionally, Efg1p is also an activator of several hypha-specific genes, including 
ALS3, HWP1, and ECE1 (Braun & Johnson, 2000; Leng et al., 2001; Sharkey et al., 1999). 
The binding of Efg1p to the promoters of these genes was shown to be required for the 
recruitment of the Swi/Snf chromatin remodeling complex, enabling their transcriptional 
activation during hyphal growth (Lu et al., 2008). Transcriptional profiling also revealed 
that Efg1p regulated functions that were unrelated to hyphal development, including the 
expression of yeast cell wall genes and of metabolic genes (Doedt et al., 2004; Harcus et 
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al., 2004; Sohn et al., 2003). Like other APSES proteins, Efg1p functions as an inducer and 
a repressor of gene expression, whose activity is determined by interacting with auxiliary 
proteins. One of these proteins is Flo8p, a transcriptional activator required for hyphal 
growth induced in various conditions (Cao et al., 2006). Transcriptional profiling showed 
that Flo8p controlled a subset of hypha-specific, Efg1p-regulated genes. Moreover, Flo8p 
was shown to interact with Efg1p using a two-hybrid assay and by immunoprecipitation, 
suggesting that Flo8p functions with Efg1p to regulate morphogenesis (Cao et al., 2006) 
(Figure 1.8). 
 
The cAMP signaling pathway plays a significant role in virulence, as it controls the 
expression of many genes encoding virulence factors (Sundstrom et al., 2002a; Zhao et al., 
2004). Indeed, strains lacking components of the cAMP pathway, including Ras1p, Cyr1p, 
Srv2p, Pde2p, Efg1p, and Flo8p, were compromised in virulence in a mouse model of 
systemic candidiasis (Bahn & Sundstrom, 2001; Bahn et al., 2003; Cao et al., 2006; 
Leberer et al., 2001; Lo et al., 1997; Rocha et al., 2001). In addition, both tpk2/tpk2 and 
efg1/efg1 mutants were attenuated in virulence in a mouse model of oropharyngeal 
candidiasis (Park et al., 2005), while only the efg1/efg1 mutant was unable to cause 
lethality in an immunodeficient mouse model of oro-esophageal candidiasis (Westwater et 
al., 2007). These findings demonstrate the role of the cAMP pathway in pathogenesis. 
However, cAMP signaling is not involved in all types of Candida infections, as an 
efg1/efg1 mutant retained its virulence in an infection model that reflects hypha induction 
via physical contact (i.e. embedded growth) (Riggle et al., 1999).  
 
1.3.3 The Czf1p signaling pathway 
Filamentation in embedded conditions is induced in response to physical cues in the 
environment rather than to chemical cues such as pH, morphogens, or starvation (Brown et 
al., 1999). The transcription factors Czf1p, Efg1p, and Flo8p regulate filamentous growth 
in embedded conditions, as a czf1/czf1 mutant strain was compromised for filamentation 
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while efg1/efg1 and flo8/flo8 mutants were hyperfilamentous (Brown et al., 1999; Cao et 
al., 2006). Thus, filamentation in these conditions is positively and negatively regulated by 
Czf1p and the cAMP signaling pathway, respectively (Figure 1.8).  
 
Several lines of evidence indicate that a complex autoregulatory loop involving 
CZF1 and EFG1 regulates filamentation in embedded conditions, whereby Czf1p promotes 
filamentation by antagonizing Efg1p function (Giusani et al., 2002). First, Efg1p is a 
repressor of filamentation induced in embedded conditions (Giusani et al., 2002). In 
addition, Efg1p and Czf1p were shown to interact physically in the yeast two-hybrid 
system (Giusani et al., 2002). Efg1p was also shown to bind the CZF1 promoter and was 
required for its expression in embedded conditions, suggesting Efg1p is an activator of 
CZF1 (Vinces et al., 2006). Moreover, CZF1 is an autoregulated gene, as its 
overexpression downregulated its transcript levels (Vinces et al., 2006). The current model 
reflecting these findings  suggests that in embedded conditions, CZF1 expression is induced 
in an Efg1p-dependent manner (Vinces et al., 2006). Increased Czf1p levels antagonize 
Efg1p function, thereby relieving Efg1p-mediated repression of filamentation. Czf1p 
negatively regulates its own expression by binding to its promoter close to the Efg1p-
binding site, which blocks Efg1p-mediated activation of CZF1. A decline in Czf1p levels 
may enable Efg1p to regain activity. Cyclical modulations of Czf1p and Efg1p levels 
appear necessary for filamentation in embedded conditions (Vinces et al., 2006).  
 
1.3.4 The Cph2p-Tec1p signaling pathway 
An additional signaling pathway is defined by the transcription factors Cph2p and 
Tec1p (Figure 1.8). CPH2 encodes a Myc family bHLH transcription factor required for 
hyphal growth on solid Lee’s and serum-containing media and in liquid Lee’s medium 
(Lane et al., 2001b). The function of Cph2p in hyphal growth is mediated in part through 
Tec1p, as ectopic expression of TEC1 corrected the filamentation defect of a cph2/cph2 
mutant strain. Additionally, Cph2p was required for TEC1 expression in Lee’s medium, 
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and it was shown to bind to two sterol regulatory element-1-like sequences and to the E-
box motif in the TEC1 promoter, suggesting Cph2p is an activator of TEC1 (Lane et al., 
2001b). Epistasis analysis revealed that Cph2p functions independently of the MAP kinase 
and cAMP signaling pathways (Lane et al., 2001b). The upstream regulators of Cph2p have 
not been identified yet, but casein kinase II, PKC, and PKA may be involved in its 
activation via phosphorylation. Cph2p appears to play minor roles in virulence (Chamilos 
et al., 2009; Noble et al., 2010). 
 
Tec1p is a member of the TEA/ATTS family of transcription factors which 
recognize and bind to the consensus sequence 5’ CATTCY 3’ in target promoters via the 
TEA DNA-binding region. The S. cerevisiae Tec1p homologue functions with Ste12p to 
control filamentation and invasive growth of haploid and diploid strains, respectively 
(Madhani & Fink, 1997). In C. albicans, Tec1p is involved in hyphal growth, expression of 
hypha-specific genes, virulence, and biofilm formation (Homann et al., 2009; Nobile & 
Mitchell, 2005; Nobile et al., 2006a; Schweizer et al., 2000). A tec1/tec1 mutant strain was 
attenuated in several models of infection (Chamilos et al., 2009; Fuchs et al., 2010; 
Schweizer et al., 2000) and in a model of systemic infection, despite the fact the mutant 
strain filamented. These results suggest that Tec1p is involved in virulence-related activities 
other than hyphal growth.  
 
In response to hypha-inducing signals, TEC1 transcript and protein levels increased 
rapidly (Schweizer et al., 2000; Shareck et al., 2011) (Figure 4.12). TEC1 induction 
depended in part on Efg1p, while TEC1 overexpression partially restored filamentation to 
an efg1/efg1 mutant, indicating Tec1p functions in part downstream of Efg1p (Lane et al., 
2001a). Conversely, EFG1 overexpression did not correct the filamentation defect in a 
tec1/tec1 mutant strain and Tec1p did not regulate EFG1 transcription (Schweizer et al., 
2000). Furthermore, in response to serum, TEC1 was required for the induction of CDC24, 
which suggests there may be a positive feedback loop between Tec1p and the Cdc24p-
Cdc42p branch of the MAP kinase pathway (Bassilana et al., 2005).  
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TEC1 was required for the expression of BCR1, which encodes a C2H2 zinc finger 
protein required for biofilm formation and for the expression of hypha-specific adhesins 
such as HYR1, HWP1, RBT5, ALS3, and ALS1 (Nobile & Mitchell, 2005; Nobile et al., 
2006a). Thus, Bcr1p functions downstream of Tec1p (Figure 1.8). Interestingly, BCR1 was 
not required for hyphal growth, and although it promoted biofilm formation in vivo, it was 
not required for virulence in two models of infection (Chamilos et al., 2009; Nobile et al., 
2006a). 
 
1.3.5 The Rim101p pH signaling pathway 
A pH-responsive pathway enables the pathogenic yeast to sense, respond, and adapt 
to external pH. The Rim101p signaling pathway, studied extensively in other fungi, 
including A. nidulans and S. cerevisiae, has been reviewed elsewhere (Davis, 2003; Davis, 
2009; Penalva et al., 2008). In C. albicans, the Rim101p signaling pathway not only 
controls pH-regulated gene expression, but also pH-induced morphogenesis, whereby 
acidic and alkaline conditions favor yeast growth and hyphal growth, respectively (Davis, 
2003). Components of the pathway include the Rim101p transcription factor, Rim21p, 
Dfg16p, Rim20p, Rim13p, and Rim8p (Davis, 2003) (Figure 1.9). Deletion of RIM101 or 
of any gene required for the activation of Rim101p inhibited pH-dependent gene expression 
and hyphal growth induced at alkaline pH (Davis et al., 2000b; Li et al., 2004).  
 
The current model for the Rim101p signaling pathway suggests that environmental 
pH is sensed by the plasma membrane receptor proteins Dfg16p and Rim21p (Barwell et 
al., 2005; Calcagno-Pizarelli et al., 2007). At neutral-alkaline pH, these sensor proteins are 
stimulated, thereby triggering the ubiquitination of the arrestin-like protein Rim8p and 
promoting endocytosis (Herranz et al., 2005). The endosomal-sorting complex required for 
trafficking (ESCRT) protein module is recruited (Xu et al., 2004). Rim13p and Rim20p are 
also recruited and brought in proximity of the inactive full-length transcription factor 
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Rim101p (Boysen & Mitchell, 2006; Li et al., 2004). The calpain-like protease Rim13p 
cleaves the inhibitory C-terminal domain of Rim101p, while Rim20p is thought to interact 
with Rim101p, acting as a scaffold to facilitate the proteolytic cleavage (Kullas et al., 
2004). Once activated, Rim101p translocates into the nucleus, where it regulates pH-
dependent genes (Li et al., 2004).  
 
Transcriptional profiling revealed that Rim101p regulates the expression of genes 
involved in hyphal development, cell wall structure, virulence, and iron acquisition (Bensen 
et al., 2004; Nobile et al., 2008; Thewes et al., 2007). However, expression of the hypha-
specific gene HWP1 was not abolished in a rim8/rim8 mutant. This is due to the Rim101p 
pathway signaling through Efg1p (El Barkani et al., 2000) (Figure 1.8). As for pH-
dependent genes, Rim101p functions as an activator of alkaline-induced genes and a 
repressor of alkaline-repressed genes (i.e. PHR2) by binding directly to respective 
promoters (Baek et al., 2006; Ramon & Fonzi, 2003). Moreover, Rim101p binds its own 
promoter which contains multiple Rim101p consensus sequences (Ramon et al., 1999).  
 
The Rim101p signaling pathway is required for C. albicans pathogenesis. Strains 
deleted for RIM101 and RIM8 were attenuated in virulence in a model of systemic 
candidiasis (Davis et al., 2000a). In addition, RIM101 and RIM13 were required for 
virulence in models of oropharyngeal candidiasis and keratomycosis, respectively (Mitchell 
et al., 2007; Nobile et al., 2008). 
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Figure 1. 9 The Rim101p pH signaling pathway in C. albicans.  
In neutral-alkaline environments, sensors Rim20p and Dfg16p are stimulated, leading to the 
ubiquitination of Rim8p. The endosomal-sorting complex required for trafficking (ESCRT) protein 
module is recruited as well as Rim20p and Rim13p. The calpain-like protease Rim13p cleaves off 
the inhibitory C-terminal region of Rim101p, thereby activating Rim101p. Processed Rim101p 
activates alkaline-induced genes and represses acid-induced genes. Rim101p operates via Efg1p to 
promote hyphal development in response to alkaline pH. Adapted from Davis (2009). 
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1.3.6 The Tup1p signaling pathway 
In the absence of morphogenetic signals, the yeast-to-hypha transition is repressed 
by the Tup1p signaling pathway (Figure 1.8). Tup1p is a repressor of filamentous growth 
and of hypha-specific gene expression, as its deletion resulted in constitutively filamentous 
cells in which several hypha-specific genes were derepressed (Braun & Johnson, 1997; 
Braun et al., 2000; Sharkey et al., 1999). In S. cerevisiae, Tup1p represses the transcription 
of various genes by forming a repressor complex with the corepressor Ssn6p (Smith & 
Johnson, 2000). This complex is recruited to the promoters of target genes by sequence-
specific DNA-binding proteins. In C. albicans, the N-terminal domain of Tup1p enables 
interactions with the corepressor Ssn6p while the seven C-terminal conserved WD40 
repeats promote interactions with DNA-binding proteins.  
 
In C. albicans, Nrg1p and Rfg1p are two DNA-binding proteins which function 
with Tup1p to negatively regulate hyphal growth and hyphal gene expression (Braun & 
Johnson, 1997; Braun et al., 2001; Kadosh & Johnson, 2001; Khalaf & Zitomer, 2001; 
Murad et al., 2001a; Murad et al., 2001b). In a nrg1/nrg1 mutant, pseudohyphal growth 
and hyphal gene expression were derepressed (Braun et al., 2001; Garcia-Sanchez et al., 
2005; Kadosh & Johnson, 2005; Murad et al., 2001a; Murad et al., 2001b). Similarly, 
several hyphal genes were derepressed in a rfg1/rfg1 mutant, but the hyperfilamentous 
phenotype was not as dramatic as that seen in a nrg1/nrg1 mutant (Kadosh & Johnson, 
2001; Khalaf & Zitomer, 2001).  
 
NRG1 encodes a sequence-specific DNA-binding protein of the zinc finger family. 
It recognizes and binds to the Nrg1p response element (NRE) (A/C)(A/C/G)C3T in target 
promoters (Murad et al., 2001b). Rfg1p, a high mobility group protein, is a homologue of 
the S. cerevisiae hypoxic regulator Rox1p (Kadosh & Johnson, 2001; Khalaf & Zitomer, 
2001). In S. cerevisiae, the relief of Tup1p repression is achieved by inactivating or 
removing DNA-binding proteins (Smith & Johnson, 2000). In C. albicans, Tup1p 
repression is relieved by downregulating NRG1 transcript levels at the onset of the yeast-to-
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hypha transition, which enables hyphal development and expression of hypha-specific 
genes (Banerjee et al., 2008; Braun et al., 2001). Recent findings also showed that Nrg1p 
activity was regulated at the posttranslational level (Brown et al., 2007). It is not clear how 
Rfg1p is modulated, although there is evidence it may also be regulated at the 
posttranslational level (Kadosh & Johnson, 2001). 
 
Findings by Kadosh & Johnson (2005) revealed that the relief of Tup1p-mediated 
repression played a key role in the onset of the hyphal growth program. In addition, while 
Nrg1p and Rfg1p were shown to function mostly through Tup1p, Tup1p regulated several 
genes independently of both DNA-binding proteins (Kadosh & Johnson, 2005). Moreover, 
Ssn6p was not required for the repression of most Tup1p- and Nrg1p-regulated genes 
(Garcia-Sanchez et al., 2005). Although this does not exclude the possibility that Ssn6p is 
present in Tup1p-containing repression complexes, Tup1p repression appears to be 
mediated mainly by Nrg1p and, to a lesser extent, by Rfg1p (Brown et al., 2007).  
 
Tup1, Nrg1p, and Rfg1p were required for virulence in a mouse model of systemic 
candidiasis (Braun et al., 2000; Braun & Johnson, 2000; Kadosh & Johnson, 2001; Kadosh 
& Johnson, 2005; Murad et al., 2001b). Such results appear incongruous, given that hypha-
specific genes, many of which encoded virulence factors, were derepressed in strains 
deleted for each of these repressors. Two reasons may account for these findings. First, 
compared to parental strains, all three mutant strains had slower growth rates in vitro, 
which may have affected their growth rates in vivo (Kadosh & Johnson, 2001; Murad et al., 
2001a). Second, constitutively filamentous cells may not be disseminated efficiently in 
systemic models of infection when cells are inoculated directly into the bloodstream (Gow 
et al., 2002). Indeed, aberrant trafficking accounted for the apparent attenuation in 
virulence of a nrg1/nrg1 mutant in a model of systemic candidiasis (Nobile et al., 2008). 
Moreover, a nrg1/nrg1 mutant exhibited normal virulence in a model of oropharyngeal 
candidiasis, in which cells are applied directly to the oral mucosa (Nobile et al., 2008). In 
addition, the depletion of NRG1 correlated with heightened virulence, while its 
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overexpression attenuated virulence in a model of systemic candidiasis (Saville et al., 2003; 
Saville et al., 2006). Thus, these findings question the attenuation in virulence of strains 
lacking TUP1, NRG1, and RFG1. 
 
1.3.7 The transcription factor Ume6p 
In C. albicans, UME6 encodes a zinc finger DNA-binding protein involved in 
morphogenesis. UME6 was not required for germ tube formation, but it was essential for 
hyphal extension under a variety of hypha-inducing conditions (Banerjee et al., 2008; 
Zeidler et al., 2009). UME6 expression was induced in a Ras1p-, Cph1p-, Efg1p-, Flo8p- 
and Tec1p-dependent manner, suggesting that it is a downstream target of these 
morphogenesis regulators (Zeidler et al., 2009). Accordingly, ectopic overexpression of 
UME6 rescued the filamentation defect of ras1/ras1 and cph1/cph1 efg1/efg1 mutant 
strains, placing it downstream of the MAP kinase and cAMP-PKA signaling pathways 
(Figure 1.8). Conversely, UME6 was derepressed in strains lacking TUP1, NRG1, and 
RFG1, indicating the transcription factor is also a target of the Tup1p signaling pathway 
(Banerjee et al., 2008; Kadosh & Johnson, 2005; Zeidler et al., 2009). UME6 was required 
for the expression of hypha-specific genes, including HWP1, ECE1, RBT1, RBT4, HYR1, 
PHR1, and HGC1 (Banerjee et al., 2008; Carlisle et al., 2009; Zeidler et al., 2009) and 
played a role in virulence in a mouse model of systemic candidiasis (Banerjee et al., 2008; 
Carlisle et al., 2009; Zeidler et al., 2009).  
 
The role of UME6 in filamentation has further been described. The transcriptional 
regulator was shown to control the level and duration of the hypha-specific G1 cyclin 
HGC1, the only hypha-specific gene required for hyphal growth (Carlisle & Kadosh, 2010; 
Zheng & Wang, 2004) (see section 1.4.3). In response to hypha-inducing signals, UME6 is 
induced as a result of the activation of the cAMP signaling cascade and the relief of 
transcriptional repression exerted by Tup1p-Nrg1p. Once induced, Ume6p is involved in 
regulating HGC1 expression, either by binding directly to the HGC1 promoter and 
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directing its transcription or by stabilizing the HGC1 transcript (Carlisle & Kadosh, 2010). 
In addition, Ume6p cellular levels were shown to determine morphology in C. albicans, 
whereby high UME6 expression levels drove hyphal growth, while moderate levels yielded 
pseudohyphal cells. These findings demonstrate that the pseudohyphal morphology is an 
intermediate morphological state between yeast and hyphal morphologies (Carlisle et al., 
2009) (see section 1.1.1).  
 
 
1.4 Downstream targets of morphogenetic signaling pathways 
A virulence factor is defined as “an attribute whose absence in the fungus eliminates 
or reduces (…) damage in a defined host system in vivo” (Odds et al., 2007). In C. 
albicans, virulence factors vary according to the type, site and stage of infection, and the 
nature of the host response. They include factors that promote adhesion to host cells or to 
host cell proteins and that degrade and destroy host tissue barriers, thereby enabling 
invasion. Morphogenesis also contributes to overall virulence. Indeed, C. albicans has 
devised a strategy to co-regulate the yeast-to-hypha transition with the expression of many 
of its virulence factors (Kumamoto & Vinces, 2005). By coordinating hyphal development 
and the production of virulence factors, C. albicans maximizes its pathogenic properties 
and activities, thereby ensuring its success as a pathogen. 
 
It is noteworthy to mention another virulence attribute of C. albicans, namely its 
ability to adapt metabolically, to survive and to thrive in a multitude of different niches 
(Kumamoto, 2008). For instance, upon phagocytosis by neutrophils or macrophages, C. 
albicans switches from a fermentative to an oxidative metabolism (Fradin et al., 2007; 
Lorenz et al., 2004). Likewise, phenotypic swiching enables cells to survive in harsh 
environments and evade the innate immune system. Stress response is another means by 
which C. albicans counteracts host immunological defenses. For the purpose of this review, 
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only hypha-specific virulence factors are discussed, as these factors are downstream targets 
of morphogenetic signaling pathways (discussed in section 1.3).  
 
The yeast-to-hypha transition also coincides with a change in cell polarity, cell 
cycle, and cell wall biosynthesis. The machinery that orchestrates these changes is 
controlled by a set of cyclin-dependent kinases (CDKs) which operate by associating with 
various cyclins, including the hypha-specific G1 cyclin Hgc1p (Whiteway & Oberholzer, 
2004; Zheng & Wang, 2004; Zheng et al., 2007). Because they are downstream outputs of 
morphogenetic pathways, Hgc1p and the CDK Cdc28p are discussed and their roles in 
morphogenesis are briefly reviewed.  
 
1.4.1 Virulence factors 
1.4.1.1 Adhesins 
Adhesins are molecules that promote the adherence of C. albicans cells to host cells 
or host-cell ligands (Calderone & Fonzi, 2001; Sundstrom, 1999). The most notable 
adhesins in C. albicans are encoded by HWP1 and genes of the ALS family. In addition, 
RBT1 encodes a GPI-anchored cell wall protein similar to Hwp1p. HWP1, RBT1, ALS1, 
and ALS3 are expressed exclusively upon the yeast-to-hypha transition (Bastidas et al., 
2009; Hoyer et al., 1998; Staab et al., 1996). While ALS1, ALS3, and HWP1 are 
downstream effectors of transcription factors Efg1p, Bcr1p, and Tec1p (Argimon et al., 
2007; Nobile & Mitchell, 2005; Schweizer et al., 2000), RBT1 is positively regulated by 
Efg1p and Rim101p (Bensen et al., 2004; Sohn et al., 2003). Repressors Tup1p, Nrg1p, and 
Rfg1p are also involved in regulating expression of these adhesins (Braun et al., 2001; 
Garcia-Sanchez et al., 2005; Kadosh & Johnson, 2001; Kadosh & Johnson, 2005; Murad et 
al., 2001a; Murad et al., 2001b).  
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HWP1 encodes a hypha-specific cell wall mannoprotein whose N-terminal domain 
resembles mammalian transglutaminase substrates and is surface-exposed while its C-
terminal domain is cross-linked to the cell wall (Staab et al., 1996). A hwp1/hwp1 mutant 
strain was less adhesive to oral epithelial cells and was attenuated in virulence in models of 
oropharyngeal and systemic infections, indicatig that HWP1 plays a role in adherence to 
host cells and in virulence (Staab et al., 1999; Sundstrom et al., 2002b). By mimicking host 
cell proteins, Hwp1p enables C. albicans cells to be cross-linked to host oral epithelial cells 
(Staab et al., 1999). HWP1 is also involved in cell-cell interactions that are essential for 
biofim formation (Nobile et al., 2006a; Nobile et al., 2006b). HWP1 is expressed in vivo, 
as its transcripts were detected in C. albicans clinical samples originating from oral and 
vaginal infections (Cheng et al., 2003a; Naglik et al., 2006). As for RBT1, it was shown to 
be required for virulence in two models of infection (Braun et al., 2000).  
 
The ALS (agglutinin-like sequence) gene family encodes eight cell-surface GPI-
anchored proteins required for adherence of C. albicans cells to host tissues. The gene 
product of ALS1 mediates adherence to human umbilical vein endothelial cells (HUVEC), 
but not to buccal epithelial cells (BEC) (Zhao et al., 2004) and is essential for virulence in a 
model of systemic infection (Calderone & Fonzi, 2001). In addition, Als3p is involved in 
adherence to BEC and to HUVEC (Zhao et al., 2004) and in biofilm formation (Nobile & 
Mitchell, 2005). Both Als1p and Als3p are required for cell-cell adherent interactions 
during biofilm formation and mediate cellular aggregation in response to rapamycin 
treatment (Bastidas et al., 2009; Nobile et al., 2006a). Individual ALS genes are expressed 
in vivo, as several ALS transcripts were detected in clinical samples and in various models 
of infection (Cheng et al., 2005; Green et al., 2004; Green et al., 2006). 
 
1.4.1.2 Extracellular hydrolytic enzymes 
C. albicans produces extracellular hydrolytic enzymes, including secreted aspartic 
proteases (SAPs), phospholipases, and lipases, which have been reviewed elsewhere 
42 
 
 
(Hruskova-Heidingsfeldova, 2008; Naglik et al., 2004; Schaller et al., 2005). At least ten 
different SAP genes encode preproenzymes that are cleaved during transport through the 
secretory pathway (Naglik et al., 2003). SAPs are involved in the degradation of host 
barriers during tissue invasion and the destruction of host defence molecules or nutrient 
supply (Naglik et al., 2003). C. albicans  mutants in which various SAP genes were 
disrupted had a reduced capacity to damage vaginal and oral epithelial cells in some in vitro 
models, but not in others (De Bernardis et al., 1999; Hube et al., 1997; Lermann & 
Morschhauser, 2008; Naglik et al., 2008; Schaller et al., 1999). In these mutants, there 
appears to be a compensatory mechanism whereby some SAP genes are upregulated as a 
means to compensate for the disruption of other SAPs (Correia et al., 2010; Lermann & 
Morschhauser, 2008). In addition, SAP gene expression varies according to growth 
conditions and to types and stages of Candida infections (Hube et al., 1994; White & 
Agabian, 1995). Only SAP4, SAP5, and SAP6 are expressed in hypha-specific Efg1p- and 
Tec1p-dependent fashions (Felk et al., 2002; Schweizer et al., 2000). In vivo, SAP5 and 
SAP9 are the most highly expressed proteinase genes (Naglik et al., 2008). 
 
The term phospholipase (PL) describes a heterogeneous group of enzymes capable 
of hydrolyzing one or more ester linkages in phospholipids, the major component of 
biological membranes (discussed in section 1.7.1). In C. albicans, PLs are involved in 
damaging cell membranes and invading host cells, and differ in terms of their modes of 
action and their targets within a phospholipid molecule. Four subclasses exist, including 
PLAs (Banno et al., 1985), PLBs (Barrett-Bee et al., 1985; Hoover et al., 1998), PLCs 
(Pugh & Cawson, 1977), and PLDs (Hube et al., 2001). C. albicans harbors two genes 
coding for PLBs, three for PLCs and one for PLD. PLB1 and PLB5 encode secreted 
phospholipase B proteins which were required for virulence in a model of systemic 
infection (Leidich et al., 1998; Mukherjee et al., 2001; Theiss et al., 2006). Similarly, 
PLD1 was essential for virulence in two mouse models of oral candidiasis, but not in an in 
vitro model of oral candidiasis (Hube et al., 2001). PLB1, PLB5, and PLD1 are expressed 
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during the yeast-to-hypha transition (Goyard et al., 2008; Hube et al., 2001; Theiss et al., 
2006). PLD1 also contributes to hyphal growth on solid medium. 
 
Figure 1. 10 Several virulence factors contribute to early events in the pathogenesis of candidiasis. 
(A) At the mucosal surface, attachment (1) of C. albicans cells to host cells is promoted by adhesins 
such as Als1p, Als3p, and Hwp1p. Tissue invasion (2) results from C. albicans cells forming 
filaments or being taken in by host cells via persorption or induced phagocytosis. Subsequent tissue 
degradation (3) is caused by secreted factors (SAPs, PLs), by mechanical force exerted by hyphae 
or by a combination of both. (B) C. albicans yeast and hyphae with predominantly hyphae invading 
an epithelial surface are shown. Adapted from Calderone & Fonzi (2001); Gow et al. (2002).  
 
 
C. albicans also secretes lipases that catalyze the hydrolysis of ester bonds at the 
interface between the insoluble triacylglycerol phase and the aqueous phase in which the 
enzyme is dissolved. Ten genes encoding lipases (LIP1-10) have been identified in C. 
albicans. Interestingly, transcripts of most lipase genes were detected during the yeast-to-
hypha transition (Hube et al., 2000). LIP genes are expressed in a wide range of Candida 
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infections, both in vitro and in vivo, yet the role and function of lipases in infection remains 
to be elucidated (Schaller et al., 2005). 
 
1.4.1.3 Morphogenesis 
The role of hyphae in virulence has been difficult to assess given that most strains 
defective in filamentation lack transcription factors that regulate both hyphal growth and 
the expression of virulence genes. These strains are unable to produce hyphae and are often 
compromised in virulence. However, it is impossible to determine whether reduced 
virulence stems from the absence of hyphae or from the absence of expression of virulence 
genes that are co-regulated with hyphal growth. The identification and characterization of 
the G1 cyclin encoded by HGC1 solved this conundrum. A hypha-specific gene, HGC1 is 
regulated by the cAMP-PKA and Tup1p signaling pathways (Zheng & Wang, 2004). An 
hgc1/hgc1 mutant exhibited a severe filamentation defect in various hypha-inducing 
conditions and was dramatically attenuated in a model of systemic candidiasis, suggesting 
that HGC1 is involved in hyphal growth and in virulence. To this date, HGC1 remains the 
only HSG required for hyphal development. Strikingly, several HSGs, including HWP1, 
HYR1, and ECE1 were still expressed in an hgc1/hgc1 mutant despite the fact cells were 
non filamentous (Zheng & Wang, 2004). These findings demonstrate that virulence is 
associated to the hyphal form, and does not only stem from the form-specific virulence 
genes that are expressed.  
 
Additional lines of evidence demonstrate the association between the yeast-to-hypha 
transition and virulence. First, impairing filamentation using engineered strains in which 
morphogenesis was manipulated externally attenuated virulence in a model of systemic 
candidiasis (Carlisle et al., 2009; Saville et al., 2003; Saville et al., 2006). Second, 
filamentation was necessary for C. albicans to evade phagocytes (Lorenz et al., 2004), to 
escape from blood vessels (Phan et al., 2000), and to colonize medical devices by forming 
biofilms (Nobile & Mitchell, 2005; Nobile et al., 2006b). Third, hyphae are commonly 
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observed in biopsies of C. albicans-infected organs (Odds, 1988a). Thus, morphogenesis 
contributes to the overall virulence of C. albicans. 
 
1.4.2 Hgc1p and the cyclin-dependent kinase Cdc28p  
In C. albicans, morphogenesis is the transition from growth in a budding yeast form 
to growth in a hyphal form. Thus, the change in cell shape involves a change in growth 
patterns. In S. cerevisiae and C. albicans yeast cells, growth pattern changes (from isotropic 
to polarized stages) are cell-cycle dependent and controlled by the cyclin-dependent kinase 
(CDK) Cdk1p/Cdc28p which associates sequentially with G1 and G2 cyclins. In contrast, 
during hyphal growth, cells commit to continuous polarized growth. Curiously, although 
hyphal growth is cell cycle-independent, the CDK Cdc28p and various cyclins are involved 
in morphogenesis (Hazan et al., 2002; Wang, 2009). Homologues of S. cerevisiae cyclins 
have been identified, including G1 cyclins Ccn1p, Hgc1p, and Cln3p and B-type cyclins 
Clb2p and Clb4p. Ccn1p and Cln3p are required for hyphal growth (Bachewich & 
Whiteway, 2005; Chapa y Lazo et al., 2005; Loeb et al., 1999), while B-type cyclins Clb2p 
and Clb4p negatively regulate polarized growth (Bensen et al., 2005).  
 
Compared to other cyclins, Hgc1p is the main cyclin involved in hyphal growth, as it 
promotes filamentation in response to all hypha-inducing signals (Zheng & Wang, 2004). 
Unlike other cell-cycle regulated genes, HGC1 is a gene whose expression is induced only 
upon the yeast-to-hypha transition, as a result of the activation of the cAMP-PKA signaling 
pathway and the derepression of the Tup1p-Nrg1p signaling pathway (see sections 1.3.2; 
1.3.6). Hgc1p is involved in polarized growth, as it localizes to apical cells of hyphae, 
where it maintains the localization of actin and polarisome component Spa2p at the hyphal 
tip. In addition, Hgc1p interacts with Cdc28p, thereby forming the Cdc28pHgc1p complex 
(Zheng & Wang, 2004). Recent findings have demonstrated the role of CDKs in hyphal 
growth by establishing links between Cdc28pHgc1p and key components of the polarity 
machinery, including the Cdc42p module (Zheng et al., 2007), the transcription factor 
Efg1p (Wang et al., 2009), and the septins Cdc11p (Sinha et al., 2007) and Sep7p 
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(Clemente-Blanco et al., 2006; Gonzalez-Novo et al., 2008). These findings have been 
reviewed elegantly (Wang, 2009) and are summarized in Figure 1.11.  
 
Interestingly, some molecular events involved in polarized growth are activated 
prior to the expression of hypha-specific genes. Indeed, G1 cyclin Ccn1p, present in cells 
prior to Hgc1p, is required to rapidly establish polarized growth. Cdc28Ccn1p phosphorylates 
Cdc11p and the Spitzenkörper component Sec2p immediately upon hyphal induction, 
independently of the MAP kinase and cAMP-PKA signaling pathways (Bishop et al., 2010; 
Sinha et al., 2007). Concomitantly, morphogenetic signaling pathways are activated, 
resulting in HGC1 transcription. Once it reaches sufficient levels, Hgc1p associates with 
Cdc28p, thereby replacing Ccn1p, which is destined to degradation in the cell cycle. 
Contrary to Ccn1p, Hgc1p is required to maintain polarized growth. Thus, sustained HGC1 
expression is crucial to hyphal growth, given that the Hgc1p protein is degraded rapidly 
(Wang et al., 2007). Recent findings have shown that the transcription factor Ume6p is 
required to maintain both the levels and durations of HGC1 expression in response to 
hypha-inducing signals (Carlisle & Kadosh, 2010). Together, these findings suggest that 
the hyphal growth program is initiated at the posttranscriptional level, but is maintained by 
transcriptional events (Sinha et al., 2007).  
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Figure 1. 11 Role of cyclin-dependent kinases in morphogenesis in C. albicans.  
(A) The Rho-GTPase Cdc42p cycles between a GDP-bound inactive state and a GTP-bound active 
state. The guanine nucleotide exchange factor (GEF) Cdc24p activates Cdc42p to its GTP-bound 
form and GTPase-activating proteins (GAPs) Rga2p and Bem3p return it to its GDP-bound inactive 
form. High levels of Cdc42p-GTP are required to sustain polarized growth during morphogenesis. 
Upon hyphal induction, Cdc28pHgc1p inactivates Rga2p by hyperphosphorylation, thereby inhibiting 
its GAP activity and resulting in a local increase of Cdc42p-GTP. (B) In C. albicans, hyphal 
development depends on two cyclin-dependent kinases (CDKs) which promote germ tube 
formation and ensure continuous hyphal extension. Upon hyphal induction, Cdc28Ccn1p is activated 
immediately and phosphorylates Cdc11p, thereby promoting germ tube formation. Meanwhile, 
activation of the cAMP signaling pathway results in the transcriptional activation of HGC1. 
Cdc28pHgc1p phosphorylates Cdc11p and Rga2p, thereby maintaining polarized growth. The CDK 
also phosphorylates Efg1p and Sep7p, thereby preventing cell separation after cytokinesis. Adapted 
from Wang (2009).  
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1.5 Candida infections 
In the genus Candida, C. dubliniensis, C. glabrata, C. krusei, C. lusitaniae, C. 
parapsilosis, and C. tropicalis are encountered as gut commensals and as opportunistic 
pathogens, yet C. albicans remains the species most commonly associated with infections 
(Miceli et al., 2011; Odds et al., 2007). C. albicans is a normal inhabitant of human 
microbiota, colonizing asymptomatically the oral cavity and gastrointestinal tracts of 60 to 
90% of healthy adults and the genitourinary tracts of 15 to 25% of healthy women (Fidel, 
2002) (Figure 1.12). C. albicans is also found on the skin, albeit to a lesser extent (Berman 
& Sudbery, 2002). Generally, few healthy carriers develop clinical signs of disease. 
However, when immunological and mechanical defenses are compromised, C. albicans 
may establish an infection, revealing its opportunistic nature. Several factors, including 
natural, dietary, mechanical, and iatrogenic factors (Table I), may predispose to disease by 
altering the host environment, enabling C. albicans to proliferate, to invade tissues, and to 
cause an infection, i.e. candidiasis (Odds, 1988a).  
 
 
Table I Predisposing factors for candidiasisa 
Types of factors 
Natural microbial infections, AIDS, endocrine dysfunction (e.g. diabetes), 
lymphocyte defects, phagocyte abnormalities, pregnancy, infancy, old 
age 
Dietary excess (e.g. carbohydrate-rich diets), deficiencies (e.g. vitamin 
deficiencies) 
Mechanical trauma, burns, wounds, occlusion, prosthetic devices (e.g. dentures), 
thumb sucking 
Iatrogenic antibiotics eliminating the gut microflora, immunosuppressive drugs 
altering host defenses, surgery, insertion of mechanical devices (e.g. 
catheters) 
aadapted from Odds (1988a) 
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The type of Candida infection is dictated by a host’s immune status and microbial 
flora and by the site of carriage (Hube, 2004). C. albicans is a successful pathogen as it can 
proliferate in a multitude of host niches, thereby establishing disease at various body sites. 
Different forms of oral infections are seen in infants, the elderly, and patients infected with 
human immunodeficiency virus (HIV). Vulvovaginitis arises mainly in women; infections 
of the male genitalia are much less common, but still reported. Cutaneous infections with 
Candida are seen on areas of the skin that are moistened by occlusion or maceration. 
Generally, these superficial forms of candidiasis (section 1.5.1) are easy to diagnose and to 
treat.  
 
In addition to causing superficial mycoses, C. albicans is also the causative agent of 
invasive candidiasis (see section 1.5.2). When the pathogenic yeast gains access to the 
bloodstream, often from the gut, but also via catheters and other devices, it can disseminate 
and infect deep tissues and organs. Such infections, seen in immunocompromised 
individuals only, are severe, difficult to treat and often lethal. Invasive candidiasis has 
become increasingly important due to a growing population of immunocompromised 
and/or hospitalized patients with severe underlying disease (Enoch et al., 2006; Pfaller & 
Diekema, 2007). Indeed, C. albicans is the most common cause of disseminated and 
invasive fungal infections in hospital settings, with associated mortality rates of 38-49% 
(Horn et al., 2009; Miceli et al., 2011; Pfaller & Diekema, 2007). Additionally, it is now 
the third or fourth leading cause of microbial septicemia in hospital settings, having 
outstripped many bacterial infections in terms of incidence and morbidity (Almirante et al., 
2005; Beck-Sague & Jarvis, 1993; Miceli et al., 2011; Tortorano et al., 2004). 
 
1.5.1 Skin and mucosal candidiasis 
Candida infections of the skin and mucous membranes include oropharyngeal, 
esophageal, vulvovaginal, and gastrointestinal candidiasis. Oropharyngeal candidiasis 
(OPC) involves infections of the hard and soft palate, tongue, buccal mucosa, and floor of 
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the mouth caused by C. albicans. It presents either as white, curd-like lesions (thrush or 
pseudomembranous candidiasis) or reddened patches (erythematous candidiasis) 
(Laudenbach & Epstein, 2009). Thrush is characterized by removable white plaques that 
may be scraped away to reveal a bleeding surface. Symptoms of OPC usually include an 
alteration of taste, inflammation in the mouth with oral pain, and burning of the mouth. 
Thrush occurs in infants, the elderly, HIV-infected individuals, and patients afflicted with 
natural predisposing factors (see Table I) or undergoing broad-spectrum antibiotic therapy 
(Cannon et al., 1995). Erythematous OPC (a reddened area without removable white spots 
or plaques) has been reported mainly in patients with HIV infection, but also in patients 
with denture stomatitis. In addition to thrush and erythematous OPC, hyperplastic 
candidiasis (Candida leukoplakia) and angular cheilitis (perlèche) are two other subtypes of 
OPC (Ruhnke, 2002). OPC is usually present at the time esophageal candidiasis (EC) is 
diagnosed. Patients with EC may present with dysphagia (difficulty swallowing) or 
odynophagia (pain while swallowing) and develop ulcers and erosions on the esophagus 
(Ruhnke, 2002).  
 
The benign vulvovaginal candidiasis (VVC) or vaginitis is the most common type 
of Candida infection. An estimated 75% of all women experience at least one episode of 
VVC in their lifetime, while 5 to 10% develop recurrent VVC (Ruhnke, 2002; Sobel, 
2002). Candidiasis of the male genitalia can also occur, albeit less commonly than VVC. C. 
albicans is the main causative agent in approximately 85 to 90% of VVC cases, followed 
by C. glabrata and C. tropicalis (Fidel & Sobel, 2002). VVC involves infections of the 
vaginal lumen and the vulva, causing vulvovaginal burning, itching, soreness, an abnormal 
discharge, and dyspareuria. A diagnosis of VVC is suggested clinically by pruritus (i.e. 
itching) and erythema in the vulvovaginal area, which may be seen together with white 
patches that resemble those seen in oral thrush. Factors that predispose to VVC include 
hormonal perturbations (e.g. oral contraceptive usage, hormone replacement therapy, and 
pregnancy) and any disturbance of the vaginal flora (e.g. antibiotic or immunosuppressive 
therapy) (Fidel & Finkel-Jimenez, 2007).  
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Gastrointestinal (GI) candidiasis is defined as infections of the stomach and the 
small and large intestines (Fidel & Finkel-Jimenez, 2007). It is caused by the disruption of 
the normal gut microflora, resulting in the overgrowth of C. albicans. Compared to OPC 
and VVC, GI candidiasis is relatively rare. However, it is an important risk factor for 
disseminated candidiasis in immunocompromised individuals (see section 1.5.2), including 
cancer and transplant patients receiving immunosuppressive or antibiotic prophylaxis 
therapy and HIV-infected individuals (Matthews & Witek-Janusek, 2002).  
 
Candida species, and mostly C. albicans, can cause superficial infections in both the 
skin and the nails (Odds, 1988b). The pathogenic yeast has a predilection for warm and 
moist environments, such as the skin folds under the breasts and gluteus and the bending 
creases between the fingers and toes, the armpits and groin, created by maceration and 
occlusion (Lopez-Martinez, 2010). Cutaneous candidiasis presents as erythematous rashes 
causing eruption, secretions, itching, and burning. Candida skin infection is a common 
cause of diaper rash in infants, but can also occur in the elderly, and in obese adult patients 
(Ruhnke, 2002).  
 
1.5.2 Invasive candidiasis 
Invasive Candida infections include candidemia (infection of the blood), 
hematogenously disseminated candidiasis, and deep-seated candidiasis of one or more 
organs (Filler & Kullberg, 2002; Kullberg & Filler, 2002). Invasive candidiasis stems from 
C. albicans cells being translocated from the GI tract or from the skin into the bloodstream 
(Kullberg & Filler, 2002) (Figure 1.12). Several factors promote translocation, including 
disruption of cutaneous barriers (catheters, burns, surgical wounds, and trauma) and 
mucosal barriers (surgery, chemotherapy-related mucositis, GI malignancy), GI candidiasis 
(antibiotic therapy), and impaired cell-mediated immunity (immunosuppressive therapy, 
neutropenia) (Sims et al., 2005). Deep-seated candidal infections of organs may arise from 
hematogenously disseminated candidiasis or from the direct inoculation of an organ by a 
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contaminated catheter or other medical devices (Kojic & Darouiche, 2004; Sims et al., 
2005). Although there are no specific signs that characterize candidemia or hematogenously 
 
Figure 1. 12 Infection cycles of Candida albicans.  
C. albicans is a normal resident of the skin, oral cavity, genitourinary, and gastrointestinal tracts. 
Harmless in the commensal state, C. albicans is an opportunistic pathogen, causing infection when 
immunological and mechanical host defenses are compromised. Candida infections of the skin and 
mucous membranes occur in both healthy and immunocompromised individuals (A), while invasive 
candidiasis is only seen in severely immunocompromised individuals (B, F). Invasive candidiasis 
(candidemia, hematogenously disseminated candidiasis, and deep-seated candidal infections of 
organs) generally stems from the translocation of C. albicans cells from the gastrointestinal mucosa 
into the bloodstream (B, C). C. albicans enters epithelial microvilli through persorption of yeast 
cells (D) or germination (E). After gaining access to the bloodstream, yeast cells are 
hematogenously disseminated (B) and can infect host tissues such as the kidney (F). Adapted from 
Roman et al. (2007); Chauhan et al. (2006).  
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disseminated candidiasis, these infections usually present as a persistent fever in a seriously 
ill patient despite antibacterial treatment. Some patients present with the sepsis syndrome, 
including fever, hypotension, tachycardia, and tachypnea (Kullberg & Filler, 2002). Since 
the diagnosis of invasive candidiasis is difficult to establish, antifungal therapy is often 
initiated on the presumption of this type of infection. 
 
In invasive candidiasis, C. albicans cells first enter the bloodstream, either by 
persorption or germination of cells across epithelial cells, by seeding from contaminated 
devices, by invasion of epithelially denuded surfaces, or via trauma or surgically related 
inoculation (Bendel et al., 2003; Cole et al., 1996; Hawser & Douglas, 1994). To invade 
tissues, cells exit the circulation by adhering to the endothelial lining of blood vessels and 
transmigrating across the endothelium (Figure 1.12) (Grubb et al., 2008). Two theories 
explain adhesion and transmigration processes of C. albicans cells. One theory proposes 
that yeast cells must first undergo the morphogenetic transition in order for hyphal cells to 
bind to and damage the endothelial lining of blood vessels before transmigrating from the 
bloodstream into tissues (Phan et al., 2000; Sanchez et al., 2004). Conversely, the second 
theory suggests that the yeast-to-hypha transition is not a prerequisite for yeast cells to 
extravasate from blood vessels (Bendel et al., 2003; Saville et al., 2003).  
 
Adhesion of fungal cells to endothelial cells is mediated by C. albicans cell wall 
components, including proteins (integrin-like adhesins and the ALS gene products) and 
carbohydrates (e.g. mannans) (Grubb et al., 2008). Integrin-like adhesins αMβ2, αvβ3, and 
αvβ5 mediate adhesion of yeast and/or hyphal cells to human endothelial cells by binding 
cell adhesion molecules (CAM) (Gustafson et al., 1991; Santoni et al., 2001; Spreghini et 
al., 1999). For instance, αMβ2 binds to ICAM-1 and -2, αvβ3 interacts with PECAM-1, while 
αvβ5 lacks a known ligand. The large GPI-linked cell surface glycoproteins encoded by the 
ALS genes (discussed in 1.4.1.1) have contrasting roles in adhesion and transmigration. 
Among the eight members of the Als family, Als1p, Als2p, Als3p, Als4p and Als9p are 
required for adhesion to endothelial cells. To this date, N-cadherin, which binds the hypha-
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specific Als3p, is the only ligand for the ALS gene products found on endothelial cells 
(Phan et al., 2007). Several sugar residues, found on yeast and hyphal cells, are recognized 
and bound by host pattern recognition receptors. For instance, N- and O-linked mannosyl 
residues are bound by the mannose receptor and Toll-like receptor 4 (TLR-4), respectively 
(Netea et al., 2006). Similarly, phospholipomannan and β-mannosides are recognized and 
bound by TLR-2 and galectin-3 (Jouault et al., 2003; Jouault et al., 2006). 
 
Upon adhering to endothelial cells, C. albicans cells migrate across the endothelial 
barrier. Several mechanisms have been proposed to explain this process. One model 
proposes that hyphae bind to N-cadherin at the surface of endothelial cells via the hypha-
specific protein Als3p, thus promoting their endocytosis and passage through the 
endothelial cell layer (Filler, 2006; Phan et al., 2005; Phan et al., 2007). Endothelial 
endocytosis is not restricted to hyphae, as adherent yeast cells are also endocytosed (Phan 
et al., 2000). Another model involves the extension and penetration of hyphae through 
endothelial cells, destroying them in the process. Alternatively, adherent C. albicans cells 
may pass between adjacent endothelial cells by cyclical switching of adhesion molecules 
(Grubb et al., 2008).  
 
 
1.6 Treatment of candidiasis 
Candida infections are treated with antifungal drugs. Currently, there are four main 
classes of antifungal agents which perturb essential processes involved in cell wall 
biogenesis and in ergosterol and DNA synthesis (Odds et al., 2003) (discussed in section 
1.6.1). While superficial mycoses remain fairly easy to treat with conventional antifungal 
drugs, invasive Candida infections pose a greater challenge. Indeed, treatment of such 
infections is complicated by the limited arsenal of antifungal drugs, the severe side effects 
in patients, the development of antifungal drug resistance, and the emergence of species 
refractory to conventionally used agents (Anderson, 2005; Cowen et al., 2002; Sanglard & 
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Odds, 2002). Additionally, invasive Candida infections are on the rise due to a growing 
population of immunocompromised and/or hospitalized patients with severe underlying 
disease (Enoch et al., 2006). Combined, these factors underscore the need for new targets 
or new strategies in antifungal therapy (Calugi et al., 2011; Espinel-Ingroff, 2009).  
 
1.6.1 Classical antifungal drugs 
Conventional antifungal drugs target different cellular processes that are essential 
for growth. According to their targets and modes of action, antifungal drugs can be 
classified in four categories, including polyenes, nucleic acid inhibitors, ergosterol 
biosynthesis inhibitors, and echinocandins (Figure 1.13A). The emergence of resistance is 
an important aspect of antifungal therapy. The mechanisms developed by C. albicans to 
resist to conventional antifungal agents have been reviewed elsewhere (Sanglard & Bille, 
2002; Sanglard & Odds, 2002; Sanglard & White, 2007; White et al., 1998) and are 
summarized in Figure 1.13B. 
 
1.6.1.1 Polyenes 
Discovered in the early 1950s, polyenes such as amphotericin B (AmB) and nystatin 
are heterocyclic amphipathic molecules that insert into membranes, bind to ergosterol, and 
aggregate to form pores. These pores disrupt the integrity of the plasma membrane, 
allowing small molecules to diffuse across it. Altered permeability and leakage of vital 
cytoplasmic components result in cell death (Sanglard & Bille, 2002). A natural antibiotic 
produced by Streptomyces nodosus, AmB has a fungicidal activity against Candida species 
as well as a broad spectrum of activity against other fungi (Ellis, 2002). Moreover, 
resistance to AmB is rare, given that it is fungicidal. AmB is used to treat severe, life-
threatening systemic infections caused by C. albicans or by Candida species that are 
intrinsically azole-resistant (e.g. C. glabrata and C. krusei) or that have acquired resistance 
to azoles (Rex et al., 2000).  
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Figure 1. 13 Antifungal drug targets and resistance mechanisms. 
(A) 5-FC targets DNA and RNA synthesis. Polyenes such as amphotericin B and nystatin bind to 
plasma membrane ergosterol, creating pores which lead to efflux of cations and cell death. Azoles 
inhibit the product of ERG11 that catalyzes the 14α-demethylation of lanosterol, resulting in the 
accumulation of toxic methylated sterols in the plasma membrane and the depletion of ergosterol. 
Echinocandins inhibit synthesis of β-1,3 glucan polysaccharides, thereby affecting cell wall and cell 
membrane composition and integrity. Griseofulvin interferes with microtubule assembly and 
inhibits mitosis. (B) Summary of resistance mechanisms. (see text for details). Adapted from Odds 
et al. (2003); Cannon et al. (2007).   
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Although polyenes have a greater affinity for ergosterol-containing membranes than 
for cholesterol-containing membranes, they can still bind the main sterol present in host cell 
membranes, which accounts for their toxic potential in humans. In addition, polyenes are 
insoluble in aqueous solutions, and have to be complexed with other agents for clinical 
administration. For instance, complexing AmB to sodium deoxycholate increased 
solubility, yet such formulations were quite nephrotoxic. Lipid formulations of AmB have 
since been developed to circumvent solubility and toxicity issues, and are generally better 
tolerated by patients (Laniado-Laborin & Cabrales-Vargas, 2009). 
 
1.6.1.2 5-Flucytosine 
5-Flucytosine (5-FC) belongs to the class of pyrimidine analogues that were 
developed in the 1950s as anticancer agents. 5-FC is taken up by a cytosine permease 
(Fcy1p and Fcy2p) and is deaminated by a cytosine deaminase (Fca1p) and converted to 5-
fluorouracil (5-FU), a potent antimetabolite (Sanglard & Bille, 2002). Incorporated into 
RNA, 5-FU causes premature chain termination, but it also inhibits DNA synthesis by 
affecting thymidylate synthase (Sanglard & White, 2007). 5-FC has a fungicidal activity, as 
it inhibits nucleic acid synthesis and division. However, its spectrum of activity is restricted 
to fungi that harbor the enzymes required to convert it into 5-FU, namely Candida species 
and Cryptococcus neoformans. Additionally, 5-FC is usually administered in combination 
with AmB because resistance occurs at a high frequency. Resistance to 5-FC may be due to 
a defective cytosine permease, a deficiency or lack of enzymes involved in the metabolism 
of 5-FC, or a deregulation of the pyrimidine biosynthesis pathway (Sanglard & Bille, 
2002).  
 
1.6.1.3 Ergosterol biosynthesis inhibitors 
Ergosterol biosynthesis inhibitors (EBIs) form a diverse group of antifungals which 
includes azoles, allyamines, thiocarbamates, and morpholines. These agents inhibit the 
biosynthesis of ergosterol, the main sterol of fungal membranes, resulting in its depletion 
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and replacement with unusual sterols. Altered membrane permeability and fluidity affect 
membrane-bound enzymes, resulting in the inhibition of cell growth. The ergosterol 
pathway is divided into an early pathway (producing squalene from acetate) and a late 
pathway (producing ergosterol from squalene). EBIs inhibit steps in the late pathway. For 
instance, allyamines (e.g. terbinafine) and thiocarbamates inhibit squalene epoxidase 
(product of ERG1) with fungicidal consequences in susceptible species. These include 
many filamentous fungi, but very few pathogenic yeasts. Topical or oral preparations of 
terbinafine are used to treat skin and nail infections (onychomycosis) caused by 
dermatophytes. It is usually well tolerated, but may cause gastrointestinal upset, taste 
disturbance, and transient elevation of liver enzymes (Chen & Sorrell, 2007). Morpholines 
(e.g. amorolfine) inhibit the products of ERG2 and ERG4, resulting in the formation of 
ignosterol which blocks cell growth. Amorolfine can only be used for topical treatment of 
superficial mycoses such as VVC (Sanglard & Bille, 2002).  
 
Azoles are the most important EBIs and are regrouped into two classes: imidazoles 
(ketoconazole, miconazole, and clotrimazole) and triazoles (fluconazole, voriconazole, and 
itraconazole), which have two and three nitrogen atoms in their azole ring, respectively. 
Azoles target the cytochrome P450 enzyme, 14α-demethylase, encoded by ERG11. Erg11p, 
which contains a protoporphyrin ring at its active site, catalyzes the 14α-demethylation of 
lanosterol. Azoles inhibit Erg11p’s enzymatic activity by binding to its iron atom via a 
nitrogen atom contained in the imidazole or triazole ring, thereby interfering with the 
conversion of lanosterol to ergosterol and resulting in the accumulation of methylated 
sterols in the plasma membrane (Odds et al., 2003). Azoles inhibit cell growth, but do not 
kill cells, and thus have a fungistatic rather than a fungicidal activity. Yet, they have a 
broad spectrum of activity and are less toxic than AmB, which is why they are used to treat 
various types of Candida infections. For instance, fluconazole is used to treat mucosal 
candidiasis (VVC, OPC) and chronic mucocutaneous candidiasis. It is also the drug of 
choice to treat invasive candidiasis. Itraconazole is effective to treat fluconazole-resistant 
superficial candidiasis.  
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The fungistatic properties of azoles have played a role in the emergence of 
resistance. Indeed, static drugs can leave large populations of survivor cells that are 
exposed to strong selection for resistance (Anderson, 2005). These cells accumulate 
mutations which enable them to grow in the presence of the antifungal drug. Various 
mechanisms account for the development of resistance to azoles (Figure 1.13B), including 
enhanced drug efflux mediated by multidrug transporters (Cdr1p, Cdr2p, and Mdr1p) 
(Sanglard et al., 1995; Sanglard et al., 1997; Wirsching et al., 2000), decreased affinity of 
azoles for Erg11p caused by mutations (Marichal et al., 1999), overexpression of ERG11 
(Perea et al., 2001), and alteration of the ergosterol pathway caused by the absence of 
Erg3p (Nolte et al., 1997). 
 
1.6.1.4 Echinocandins 
Recently developed, echinocandins are fungal secondary metabolites comprised of a 
hexapeptide core with a lipid side-chain responsible for antifungal activity. Echinocandins 
target β-1,3 glucan synthase, which is part of an enzyme complex involved in the synthesis 
of cell wall β-1,3 glucan polysaccharides (Sanglard & Bille, 2002). Although the 
mechanistic details of the inhibition of glucan synthesis by echinocandins is still obscure, it 
appears that the compounds bind to Fsk1p, a subunit of β-1,3 glucan synthase. Disruption 
of the cell wall structure leads to osmotic instability and ultimately to lysis of the cell (Odds 
et al., 2003). Echinocandins include caspofungin, anidulafungin, and micafungin, which 
differ in their lipid side-chains. While the latter two compounds are still in clinical trial, 
caspofungin has been approved for the treatment of Candida infections (Sanglard & White, 
2007). So far, echinocandin resistance has only been reported in C. albicans strains that 
have point mutations in Gsc1p, a subunit of β-1,3 glucan synthase (Baixench et al., 2007). 
Moreover, echinocandins appear to be well tolerated, given that they affect a fungi-specific 
target (i.e. fungal cell wall).  
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1.6.1.5 Griseofulvin 
While griseofulvin was the first antifungal drug to be developed, its mechanism of 
action is still unknown. It appears that griseofulvin interferes with microtubule assembly 
and inhibits mitosis (Odds et al., 2003). Griseofulvin has a narrow spectrum of activity, and 
is used to treat superficial mycoses caused by dermatophyte fungi, such as ringworm and 
athlete’s foot.  
 
1.6.2 Targeting virulence: a new paradigm for antifungals 
Antifungals exert either fungicidal or fungistatic activities towards C. albicans by 
interfering with processes that are essential for its growth (see section 1.6.1). Intensive 
prophylactic and therapeutic uses of antifungals have selected for drug-resistant strains 
(Anderson, 2005; Cowen & Steinbach, 2008; Sanglard & White, 2007). One way to 
preclude resistance is to develop a wider repertoire of antifungal drugs whose targets differ 
from those of conventional drugs. Interestingly, targeting virulence rather than essential 
processes has been postulated as a new paradigm for the development of antifungal agents, 
following the successful development of drugs targeting bacterial virulence in antimicrobial 
therapy (Alksne & Projan, 2000; Calugi et al., 2011; Gauwerky et al., 2009). Thus, instead 
of being killed, a pathogen is maintained in a harmless form by hindering its virulence 
attributes which contribute to pathogenicity. The rationale for the development of drugs 
targeting virulence instead of growth is that resistance to such agents is less likely to occur, 
given that selective pressure is reduced on non-essential targets that are only required to 
colonize host environments (Jiang et al., 2002).  
 
In C. albicans, virulence factors are “attributes whose absence in the fungus 
eliminates or reduces (…) damage in a defined host system in vivo” (Odds et al., 2007) 
(discussed in section 1.4.1). Virulence factors that are eligible as targets for the 
development of new antifungal drugs have been reviewed recently, and include secreted 
aspartic proteases (SAPs), phospholipases, calcineurin, inositol phosphoryl ceramide 
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synthase (Ipc1p), elastase, and hyphal formation (Calugi et al., 2011; Gauwerky et al., 
2009). Several molecules have been shown to be effective against some of these virulence 
factors. For instance, pepstatin A, saquinavir, and indinavir are peptidomimetic SAP 
inhibitors, which reduced proteinase activity and attenuated virulence in a model of 
mucosal infection (Korting et al., 1999). Antibodies developed against virulence factors of 
C. albicans, including a 65-kDa mannoprotein and Sap2p, inhibited the adherence of C. 
albicans to epithelial cells and protected against VVC (De Bernardis et al., 2007). Two 
immunosuppressive agents, tacrolimus (FK106) and cyclosporin A, which target the 
virulence factor calcineurin, enhanced the efficacy of antifungal drugs such as fluconazole 
(Cruz et al., 2002; Sanglard et al., 2003; Steinbach et al., 2007). While these experimental 
findings are promising, the clinical potential of most of these agents has yet to be 
demonstrated.  
 
1.6.3 Morphogenesis, a target for the development of novel antifungals 
Although recent findings have demonstrated that filamentation is not always 
required for virulence in systemic candidiasis, morphogenesis still belongs to the realm of 
C. albicans virulence factors (Noble et al., 2010). Several lines of evidence underscore the 
association between the morphogenetic transition and virulence (discussed in 1.4.1.3). 
Indeed, the ability to switch between different morphological forms is required for 
virulence in systemic candidiasis (Lo et al., 1997; Saville et al., 2003; Zheng & Wang, 
2004), as well as for cells to evade phagocytes (Lorenz et al., 2004), to escape from blood 
vessels (Phan et al., 2000), and to colonize medical devices by forming biofilms (Nobile & 
Mitchell, 2005; Nobile et al., 2006b).  
 
Because morphogenesis contributes to virulence in C. albicans, it may constitute a 
target for the development of antifungal drugs. Indeed, impairing morphogenesis has been 
shown to be a means to treat systemic candidiasis. Using engineered strains in which the 
yeast-to-hypha transition was manipulated externally, the overexpression of NRG1, the 
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repressor of filamentation, inhibited hyphal growth and attenuated virulence in a model of 
systemic candidiasis (Saville et al., 2003; Saville et al., 2006).  
 
In parallel, molecules have been reported to modulate morphogenesis in C. 
albicans, and may harbor antifungal properties (reviewed in Chapter 3). Among these 
molecules, fatty acids such as butyric, capric, and undecylenic acids were shown to inhibit 
germ tube formation in C. albicans (McLain et al., 2000; Murzyn et al., 2010; Noverr & 
Huffnagle, 2004). Likewise, a fatty acid-enriched whey fraction also inhibited the yeast-to-
hypha transition (Clement et al., 2007). The hypha-inhibiting properties of whey were 
attributed to lauric, myristoleic, conjugated linoleic and arachidonic acids. The effect of 
conjugated linoleic acid (CLA) on hyphal growth in C. albicans was further characterized 
and its mode of action was addressed (see Chapter 2).  
 
 
1.7 Ras1p, a membrane-associated protein 
1.7.1 Brief overview of plasma membrane constituents 
The structure and organization of C. albicans cells resemble that of other eukaryotic 
cells. Except for their fungi-specific cell wall, yeast cells have a plasma membrane that 
forms a barrier surrounding the cytosol which contains intracellular organelles such as 
ribosomes, double-membraned mitochondria and nuclei, glycogen granules and vacuoles 
(Odds, 1988a). Approximately 7.5 nm wide, the plasma membrane is a lipid bilayer which 
contains a mixture of lipids and proteins, held together mainly by noncovalent interactions. 
The plasma membrane is a dynamic and fluid structure, as its lipid molecules are arranged 
as a continuous double layer dotted with proteins that can move laterally and rotate on 
themselves (van der Rest et al., 1995).  
 
Membrane lipids, which vary in size and composition, include phospholipids, 
sterols (ergosterol), and glycolipids (van der Rest et al., 1995). Phospholipids consist of 
two fatty acyl chains ester-linked to glycerol-3-phosphate. Differences in the length and 
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saturation of the fatty acyl chains influence the ability of phospholipid molecules to pack 
against one another, thereby affecting membrane fluidity (discussed below). Ergosterol, a 
compact and rigid hydrophobic molecule with a polar hydroxyl group, determines 
membrane rigidity. Ergosterol is also involved in the formation of lipid rafts, which are 
sterol- and sphingolipid-enriched microdomains (Lingwood & Simons, 2010). As for 
glycolipids, they are sugar-containing lipid molecules, mostly found on the outer leaflet of 
the lipid bilayer.  
 
Fatty acids, being constituents of phospholipids, influence the structure of the 
membrane. For instance, an increase in the ratio of unsaturated to saturated fatty acids 
increases membrane fluidity. This is caused by the kinks created by the double bonds 
present in unsaturated fatty acyl chains which decrease the packing ability of 
phospholipids, thereby increasing membrane fluidity. In contrast, packing increases with 
increasing length of acyl chains and decreasing extent of unsaturation, resulting in a more 
ordered structure with decreased fluidity (Alberts et al., 2002). In yeast, fatty acids can be 
synthesized de novo or taken up from the exterior (Black & DiRusso, 2007). Moreover, 
exogenous fatty acids can be incorporated into membrane phospholipids, and can modulate 
the fatty acid profile of phospholipids (Ells et al., 2009; Petschnigg et al., 2009). 
  
Plasma membrane proteins include transport proteins, receptor proteins, and 
signaling proteins involved in sensing and signaling, selective uptake and/or secretion of 
solutes across the membrane, and cell wall biogenesis and maintenance (Delom et al., 
2006). There are two types of membrane proteins: integral or transmembrane proteins and 
peripheral proteins. Integral membrane proteins span the membrane through one or more 
transmembrane domains which interact strongly with the membrane. In contrast, peripheral 
membrane proteins interact with the membrane, but do not transverse it. These proteins can 
associate with the membrane indirectly by interacting with integral membrane proteins, or 
directly by interacting with membrane phospholipids through anchor groups. Anchor 
groups include prenyl, farnesyl, and geranylgeranyl groups (hydrocarbon moiety), 
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myristoyl and palmitoyl groups (fatty acyl), and glycosylphosphatidylinositol (GPI) 
anchors (Alberts et al., 2002). Such lipid modifications enable cytosolic precursors to 
associate with specific membranes and ensure their proper targeting and subcellular 
localization.  
 
1.7.2 Ras membrane attachment and subcellular trafficking 
Ras proteins are membrane-associated proteins. Proteomic analyses have shown that 
the C. albicans Ras homologue (Ras1p) is a member of the plasma membrane proteome 
(Alvarez & Konopka, 2007; Cabezon et al., 2009). Synthesized in the cytosol, Ras proteins 
undergo posttranslational modifications by lipids, which dictate their interactions with 
distinct membrane compartments and their subcellular localizations. Like the majority of 
Ras proteins, C. albicans Ras1p terminates with the C-terminal CAAX lipid-conjugation 
motif required for membrane anchorage (Zhu et al., 2009). CAAX processing of 
mammalian Ras proteins is sequential (Figure 1.14). First, farnesyl transferase, a cytosolic 
enzyme, attaches a farnesyl group to the cysteine residue of the CAAX motif, constituting 
the initial prenylation (or farnesylation) modification. Next, the farnesylated CAAX 
sequence targets Ras to the cytosolic surface of the endoplasmic reticulum (ER), where the 
terminal three amino acids (AAX) are removed proteolytically and the C-terminal 
farnesylated-cysteine is methylated. Ras is then palmitoylated by a protein acyl transferase 
(palmitoyl transferase) that attaches palmitic acid via a thioester linkage to the thiol (-SH) 
group of the cysteine residue located immediately upstream of the farnesylated cysteine. 
Once palmitoylated, Ras enters the exocytic pathway, trafficking through the Golgi to the 
plasma membrane (Hancock, 2003). Farnesyl and palmitoyl anchor groups enable Ras to 
interact with membrane phospholipids and to associate stably to the plasma membrane.  
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Figure 1. 14 Membrane trafficking of mammalian Ras proteins.  
Mammalian Ras proteins undergo sequential posttranslational modifications. First, farnesyl 
transferase (PFTase), a cytosolic enzyme, attaches a farnesyl group to the cysteine residue of the 
CAAX motif, constituting the initial prenylation (or farnesylation) modification. Second, the 
farnesylated CAAX sequence targets Ras to the cytosolic surface of the endoplasmic reticulum 
(ER), where the terminal three amino acids (AAX) are removed proteolytically and the C-terminal 
farnesylated-cysteine is methylated with S-adenosylmethionine (SAM). At that point, K-Ras exits 
the ER and traffics to the plasma membrane through a poorly characterized pathway that bypasses 
the Golgi. As for H-Ras and N-Ras, they are palmitoylated by an ER-localized palmitoyl transferase 
(RPT), which attaches palmitoyl CoA (Palm-CoA) via a thioester linkage to the thiol (-SH) group of 
the cysteine residue located immediately upstream of the farnesylated cysteine. Once palmitoylated, 
H-Ras and N-Ras enter the classic secretory pathway, trafficking through the Golgi to the plasma 
membrane. Adapted from Hancock (2003).  
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Besides being important for the subcellular localization of Ras, another role has 
been uncovered for palmitoylation (Rocks et al., 2005). Two mammalian Ras isoforms, H- 
and N-Ras, undergo dynamic cycles of depalmitoylation/palmitoylation, which are 
accompanied by changes in their subcellular localization between the plasma membrane 
and the ER/Golgi (Figure 1.15). Palmitoylated Ras accumulates at the plasma membrane, 
where it is depalmitoylated and recycled to the ER/Golgi. Depalmitoylated Ras is then 
palmitoylated again at the ER/Golgi and targeted back to the membrane. This continuous 
cycle maintains Ras in specific intracellular compartments, enabling Ras signaling to be 
fine-tuned, given that its subcellular location modulates its signal output (Hancock, 2003; 
Omerovic et al., 2007; Rocks et al., 2005). However, it is not known whether or not the Ras 
depalmitoylation/palmitoylation cycle operates in S. cerevisiae. Moreover, trafficking from 
the ER to the plasma membrane of yeast Ras appears to depend on functional mitochondria, 
rather than on a functional secretory pathway (Linder & Deschenes, 2007; Wang & 
Deschenes, 2006). 
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Figure 1. 15 Depalmitoylation/palmitoylation cycle model of subcellular trafficking of H-Ras and 
N-Ras. 
Farnesylation of the CAAX sequence targets H-Ras and N-Ras (H/N-Ras) to the endoplasmic 
reticulum (ER). (2) Farnesylated H/N-Ras become palmitoylated by a protein acyltransferase 
(PAT), also known as palmitoyl transferase. Dual-lipid-modified H/N-Ras can then traffic to the 
Golgi (3) and plasma membrane (4) via the classic secretory pathway. (5) At the plasma membrane, 
an acylprotein thioesterase (APT) removes the palmitoyl group, allowing farnesylated H/N-Ras to 
be recycled to the ER/Golgi (6). (7) Another PAT might also repalmitoylate farnesylated H/N-Ras 
on the Golgi membrane. The depalmitoylation/palmitoylation cycle accounts for the dynamic 
subcellular trafficking of Ras. Adapted from Linder & Deschesnes (2007).  
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1.8 Rationale, hypotheses, and research objectives 
In Candida albicans, morphogenesis is induced by a variety of environmental cues 
which activate a complex web of signaling pathways composed of transducers, kinases, and 
transcription factors (discussed in sections 1.2 and 1.3). The yeast-to-hypha transition is a 
virulence factor of the pathogenic yeast (discussed in 1.4.1.3). A corollary to this idea is 
that morphogenesis may constitute a target for the development of new antifungal agents. 
Two reasons support this rationale. First, proof-of-concept experiments using engineered 
strains in which the yeast-to-hypha transition was manipulated externally demonstrated that 
harnessing morphogenesis was a means to treat systemic candidiasis (Saville et al., 2003; 
Saville et al., 2006). Second, targeting virulence processes instead of essential processes is 
a new paradigm for antifungal drug development (discussed in 1.6.2). Agents that target 
virulence factors are believed to reduce selective pressure exerted on pathogens and limit 
the emergence of resistance (Jiang et al., 2002). Concurrently, several small molecules have 
been reported to modulate morphogenesis (reviewed in Chapter 3). Among these 
molecules, a fatty acid-enriched whey fraction inhibited the yeast-to-hypha transition in C. 
albicans. Its hypha-inhibiting properties were attributed to several fatty acids, including 
conjugated linoleic acid (Clement et al., 2007). By inhibiting hyphal growth, conjugated 
linoleic acid (CLA) interferes with an important attribute of pathogenesis of C. albicans, 
and may harbor therapeutic properties. However, before assessing its therapeutic potential 
in a clinical context, it is mandatory to address CLA’s mechanism of action. For instance, 
CLA may inhibit the yeast-to-hypha transition by targeting a signaling pathway and/or a 
regulator involved in morphogenesis (discussed in section 1.3).  
 
The objectives of this work were to characterize the hypha-inhibiting effects of 
CLA, to identify potential targets mediating these effects, and to elucidate the mechanism 
by which CLA inhibits the yeast-to-hypha transition in C. albicans. These objectives were 
addressed using a combination of methods. A genomic approach using transcriptional 
profiling experiments was chosen to gain insight into the transcriptional response of cells to 
CLA on a genome-wide scale. A phenotypic screen of C. albicans mutant strains deleted 
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for potential CLA targets was also performed to eliminate secondary/indirect CLA targets. 
Quantitative Northern blot and/or quantitative PCR analyses were conducted to examine 
the kinetics of expression of several genes. Western blotting techniques were used to 
examine Ras1p cellular levels, while fluorescence microscopy was used to study the 
protein’s subcellular localization. 
 
By shedding light on CLA’s cellular target and its mode of action, it should be 
possible to predict whether or not the fatty acid could cause deleterious effects in humans, 
given that the level of conservation between human and yeast is high. In the long run, this 
work may constitute the rationale for a clinical study examining CLA’s therapeutic 
potential in the context of a Candida infection. In addition, this study should enable us to 
revisit the roles of signaling pathways and morphogenetic regulators in hyphal growth and 
to expose new findings pertaining to the wiring of these pathways. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Chapter 2. Conjugated linoleic acid inhibits hyphal 
growth in Candida albicans by modulating Ras1p 
cellular levels and downregulating TEC1 expression 
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A fatty acid-enriched whey fraction inhibited the yeast-to-hypha transition in C. 
albicans. Its hypha-inhibiting properties were attributed to several fatty acids, including 
conjugated linoleic acid (CLA) (Clement et al., 2007). The following study addresses the 
mechanism by which CLA inhibits hyphal growth in C. albicans. To gain insight into the 
mode of action of CLA, gene expression analyses were performed. These analyses also 
allowed the transcriptional program regulating the yeast-to-hypha transition in Spider 
medium to be characterized. These findings, i.e. the hyphal growth program in Spider 
medium and the mechanism by which CLA blocks the yeast-to-hypha transition, are 
presented in this chapter, whose content has been published in an article entitled 
“Conjugated linoleic acid inhibits hyphal growth in Candida albicans by modulating Ras1p 
cellular levels and downregulating TEC1 expression” in the scientific journal Eukaryotic 
Cell in 2011 (Shareck, J., Nantel, A. & Belhumeur, P.). Supplementary data can be found at 
the following address: http://ec.asm.org/cgi/content/full/10/4/565/DC1. Supplementary 
Tables S1 and S4 are also presented in the Appendix section. 
 
I designed and performed most of the experiments. I grew the cells and isolated 
their RNA for the gene expression profiling experiments, which were designed by Nantel. 
Nantel also labeled the RNA, performed the hybridizations, and conducted the statistical 
analyses. The microscopy experiment performed to localize GFP-Ras1p was suggested by 
Belhumeur. I analyzed the data, assembled the figures, and wrote the manuscript, which 
Belhumeur and Nantel corrected. I estimate my contribution to being close to 90%.  
 
It is notable to mention that at the time this work was undertaken, most signaling 
pathways involved in the regulation of the yeast-to-hypha transition had already been 
identified. Comprehensive reviews describing the wiring of morphogenetic signaling 
pathways into a complex network were published in 2007 (Biswas et al., 2007; Brown et 
al., 2007). Additionally, several molecules had been shown to modulate morphogenesis, 
but their mechanisms of action had seldom been investigated. The quorum sensing 
molecule farnesol was the best documented inhibitor of hyphal growth: its hypha-inhibiting 
effects had been characterized (Hornby et al., 2001; Mosel et al., 2005) and reported to 
involve a two-component signal transduction kinase (Kruppa et al., 2004). Additionally, 
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several gene expression analyses had been performed to investigate its transcriptional 
effects (Cao et al., 2005; Enjalbert & Whiteway, 2005). The first studies addressing 
farnesol’s molecular mechanism of action were published in 2008 (Davis-Hanna et al., 
2008; Kebaara et al., 2008). A receptor or a binding protein for farnesol has yet to be 
identified.  
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2.1 Abstract 
The polymorphic yeast Candida albicans exists in yeast and filamentous forms. 
Given that the morphogenetic switch coincides with the expression of many virulence 
factors, the yeast-to-hypha transition constitutes an attractive target for the development of 
new antifungal agents. Since an untapped therapeutic potential resides in small molecules 
that hinder C. albicans filamentation, we characterized the inhibitory effect of conjugated 
linoleic acid (CLA) on hyphal growth and addressed its mechanism of action. CLA 
inhibited hyphal growth in a dose-dependent fashion, in both liquid and solid hypha-
inducing media. The fatty acid blocked germ tube formation without affecting cellular 
growth rates. Global transcriptional profiling revealed that CLA downregulated the 
expression of hypha-specific genes and abrogated the induction of several regulators of 
hyphal growth, including TEC1, UME6, RFG1, and RAS1. However, neither UME6 nor 
RFG1 was necessary for CLA-mediated hyphal growth inhibition. Expression analysis 
showed that the downregulation of TEC1 expression levels by CLA depended on RAS1. In 
addition, while RAS1 transcript levels remained constant in CLA-treated cells, its protein 
levels declined with time. With the use of a strain expressing GFP-Ras1p, CLA treatment 
was also shown to affect Ras1p localization to the plasma membrane. These findings 
suggest that CLA inhibits hyphal growth by affecting the cellular localization of Ras1p and 
blocking the increase in RAS1 mRNA and protein levels. Combined, these effects should 
prevent the induction of the Ras1p signaling pathway. This study provides the biological 
and molecular explanations that underlie CLA’s ability to inhibit hyphal growth in C. 
albicans.  
 
 
2.2 Introduction 
Over the past decades, opportunistic fungal infections have gained importance 
among hospital-acquired infections due to a growing community of individuals 
immunocompromised by HIV infection, cancer treatment, or organ transplantation 
(Richardson & Lass-Florl, 2008). The opportunistic pathogen Candida albicans, a member 
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of the normal human microbiota, inhabits the gastrointestinal and genitourinary tracts, 
mucous membranes, and skin. It is responsible for various forms of diseases, ranging from 
superficial infections of mucosal surfaces to severe, life-threatening systemic infections that 
largely depend on a host’s physical and physiological conditions. C. albicans is the fourth 
leading cause of nosocomial infections and the most common fungal species causing 
bloodstream infections, with associated mortality rates of 38-49% (Edmond et al., 1999, 
Wisplinghoff et al., 2004, Pfaller & Diekema, 2007). Treatment of such infections is 
complicated by a limited number of antifungal drugs, many of which have adverse side-
effects, and by emerging resistance to all clinically useful antifungals. 
 
The success of C. albicans as a pathogen stems from its ability to deploy a full 
armada of activities that contribute to its virulence, including the production of proteases, 
adhesins, and phospholipases as well as its ability to switch morphologically and 
phenotypically (Kumamoto & Vinces, 2005, Brown et al., 2007a). The most studied 
morphological switch, the yeast-to-hypha transition, is induced by a variety of 
environmental cues, including elevated temperature, neutral or alkaline pH, nitrogen and/or 
carbon starvation, and growth in serum (Ernst, 2000). A complex network of signaling 
pathways regulate hyphal growth (Biswas et al., 2007, Whiteway & Bachewich, 2007, 
Brown et al., 2007b), among which the Ras1p-cyclic AMP (cAMP)-protein kinase A 
(PKA) and the mitogen-activated protein (MAP) kinase pathways play major roles. Both 
cascades are controlled by the small GTPase Ras1p (Leberer et al., 2001). Membrane-
bound, Ras1p binds the Ras-association domain of the adenylate cyclase Cyr1p, thereby 
stimulating the cyclization of ATP into cAMP (Fang & Wang, 2006). Upon binding cAMP, 
the regulatory subunit of PKA Bcy1p releases the catalytic subunits Tpk1p and Tpk2p, 
thereby activating PKA (Cassola et al., 2004). The transcription factor Efg1p is a 
downstream target of PKA (Stoldt et al., 1997, Bockmuhl & Ernst, 2001). Ras1p also 
impinges on the MAP kinase pathway, downstream of which lies the transcription factor 
Cph1p (Liu et al., 1994). Other transcription factors involved in hyphal growth include 
Tec1p, Flo8p, Cph2p, Ume6p, Rim101p and Czf1p (Schweizer et al., 2000, Lane et al., 
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2001a, Cao et al., 2006, Lane et al., 2001b, Banerjee et al., 2008, Zeidler et al., 2009, Davis 
et al., 2000, Brown et al., 1999). Hyphal growth is negatively controlled by the general 
repressor Tup1p in association with the DNA-binding proteins Nrg1p and Rfg1p (Braun & 
Johnson, 1997, Murad et al., 2001, Braun et al., 2001, Kadosh & Johnson, 2001). 
Activation of these signal transduction cascades modulates the expression of hypha-specific 
genes, many of which are involved in virulence (Biswas et al., 2007, Brown et al., 2007b).  
 
Although it has recently been demonstrated that the yeast-to-hypha transition is not 
always required for infectivity in systemic candidiasis (Noble et al., 2010), it is generally 
accepted that hyphal growth is critical for virulence in various types of C. albicans 
infections. Several lines of evidence link the yeast-to-hypha transition to pathogenicity, the 
first being that mutants locked in either yeast (cph1/cph1, efg1/efg1, and hgc1/hgc1) or 
filamentous forms (tup1/tup1 and nrg1/nrg1) are avirulent in systemic candidiasis (Lo et 
al., 1997, Zheng & Wang, 2004, Braun et al., 2000, Murad et al., 2001). Filamentation is 
required for C. albicans to evade phagocytes and escape from blood vessels (Lorenz et al., 
2004, Phan et al., 2000). Colonization of medical devices by biofilms depends on hyphal 
development and the expression of hypha-specific gene products (Nobile et al., 2006). In 
parallel, using C. albicans strains in which hyphal growth can be manipulated externally, 
several groups have shown that inhibiting filamentation is a means by which virulence may 
be attenuated during systemic candidiasis (Saville et al., 2006, Carlisle et al., 2009). 
Moreover, small molecules that block filamentation have been shown to exert a protective 
effect in mucosal candidiasis (Hisajima et al., 2008) and to reduce C. albicans-induced 
damage to endothelial cells (Toenjes et al., 2005). Not only do these findings demonstrate 
an association between filamentation and virulence in C. albicans, but they also suggest 
that the yeast-to-hypha transition may constitute a therapeutic target. 
 
We recently isolated fatty acids from bovine whey that had the ability to inhibit 
germ tube formation in C. albicans (Clement et al., 2007). Given that the inability to switch 
to a hyphal form reduces the virulence potential of C. albicans, we characterized the 
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inhibitory effect of conjugated linoleic acid (CLA) on hyphal growth and investigated its 
mechanism of action. We demonstrate that CLA inhibits hyphal development in a dose-
dependent fashion, in both liquid- and solid-inducing media. Global gene expression 
analysis reveals that CLA affects the expression of hypha-specific genes and of several 
morphogenesis regulators, including RAS1, TEC1, and UME6. We show that Ras1p is 
required for CLA to downregulate TEC1 expression levels. We demonstrate that in 
presence of CLA, Ras1p cellular levels decrease. In addition, CLA causes the 
delocalization of Ras1p from the plasma membrane. These findings suggest that CLA 
inhibits hyphal growth in C. albicans by affecting Ras1p signaling and downregulating the 
expression of downstream targets, including TEC1 and UME6. 
 
 
2.3 Material and methods 
2.3.1 Strains and growth conditions 
The yeast strains used in this study are listed in Table II. Strains were streaked out 
onto YPD plates (1% yeast extract, 2% peptone, 2% dextrose, 2% Bacto agar) and grown at 
30°C for 24-48 h. In all of the experiments performed, strains were propagated overnight in 
YPD at 30°C to an optical density at 600 nm (OD600) of ~12-14. Hyphal inductions were 
performed at 37°C on solid and in liquid media, using Spider (Liu et al., 1994), Lee’s (Lee 
et al., 1975), and buffered alkaline (pH 8.0) M199 (Wisent). Media were solidified with 2% 
Bacto agar (Oxoid). When necessary, media were supplemented with uridine (50 μg ml-1). 
Conjugated linoleic acid (CLA) (Cayman Chemicals) was diluted in ethanol as a 1,000× 
stock and added to media in concentrations ranging from 0 to 250 μM. Ethanol was used as 
drug vehicle (final concentration ≤ 0.5%). 
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Table II Candida albicans strains used in this study 
Strain Parent Genotype Reference 
SC5314  Candida albicans wild type clinical isolate Gillum et al. (1984) 
CAI4  ura3::λimm434/ura3::λimm434 Fonzi & Irwin (1993) 
ZK3379 CAI4 HWP1-lacZ-URA3 Hogan et al. (2004) 
MRC6 CAI4 fox2::hisG/fox2::hisG RPS10/rps10::URA3 Ramirez & Lorenz 
(2007) 
MRC10 CAI4 icl1::hisG/icl1::hisG RPS10/rps10::URA3 Ramirez & Lorenz 
(2007) 
HLC52 CAI4 efg1::hisG/efg1::hisG-URA3-hisG  Lo et al. (1997) 
CDH107 CAI4 ras1::hisG/ras1::hisG-URA3-hisG Leberer et al. (2001) 
BCa2-10 CAI4 tup1::hisG/tup1::hisG-URA3-hisG Braun & Johnson (1997) 
BCa23-3 CAI4 nrg1::hisG/nrg1::hisG-URA3-hisG  Braun et al. (2001) 
DK129 CAI4 rfg1::hisG/rfg1::hisG-URA3-hisG  Kadosh & Johnson 
(2001) 
IIHB6 CAI4 tpk1::hisG/tpk1::hisG-URA3-hisG Bockmuhl et al. (2001) 
TPO7.4 CAI4 tpk2::hisG/tpk2::hisG-URA3-hisG Sonneborn et al. (2000) 
WY-ZXD3 CAI4 RAS1/GFP-RAS1-hisG-URA3-hisG Zhu et al. (2009) 
RM1000  ura3::λimm434/ura3::λimm434 
his1::hisG/his1::hisG 
Negrego et al. (1997) 
MRC41 RM1000 ctf1::HIS1/ctf1::hisG RPS10/rps10::URA3 Ramirez & Lorenz 
(2009) 
BWP17  ura3::λimm434/ura3::λimm434 
arg4::hisG/arg4::hisG 
his1::hisG/his1::hisG 
Wilson et al. (2000) 
CJN308 BWP17 tec1::Tn7-UAU1/tec1::Tn7-URA3 Nobile & Mitchell 
(2005) 
SN95  ura3::λimm434/URA3 iro1::λimm434/IRO1 
arg4/arg4  his1/his1 
Noble & Johnson (2005) 
SN152 SN95 ura3::λimm434/URA3 iro1::λimm434/IRO1 
arg4/arg4 leu2/leu2 his1/his1  
Noble & Johnson (2005) 
DK318 SN95 arg4::ARG4/arg4 his1::HIS1/his1  Banerjee et al. (2008) 
DK312 SN152 arg4::ARG4/arg4 leu2/leu2 his1/his1 
ume6:: C.m.LEU2/ume6::C.d.HIS1  
Banerjee et al. (2008) 
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2.3.2 Hyphal growth assays in liquid and on solid media 
To quantify the inhibitory effect of CLA on C. albicans hyphal growth, β-
galactosidase activity was measured using the C. albicans reporter strain ZK3379 in which 
lacZ is under the control of the hypha-specific HWP1 promoter (Hogan et al., 2004). 
Briefly, cells from an overnight culture were washed in sterile distilled water and diluted to 
1 × 106 cells ml-1 in prewarmed media. Twenty-four-well polystyrene microplates (Costar 
3526; Corning, NY) were seeded with 1 ml of inoculated medium per well. Working 
solutions of CLA were freshly prepared and added immediately to seeded wells in volumes 
of 5 μl, yielding final concentrations ranging from 0 to 50 μM. Microplates were incubated 
statically in a water bath set to 37°C for 4 h. β-galactosidase activity was quantified as 
described previously (Kippert, 1995). Data are represented as the means and standard 
deviations of results from replicate assays performed on three independent days. To assess 
the effect of CLA on colony morphology, C. albicans cells from an overnight culture were 
washed in sterile distilled water and spread (ca. 100 colonies per plate) on plates of 
solidified medium supplemented with ethanol or CLA (100 μM). Plates were incubated at 
37°C for 3-4 days and photographed using a LEICA MZ FLIII Fluorescence 
Stereomicroscope mounted with a Micropublisher camera. To examine the effect of CLA 
on hyphal growth of C. albicans wild-type and mutant strains, cells from an overnight 
culture were washed in sterile distilled water and diluted to a concentration of 1 × 106 cells 
ml-1 in prewarmed Spider medium supplemented with ethanol or CLA (25 μM). Flasks 
were shaken at 150 RPM at 37°C. Aliquots of cells were harvested at various time points, 
fixed with 3.7% formaldehyde for 30 min at room temperature, washed twice with 1× 
phosphate-buffered saline (PBS), and visualized by differential interference contrast (DIC) 
microscopy using an upright Nikon microscope with a 100× immersion oil objective and a 
10× projection lens mounted with a Nikon DXM1200F digital camera. To distinguish 
hyphae from pseudohyphae, fixed cells were washed twice in water, stained for 5 min with 
4’-6’diamidino-2-phenyl-indole (DAPI; 1 mg ml-1) diluted 1:1,000 and calcofluor white (1 
mg ml-1) diluted 1:10, examined microscopically using epifluorescence, and classified 
according to the criteria of Sudbery et al. (2004). To ensure that CLA treatment did not 
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compromise cellular growth rates, growth curves were generated. SC5314 cells from an 
overnight culture were diluted to 1 × 106 cells ml-1 in Spider medium supplemented with 
ethanol or CLA (25 μM). Flasks were shaken at 150 RPM at 30°C. OD600 was measured 
every hour for 7 h. Data are means and standard deviations of results from duplicate 
biological samples. The effect of CLA (250 μM) on cellular growth rates in YPD at 30°C 
was assessed similarly. 
 
2.3.3 Gene expression profiling 
SC5314 cells grown overnight in YPD at 30°C were washed in sterile distilled water 
and diluted to 5 × 106 cells ml-1 (OD600 of 0.1) in Spider medium supplemented with 
ethanol or CLA (100 μM). Cultures were shaken at 150 RPM at either 30°C or 37°C for 90 
min. Cells were collected by vacuum filtration on 0.45-μm membrane filters (MF-Millipore 
Membrane Filters) and frozen in an ethanol bath at -80°C. Total RNA was isolated from 
quadruplicate independent biological samples using an RNeasy mini kit (Qiagen). Briefly, 
frozen cells were thawed out in RNeasy buffer RLT at a ratio of 3:1 (vol/vol) buffer/pellet. 
Resuspended cells were divided into 1-ml aliquots in 2-ml screw-cap microcentrifuge tubes 
containing 0.6 ml of 0.5-mm-diameter acid-washed glass beads. Samples were 
homogenized 6 times, for 5 min each, in a BeadBeater set at maximum speed. Lysates were 
kept on ice between each cycle. Total RNA was extracted from homogenized samples 
according to the Qiagen RNeasy protocol. For the two-color microarray experiments, RNA 
from cells grown at 37°C, or in the presence of CLA at 30°C or 37°C was compared to 
RNA from cells grown at 30°C. Four biological replicates were used in each experiment, 
which included two Cy3/Cy5 and two Cy5/Cy3 comparisons. cDNA labeling, microarray 
hybridization, washing, scanning, and statistical analysis methods were essentially 
performed as described previously (Sellam et al., 2009). In each comparison, genes with 
statistically significant modulations were identified in Volcano Plots using a 2.0-fold cut-
off point and a Welsh t test with a false-discovery rate of less than 5%. 
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2.3.4 Northern blot analysis 
Cells were grown as described above for gene expression profiling. RNA was 
prepared using the hot-phenol method. Fifteen micrograms of total RNA was separated on 
1.2% agarose-7.5% formaldehyde denaturing gels and transferred by capillary action to 
Hybond-N+ nylon membranes (GE Healthcare Life Sciences). Probes were generated by 
PCR amplification of genomic DNA and purified using an illustra GFX PCR DNA and Gel 
Band Purification Kit (GE Healthcare Life Sciences). The sequences of the primers used to 
generate all probes are listed in Table III. Fifty nanograms of probe was labeled by random 
priming using Ready-To-Go DNA Labeling Beads (GE Healthcare Life Sciences) and [α-
32P]dCTP. Unincorporated nucleotides were removed using Sephadex G-50 columns. Blots 
were hybridized overnight and washed at 65°C according to the method of Church and 
Gilbert (Church & Gilbert, 1984), scanned using a Molecular Dynamics Typhoon 
phosphorimager, and quantified with ImageQuant software (version 5.0; Molecular 
Dynamics). Data are means and standard deviations of results from duplicate biological 
samples. 
 
2.3.5 Quantitative PCR analysis of C. albicans transcripts 
For quantitative PCR (qPCR) analysis, C. albicans cells from an overnight culture 
were diluted to 1 × 106 cells ml-1 in Spider medium supplemented with ethanol or CLA (25 
μM) and grown at 37°C. Cells were collected at various time points (0, 30, 60, and 90 min) 
by vacuum filtration on 0.45-μm membrane filters (MF-Millipore Membrane Filter) and 
frozen in an ethanol bath at -80°C. Total RNA was isolated from duplicate independent 
biological samples for each condition and time point using the hot-phenol method. RNA 
was resuspended in 50 to 200 μl diethyl pyrocarbonate-treated water, quantified by 
spectrophotometer (NanoDrop 2000; Thermo Scientific), and stored at -80°C. RNA 
samples were DNase digested (rDNase I; Ambion) and used as templates in qPCR 
amplification reactions to certify them as DNA free. The lack of a PCR product indicated 
that samples were not contaminated with genomic DNA. Five hundred nanograms of total 
RNA was reverse transcribed using SuperScript II Reverse Transcriptase (Invitrogen) 
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according to the manufacturer’s instructions. Two cDNAs were synthesized for each 
biological replicate. Quantitative PCR was carried out on a Rotor-Gene 6000 (Corbett Life 
Science). The primers were designed with PrimerQuest (Integrated DNA Technologies) 
and are listed in Table III. The qPCR mixtures contained 12.5 μl FastStart SYBR Green 
Master (Roche Applied Science), 8.5 μl Milli-Q water, 200 nM each primer, and 1 μl 
cDNA product diluted 1:100, and the qPCRs were performed in duplicates. Generally, the 
difference between two threshold cycle (CT) values for the same sample was <0.5. Relative 
expression levels were calculated using the delta-delta CT method [2(CT for target condition − CT for 
ACT1 condition) − (C
T
 for target at time zero – C
T
 for ACT1 at time zero)], in which the condition was either 
ethanol or CLA treatment and ACT1 was the housekeeping gene. 
 
 
Table III Primers used in this study 
Primer Sequence (5’-3’) Product 
size 
qPCR ACT1F 5’-TCCAGA AGCTTTGTTCAGACCAGC-3’ 170 bp 
qPCR ACT1R 5’-TGCATACGTTCAGCAATACCTGGG-3’  
qPCR RAS1F 5’ GTTGTTGTTGGAGGTGGTGGTGTT 3’ 180 bp 
qPCR RAS1R 5’ GGCCAGATATTCTTCTTGTCCAGC 3’  
qPCR TUP1F 5’-CCAGCACCAACAACGTTTGACAGA-3’ 176 bp 
qPCR TUP1R 5’-TGGGCCAACTCCAAGTCATACACT-3’  
qPCR NRG1F 5’-TGGTGATTTACTGGCCAACTCCCT-3’ 180 bp 
qPCR NRG1R 5’-CATGTTGGCCATGGACATTGGTGT-3’  
ACT1F probe 5’-GTTGACCGAAGCTCCAATGAATCC-3’ 629 bp 
ACT1R probe 5’-TGCATACGTTCAGCAATACCTGGG-3’  
TEC1F probe 5’-GTTACCACCACGAGCACTGGC-3’ 486 bp 
TEC1R probe 5’-TGAAGGGTGTTGGCTATTATGCG-3’  
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2.3.6 Protein extraction and immunoblotting 
Wild-type and tagged strains were grown in Spider medium and harvested by 
following the same procedure as that described above for gene expression profiling. Total 
protein extracts were prepared using radioimmunoprecipitation assay (RIPA) buffer (25 
mM Tris-HCl [pH 7.5], 150 mM NaCl, 1% NP-40, 1% Na-deoxycholate [DOC], 0.1% 
SDS) containing 1 mM phenylmethylsulfonyl fluoride and protease inhibitors (Complete 
EDTA-Free tablets [Roche Applied Science]). Total extracts (50 μg) were resolved by 
SDS-PAGE (7.5%) and transferred to Hybond enhanced chemiluminescence (ECL) 
nitrocellulose membranes (GE Healthcare Life Sciences). To detect green fluorescent 
protein (GFP)-Ras1p, mouse anti-GFP antibodies (Roche Applied Science) (1:1,000 in 
Tris-buffered-saline-Tween [TBS-T]-5% nonfat milk) were used. Gsp1p protein levels, 
shown as a loading control, were detected using rabbit anti-Gsp1p antibodies (Belhumeur et 
al., 1993) (1:10,000 in TBS-T-5% nonfat milk) overnight at 4°C. Signals were detected 
using Lumi-Light Western Blotting Substrate (Roche Applied Science). 
 
2.3.7 Microarray data accession number 
Microarray data sets can be found at the Gene Expression Omnibus website 
(http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE25822. 
 
 
2.4 Results 
2.4.1 CLA inhibits hyphal growth in C. albicans in response to various 
hypha-inducing conditions 
CLA inhibits hyphal growth in C. albicans in response to various hypha-inducing 
conditions. Several fatty acids, including conjugated linoleic acid (CLA), were recently 
shown to inhibit Candida albicans germ tube formation in various hypha-inducing liquid 
media (Clement et al., 2007). We first assessed the inhibitory effect of CLA on hypha 
formation induced in different conditions using the C. albicans reporter strain HWP1p-lacZ 
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in which β-galactosidase activity reflects the amount of hyphal growth in cultures (Hogan 
et al., 2004). In Spider, Lee’s, and M199 (pH 8.0) media, CLA inhibited hyphal growth in a 
dose-dependent fashion, albeit to various extents (Figure 2.1A). In all media, 50 μM of the 
fatty acid reduced β-galactosidase activity by more than 80% compared to the level for 
ethanol-containing cultures, confirming that the presence of CLA impeded filamentation. In 
Spider medium supplemented with 25 μM CLA, cells grew as yeasts and short 
pseudohyphae, reflecting reduced β-galactosidase activity levels (Figure 2.1A and B). CLA 
also disrupted filamentation on solid media, being more effective in Spider medium (Figure 
2.1C). However, hyphal growth inhibition by CLA was medium-dependent. For instance, 
in RPMI 1640 and YPD-10% fetal bovine serum (FBS) liquid media, CLA inhibited 
filamentation, but effective concentrations tended to be higher (Clement et al., 2007; data 
not shown). In addition, CLA had no effect on hyphal growth induced on solid YPD-10% 
FBS, synthetic low ammonia dextrose (SLAD), or yeast nitrogen base (YNB) 
supplemented with N-acetylglucosamine or upon embedding of cells in yeast extract-
peptone (YP) medium (data not shown).  
 
Other fatty acids, such as oleic, linoleic, α- and γ-linolenic acids also modulated 
hyphal growth in C. albicans. Levels of β-galactosidase activity, as well as cellular and 
colony morphology, indicated that all fatty acids, like CLA, interfered to different extents 
with C. albicans hyphal growth induced under various conditions (data not shown). In 
addition, fatty acids, including CLA, inhibited filamentation in Candida tropicalis and 
Candida dubliniensis (data not shown), in Aspergillus fumigatus and in Fusarium 
graminearum (Clement et al., 2008); data not shown), suggesting the response to fatty 
acids and to CLA may be conserved among other fungi. 
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Figure 2. 1 Conjugated linoleic acid (CLA) inhibits hyphal growth in Candida albicans.  
(A) The effect of CLA on C. albicans hyphal growth was measured by using the C. albicans 
reporter strain ZK3379. Cells were induced to filament in Spider, Lee’s, and M199 (pH 8.0) media 
supplemented with CLA (0 to 50 μM) for 4 h at 37°C. β-galactosidase activity in CLA-treated 
cultures was measured and normalized to that of untreated cultures, in which β-galactosidase 
activity was set as 100%. Data are means and standard deviations of results from duplicate assays 
performed on three independent days. (B) Aliquots of cells grown in Spider medium in the absence 
or presence of 25 μM CLA for 4 h at 37°C were harvested and visualized at ×100 magnification 
using DIC optics. Bar = 10 μm. (C) Filamentous growth of C. albicans SC5314 was induced on 
solid media supplemented with ethanol or 100 μM CLA. Plates were incubated at 37°C for 3 to 4 
days.  
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2.4.2 CLA impedes germ tube formation without affecting cellular 
growth 
With the use of the HWP1p-lacZ strain and β-galactosidase quantification, CLA and 
other fatty acids were shown to abrogate, delay, or decrease the induction of HWP1 
promoter activity, indirectly suggesting that hyphal growth was impaired (Figure 2.1A) 
(Clement et al., 2007). To assess which step of the yeast-to-hypha transition was affected 
by CLA, we examined the morphology of cells induced to filament in Spider medium in the 
absence or presence of CLA. Untreated cells showed long germ tubes and/or very short 
filaments and long hyphae at the 1- and 3-h time points, respectively. At the same time 
points, most CLA-treated cells appeared as elongated yeasts or showed elongating buds that 
resembled germ tubes (Figure 2.2A). With the use of the criteria established by Sudbery et 
al. (2004), cells were stained with DAPI and calcofluor white and classified as yeast, 
pseudohyphae, or germ tubes/hyphae. As seen in Fig. 2B, 80-90% of untreated cells formed 
hyphae and pseudohyphae over the 3-h time course. In contrast, the majority (70 to 80%) of 
cells grown in the presence of CLA remained in the yeast form. While some CLA-treated 
cells did initiate germ tube formation, elongating filaments were not detected by the 3-h 
time point, indicating that these cells had resumed pseudohyphal and yeast growth modes. 
These findings suggest that CLA prevents germ tube formation and hyphal elongation from 
occurring. CLA also blocked hyphal elongation in cells that were already engaged in the 
hyphal growth program (data not shown).  
 
C. albicans filamentation can be inhibited by cytotoxic or cytostatic molecules 
(Toenjes et al., 2005). Since CLA interfered with hyphal growth, we assessed whether 
cellular growth rates at 30°C in Spider medium were affected by ethanol or CLA. In these 
conditions, germ tube formation is slightly induced at early time points (Figure 2.3A), but 
hyphal growth is not maintained and cells eventually resume budding growth (data not 
shown). The growth rates of untreated and CLA-treated cells were identical, suggesting that 
CLA does not inhibit hyphal growth by exerting cytotoxic or cytostatic effects (Figure 
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2.2C). Similar results were obtained for yeast cells grown in the absence or presence of 
CLA in YPD medium (data not shown).  
 
 
Figure 2. 2 CLA impedes germ tube formation of Candida albicans without affecting cellular 
growth.  
(A) C. albicans SC5314 cells were induced to filament in Spider medium at 37°C in the absence or 
presence of 25 μM CLA. Aliquots of cells were visualized as described for Figure 2.1B. Bar = 10 
μm. (B) Quantification of yeast, pseudohyphae, germ tubes (GT) and hyphae in C. albicans cultures 
shown in panel A. n was >150 for each condition and time point. (C) Yeast cells were grown as 
described for panel A at 30°C. OD600 was measured at various time points. Data are means and 
standard deviations of results from duplicate biological samples.   
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2.4.3 Gene expression analysis 
To gain further insight into the inhibitory effect of CLA on hyphal growth, we 
performed global gene expression profiling of cells grown in Spider medium in the absence 
or presence of CLA for 90 min. Transcriptional profiles of untreated cells at 37°C and 
CLA-treated cells at 37°C and 30°C were obtained by independently comparing the levels 
for each experimental condition, i.e., 37°C, 37°C with CLA, and 30°C with CLA, to those 
for the control condition, growth at 30°C. Each experiment was performed in 
quadruplicate: RNA was prepared from four independent biological replicates and used to 
perform four independent hybridizations (Figure 2.3A). Only genes that were modulated 2-
fold up or down with a P value <0.05 were deemed significantly differentially expressed. 
Data presented in Tables S1, S2, and S3 in the supplemental material show the 
transcriptional profiles of each experimental condition compared to the control condition. 
Transcriptional profiles of the experimental conditions were then compared to one another, 
i.e., 37°C versus 37°C with CLA and 30°C with CLA versus 37°C with CLA, resulting in 
two other transcriptional profiles (Table S4 and S5) and the scatter plots in Figure S1A. All 
significantly differentially expressed genes originating from the five transcriptional profiles 
generated were organized by hierarchical clustering, yielding a global transcriptional 
profile of 714 modulated transcripts (Table S6 and Figure S1B). The hierarchical clustering 
revealed that 61 genes were downregulated under all three experimental conditions (Figure 
S1B). Gene ontology (GO)-term analysis revealed these genes were involved in RNA 
metabolic processes, ribosome biogenesis, translation, and transcription, reflecting a 
repression of the translational machinery. These findings suggest that experimental growth 
conditions, i.e., 37°C and CLA treatment, are less favorable than control growth conditions, 
i.e., 30°C, and result in a metabolic decrease (Nantel et al., 2002). 
 
We first chose to investigate the transcriptional profile of cells grown in Spider 
medium at 37°C. Gene expression analysis showed that 520 genes were modulated upon 
growth at 37°C (see Table S1 in the supplemental material). Of those genes, 198 were 
upregulated while 322 were downregulated. Interestingly, ~30% of the upregulated genes 
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have been described as being induced during the yeast-to-hypha transition in Lee’s medium 
(Goyard et al., 2008) (Table S1). Hypha-specific genes such as ECE1, RBT1, IHD1, SOD5, 
HWP1, ALS3, and HGC1 were highly induced (Nantel et al., 2002, Goyard et al., 2008, 
Zheng & Wang, 2004). Genes involved in signal transduction including the GTPase RAS1, 
the adenylate cyclase CYR1, the mucin-like signaling protein gene MSB2, and the Rho1p 
GTPase-activating protein (GAP) gene BEM2, were also upregulated (Tables IV and S1). 
In addition, several transcription factors known to be involved in hyphal growth were 
among the 198 upregulated genes and included CPH1, CPH2, TEC1, BCR1, and UME6 
(Table IV). These transcription factors are components of the MAP kinase, the Ras1p-
cAMP-PKA, and the Tup1p-Nrg1p signaling pathways (Liu et al., 1994, Lane et al., 2001b, 
Lane et al., 2001a, Nobile & Mitchell, 2005, Kadosh & Johnson, 2005, Banerjee et al., 
2008, Zeidler et al., 2009), except CPH2, which appears to function independently of 
known signaling cascades (Lane et al., 2001b). Other upregulated genes encoded 
transcription factors Gat2p and Cas4p (Goyard et al., 2008) while orf19.6705 encodes a 
nucleotide exchange factor. Taken together, the transcriptional profile of cells grown at 
37°C suggests that several signaling pathways participate in orchestrating the hyphal 
growth program in Spider medium.  
 
Next, we examined the responses of cells to CLA at 30°C and 37°C. We had 
designed the microarray experiments to be able to distinguish between the transcriptional 
changes associated with morphological differences induced by growth at 37°C and those 
elicited specifically by the fatty acid. However, cultures of C. albicans grown in Spider at 
30°C still contained a significant number of pseudohyphal cells (Figure 2.3A), making it 
impossible to fully eliminate morphogenesis as a variable. Thus, transcriptional profiles of 
CLA’s effects at both temperatures turned out to be highly similar, as seen in the scatter 
plot (see Figure S1A in the supplemental material). Indeed, when the transcriptional 
profiles of CLA-treated cells at 37°C and those at 30°C were directly compared, only 33 
genes were differentially modulated (see Table S5 in the supplemental material), and many 
of these have previously been shown to be temperature regulated (Enjalbert et al., 2003).  
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Table IV Selected genes upregulated during the yeast-to-hypha transition in Spider medium 
Systematic 
name 
Gene 
name Function 
Fold-
change 
orf19.1187 CPH2 Transcriptional activator of hyphal growth 3.0 
orf19.6705  Putative guanyl nucleotide exchange factor with Sec7p domain 2.9 
orf19.4056 GAT2 Putative DNA-binding transcription factor 2.8 
orf19.5908 TEC1 TEA/ATTS transcription factor involved in regulation of hypha-specific genes 2.7 
orf19.1822 UME6 Transcription factor; required for wild-type hyphal extension 2.7 
orf19.1693 CAS4 Protein of RAM cell wall integrity signaling network; role in cell separation; required for hyphal growth 2.5 
orf19.723 BCR1 Transcription factor required for wild-type biofilm formation 2.3 
orf19.4433 CPH1 Transcription factor required for mating and hyphal growth on solid media 2.1 
orf19.5148 CYR1 Adenylate cyclase 2.0 
orf19.1760 RAS1 RAS signal transduction GTPase; regulates cAMP and MAP kinase pathways 2.1 
orf19.1490 MSB2 Mucin family member, possible sensor of cell wall damage 3.4 
orf19.6573 BEM2 Putative Rho1p GTPase-activating protein (GAP) 2.4 
 
 
We thus focused our functional analysis on the transcriptional profile of cells 
exposed to CLA at 37°C compared to cells grown at 30°C. CLA treatment resulted in the 
modulation of 296 transcripts (Table S2). One hundred fifty-five genes were upregulated 
while 141 were downregulated. GO-term analysis showed that upregulated genes belonged 
to the categories “unknown biological function” (31%), “response to chemical stimulus” 
(17.4%), “carbohydrate metabolic processes” (16.8%), and “lipid metabolic processes” 
(16.1%). Fatty acids are nonfermentable carbon sources which are converted to acetyl-
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coenzyme A (acetyl-CoA) by β-oxidation. Acetyl-CoA drives the glyoxylate cycle, 
yielding oxaloacetate, which is converted to glucose via gluconeogenesis. Transcript levels  
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Figure 2. 3 Expression levels of selected differentially expressed genes.  
(A) Transcriptional profiles of untreated cells at 37°C and CLA-treated cells at 37°C and 30°C were 
obtained by independently comparing the levels for each experimental condition, i.e., 37°C, 37°C 
with CLA and 30°C with CLA, to those for the control condition, growth at 30°C. Four biological 
replicates were used in each experiment, which included two Cy3/Cy5 and two Cy5/Cy3 
comparisons. Representative micrographs of cells used in the microarray experiments. Bar = 10 μm. 
Fold change values are shown for hypha-specific genes (B) and genes involved in signal 
transduction (C) in untreated and CLA-treated cells at 37°C. The significantly differentially 
expressed genes were obtained by comparing the transcriptional profile of cells at 37°C with that of 
CLA-treated cells at 37°C and are listed in Table S4 in the supplemental material. EtOH, ethanol. 
 
 
of hallmark genes of the β-oxidation (FAA21, POX1, PXP2, POX1-3, ECI1, POT1, FOX2, 
FOX3, PEX5, CAT2, and ANT1), glyoxylate (ICL1, MLS1, and MDH1-3), and 
gluconeogenesis (FBP1) pathways increased in the presence of CLA, which may reflect a 
flow of carbon from fatty acids to acetyl-CoA to glucose. Most of these genes have been 
described as being induced upon internalization of C. albicans by macrophages (Lorenz et 
al., 2004) or by oleic acid (Ramirez & Lorenz, 2009). Genes encoding glycolytic enzymes, 
including PGK1, PGI1, and FBA1, were also upregulated in the presence of CLA, which 
may suggest that both glycolysis and gluconeogenesis are occurring simultaneously. In 
addition, a group of genes involved in transport (15.5%), including TPO4, PDR16, CDR11, 
CDR4, RTA3, and FLU1, were upregulated in the presence of CLA. These genes encode 
transmembrane transporters which play roles in phospholipid, fatty acid, or drug 
transmembrane transport. 
 
To address the mechanism of action of CLA, we compared the transcriptional 
profiles of cells grown in the absence or presence of CLA at 37°C. Gene expression 
analysis revealed that 150 genes were significantly differentially expressed (see Table S4 in 
the supplemental material). To facilitate data mining, fold change ratios were generated by 
normalizing data obtained for CLA-treated cells to that obtained for untreated cells, 
resulting in 72 and 78 genes with upregulated (>2-fold) and downregulated (<0.5-fold) fold 
change ratios, respectively (Table S4). GO-term analysis revealed the subset of 72 CLA-
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upregulated genes was enriched in genes implicated in “lipid metabolic processes” (27.4%) 
and “transport” (15.1%). Most of the genes involved in transmembrane transport, fatty acid 
β-oxidation and peroxisome biogenesis, the glyoxylate cycle, and gluconeogenesis were 
among the genes induced in CLA-treated cells (Table S2) discussed in the previous section. 
Because cells may be metabolizing CLA and converting it to glucose, we examined 
whether the CLA-mediated inhibition of hyphal growth was linked to fatty acid 
metabolism. To do so, we analyzed the effect of CLA on filamentation of the fox2/fox2, 
icl1/icl1, and ctf1/ctf1 mutant strains, which filament normally, but cannot assimilate fatty 
acids (Ramirez & Lorenz, 2007, Ramirez & Lorenz, 2009). CLA inhibited hyphal growth 
in all three strains, suggesting that fatty acid metabolism is not involved in the inhibition of 
filamentation (data not shown).  
 
Given that lipid metabolism was not impeding hyphal growth, we focused on the 
subset of 78 CLA-downregulated genes (see Table S4 in the supplemental material). GO-
term analysis showed that genes involved in “filamentous growth” (20.8%) and 
“pathogenesis” (16.9%) were among the subset of CLA-downregulated genes. Indeed, 
expression levels of hypha-specific genes, including HWP1, ALS3, RBT1, ECE1, HGC1, 
IHD1, HYR1, SAP5, and SOD5, were greatly reduced in CLA-treated cells compared to the 
levels for untreated cells (Figure 2.3B and Table S4). CLA also blocked the induction of 
transcription factors involved in hyphal growth, such as GAT2, UME6, TEC1, and RFG1 
(Figure 2.3C). A smaller (5.2%) yet more interesting category of CLA-downregulated 
transcripts was enriched in genes involved in signal transduction, such as RAS1, BEM2, 
MSB2, and PTP3 (Figure 2.3C). As seen in Table III, transcript levels of these genes 
increased during the yeast-to-hypha transition, except for PTP3 (Table S4). CLA either 
prevented the induction or lowered the induction levels of RAS1, BEM2, and MSB2. As for 
PTP3, which encodes a protein tyrosine phosphatase, its transcript levels were repressed in 
CLA-treated cells (Figure 2.3C and Table S4). Taken together, the transcriptional data 
suggest that CLA negatively affects the expression of hypha-specific genes as well as genes 
known to regulate the yeast-to-hypha transition. 
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2.4.4 UME6 and RFG1 are not required for CLA-mediated inhibition of 
hyphal growth 
Gene expression analysis revealed that CLA reduced the expression levels of genes 
encoding regulators of hyphal growth, including TEC1, UME6, RFG1, and RAS1 (Figure 
2.3C). To determine whether these regulators were required for CLA’s effect on hypha 
formation, we examined the responses of ume6/ume6 and rfg1/rfg1 mutant strains to CLA 
when induced to filament in Spider medium at 37°C. As seen in Figure 2.4, CLA inhibited 
hyphal growth in all parental strains. Interestingly, CLA inhibited filamentation 
independently of UME6 and RFG1, indicating that neither gene is required for CLA’s 
inhibitory effect on hyphal growth (Figure 2.4). The ras1/ras1 and tec1/tec1 mutants could 
not be analyzed in a similar fashion, since these strains failed to filament in Spider medium 
as previously reported (our observations; Leberer et al., 2001, Homann et al., 2009, Zhu et 
al., 2009). 
 
Figure 2. 4 UME6 and RFG1 are not required for CLA-mediated hyphal growth inhibition.  
The DK318, CAI4, ume6/ume6 (DK312), and rfg1/rfg1 (DK129) strains were grown in Spider 
medium at 37°C in the absence or presence of 25 μM CLA for 4 h. Cells were visualized as 
described for Figure 2.1B. Bar = 10 μm.  
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2.4.5 CLA downregulates TEC1 expression in a Ras1p-dependent 
manner 
Based on the previous screen, morphogenesis regulators potentially mediating 
CLA’s effect on hyphal growth were narrowed down to Ras1p and Tec1p, since both were 
required for filamentation in Spider medium (data not shown). In its active GTP-bound 
form, Ras1p activates the adenylate cyclase Cyr1p, stimulating the cyclization of ATP to 
cAMP (Fang & Wang, 2006). Upon binding cAMP, Bcy1p, the regulatory subunit of PKA, 
releases the functionally redundant catalytic subunits Tpk1p and Tpk2p, thereby enabling 
their activity (Cassola et al., 2004). The transcription factor Efg1p, an important regulator 
of hyphal growth, is a downstream target of PKA (Bockmuhl & Ernst, 2001). In addition, 
Efg1p also regulates TEC1 expression (Lane et al., 2001a). Thus, Tec1p constitutes a 
downstream target of the Ras1p-cAMP-PKA pathway. 
 
Gene expression analysis showed that CLA reduced TEC1 expression levels (Figure 
2.3C). Given that TEC1 is induced upon the yeast-to-hypha transition, we examined how 
CLA affected the kinetics of expression of TEC1. We performed a time course analysis of 
TEC1 transcript levels in cells grown in Spider medium in the absence or presence of CLA. 
As expected, TEC1 expression was induced in untreated cells during the yeast-to-hypha 
transition (Figure 2.5A). In contrast, TEC1 mRNA levels were downregulated by an 
average of 5-fold in CLA-treated cells compared to the level for untreated cells, thus 
confirming transcriptional profiling results. Similar trends were also observed with the use 
of quantitative PCR analysis (data not shown). Furthermore, Tec1p protein levels were 
reduced in the presence of CLA, thus following the same expression pattern as the TEC1 
transcript (data not shown). 
 
A possible role for the Ras1p-cAMP-PKA signaling pathway in mediating CLA’s 
effect on TEC1 expression was then investigated. Northern blot analysis revealed that in 
Spider medium, TEC1 induction was mostly Ras1p-dependent (Figure 2.5B and C). 
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Interestingly, the effect of CLA on TEC1 expression was reduced in the absence of RAS1. 
In the parental strain, TEC1 transcript levels decreased by ~10-fold in CLA-treated cells 
compared to the level for untreated cells, while in the ras1/ras1 mutant strain, the 
downregulation only reached 1.5-fold (Figure 2.5C). On the other hand, TEC1 induction in 
Spider medium and its downregulation by CLA did not depend on the presence of either 
TPK1 or TPK2 (Figure 2.5B and C). These results may be explained by the functional 
redundancy of the two PKA isoforms (Bockmuhl et al., 2001). Since Efg1p is a regulator of 
TEC1 expression, we examined its role in mediating CLA’s effect on TEC1 mRNA levels. 
Northern analysis revealed that TEC1 induction in Spider medium depended partially on 
EFG1, as TEC1 transcript levels were 1.7-fold lower in the efg1/efg1 mutant strain 
compared to the parental strain (Figure 2.5B and C). However, EFG1 was not required for 
CLA’s repressive effect on TEC1, as the magnitudes of TEC1 downregulation by CLA (~2-
fold) were similar in parental and mutant strains (Figure 2.5C). Additionally, it should be 
noted that CLA did not modulate EFG1 mRNA and protein levels (data not shown). Taken 
together, these results implicate RAS1, but not TPK1, TPK2, or EFG1, in mediating CLA’s 
repressive effect on TEC1 expression. 
 
2.4.6 CLA reduces GFP-Ras1p protein levels and affects its localization 
Transcriptional profiling showed that RAS1 expression was upregulated 2.1-fold 
during the yeast-to-hypha transition but that it was not induced in CLA-treated cells (Figure 
2.3C). We examined CLA’s effect on RAS1 transcription at earlier time points by 
performing a time course analysis of RAS1 mRNA levels in cells grown in Spider medium 
in the absence or presence of CLA. Quantitative PCR analysis revealed that RAS1 transcript 
levels increased in untreated cells by an average of 2.7-fold, confirming results obtained by 
gene expression analysis (Figure 2.6A). On the other hand, CLA completely abrogated 
RAS1 induction, as its mRNA levels remained relatively unchanged compared to levels at 
the zero time point (Figure 2.6A). We next investigated CLA’s effect on Ras1p protein 
levels and localization using the WY-ZXD3 strain expressing a GFP-Ras1 fusion protein  
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Figure 2. 5 TEC1 downregulation by CLA is Ras1p-dependent.  
(A) Quantitative Northern blot analysis was used to examine the kinetics of expression of TEC1 in 
SC5314 cells grown in Spider medium at 37°C in the absence or presence of 100 μM CLA. TEC1 
transcript levels were quantified and normalized to those for the ACT1 loading control. Ratios were 
obtained by normalizing TEC1 transcript levels to those for untreated cells at the 30-min time point, 
which were set as 100%. (B) TEC1 expression levels in the parental, ras1/ras1 (CDH107), 
tpk1/tpk1 (IIHB6), tpk2/tpk2 (TPO7.4), and efg1/efg1 (HLC52) strains grown as described for panel 
A for 90 min. TEC1 transcript levels were quantified and normalized to those for the ACT1 loading 
control. (C) Data presented are the relative TEC1 expression levels obtained by normalizing TEC1 
transcript levels to those for parental untreated cells, which were set as 100%. Data are means and 
standard deviations of results from two independent hybridizations performed on duplicate 
biological samples. A single hybridization was performed using RNA isolated from the CAI4 and 
efg1/efg1 strains.   
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previously developed for similar analyses (Zhu et al., 2009). We monitored GFP-Ras1p 
cellular levels in cells induced to filament in Spider medium in the absence or presence of 
CLA. In untreated cells, GFP-Ras1p levels increased gradually, as did its mRNA levels 
(Figure 2.6B). Unexpectedly, in CLA-treated cells, GFP-Ras1p levels declined with time, 
as seen at the 90-min time point (Figure 2.6B). Thus, GFP-Ras1p did not follow the same 
pattern as its transcript which remained constant (Figure 2.6A). Taken together, these 
results suggest that CLA treatment reduces the steady-state levels of GFP-Ras1p.  
 
We then examined GFP-Ras1p localization in untreated and CLA-treated cells. To 
facilitate comparisons, we examined GFP-Ras1p in yeast cells grown in Spider medium in 
the absence or presence of CLA at 30°C. Under such conditions, GFP-Ras1p expression 
patterns were identical to those at 37°C, arguing that CLA’s effect on GFP-Ras1p levels 
was not temperature dependent (data not shown). As seen in Figure 2.6C (top panel), 
untreated cells demonstrated a strong fluorescent signal at the plasma membrane, 
confirming previous observations (Zhu et al., 2009). Additionally, GFP-Ras1p could be 
seen in punctate patches within cells, especially at the 30-min time point. In contrast, GFP-
Ras1p could barely be detected at the plasma membrane in CLA-treated cells. Instead, the 
fluorescent signal appeared diffuse throughout the cytoplasm or concentrated in patches 
within cells (Figure 2.6C). Moreover, the “patch” phenotype was maintained, becoming 
more obvious at later time points (data not shown). These findings indicate that CLA 
causes the delocalization of GFP-Ras1p from the plasma membrane. 
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Figure 2. 6 CLA reduces GFP-Ras1p protein levels and affects its localization.  
(A) SC5314 cells were grown in Spider medium at 37°C in the absence or presence of 25 μM CLA 
and harvested at the indicated time points. Transcript levels of RAS1 were measured by quantitative 
PCR and normalized to those for ACT1. Relative expression levels were obtained by normalizing 
data for each time point to data obtained at time zero. Data are means and standard deviations for 
duplicate biological samples. (B) Ras1p protein levels were analyzed using a strain expressing GFP-
Ras1p. Total protein extracts were prepared from SC5314 (mock) and GFP-Ras1p (WY-ZXD3) 
strains grown as described for panel A in the absence or presence of 100 μM CLA. Western blotting 
analysis was performed using anti-GFP antibodies. Gsp1p, shown as a loading control, was detected 
using antibodies raised against S. cerevisiae Gsp1p. Molecular masses (kDa) are indicated on the 
left. (C) GFP-Ras1p-expressing cells were grown in Spider medium at 30°C in the absence or 
presence of 100 μM CLA. Aliquots of cells were removed and examined directly at ×100 
magnification using epifluorescence. 
 
 
2.4.7 CLA affects the Tup1p-Nrg1p signaling pathway 
CLA affects the Tup1p-Nrg1p signaling pathway. It has been established that the 
MAP kinase, Ras1p-cAMP-PKA, and Tup1p-Nrg1p signaling pathways make independent 
contributions to filamentation (Braun & Johnson, 2000). The hyphal growth repressor 
Tup1p functions with the DNA-binding proteins Nrg1p and Rfg1p to negatively regulate 
hyphal growth and hyphal gene expression (Braun & Johnson, 1997, Braun et al., 2001, 
Murad et al., 2001, Khalaf & Zitomer, 2001, Kadosh & Johnson, 2001). Given that Tup1p 
and Nrg1p are involved in mediating the inhibitory effect of farnesol on filamentation 
(Kebaara et al., 2008), their role in the CLA-mediated hyphal growth inhibition was then 
investigated. We examined the responses of tup1/tup1 and nrg1/nrg1 mutant strains to CLA 
when induced to filament in Spider medium at 37°C. While CLA inhibited hyphal growth 
in the parental strain CAI4, tup1/tup1 and nrg1/nrg1 mutant strains remained filamentous, 
even when higher CLA concentrations were used (Figure 2.7A). This indicates that CLA, 
like farnesol, inhibits filamentation by affecting a pathway requiring Tup1p and Nrg1p.  
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Figure 2. 7 CLA affects the Tup1p-Nrg1p signaling pathway.  
(A) The CAI4, tup1/tup1 (BCa2-10), and nrg1/nrg1 (BCa23-3) strains were grown in Spider 
medium at 37°C in the absence or presence of 25 μM CLA for 4 h. Aliquots of cells were harvested 
and visualized at ×100 magnification by DIC optics. Bar = 10 μm. (B) C. albicans SC5314 cells 
were grown as described for panel A and harvested at the indicated time points. Transcript levels of 
TUP1 and NRG1 were measured as described for Figure 2.6A. 
 
 
TUP1 and NRG1 are modulated at the transcriptional level upon the yeast-to-hypha 
transition (Kebaara et al., 2008, Braun et al., 2001). According to transcriptional profiling, 
TUP1 and NRG1 were not significantly differentially expressed in response to CLA, but 
this could be due to their low expression levels. Thus, we assessed how CLA affected the 
kinetics of expression of TUP1 and NRG1. Quantitative PCR revealed that TUP1 and 
NRG1 transcript levels decreased by ~2-fold during the 90-min time course in untreated 
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cells (Figure 2.7B). In contrast, CLA prevented the downregulation of both repressors, as 
TUP1 and NRG1 mRNA levels remained unchanged compared to initial levels. These 
findings suggest that CLA may inhibit hyphal growth by preventing the relief of repression 
exerted by the Tup1p-Nrg1p pathway. 
 
 
2.5 Discussion 
While efforts have been put forth to elucidate the molecular mechanisms underlying 
the yeast-to-hypha transition in Candida albicans, small molecules affecting the 
morphogenetic switch have been identified in concurrent studies. Our findings have 
enabled us to add CLA to the growing list of molecules that modulate hyphal growth, 
which includes farnesol, dodecanol, fatty acids and lipid metabolites, rapamycin, and 
geldanamycin as well as histone deacetylase inhibitors (Hornby et al., 2001, Davis-Hanna 
et al., 2008, Kebaara et al., 2008, Clement et al., 2007, Noverr & Huffnagle, 2004, Murzyn 
et al., 2010, Bastidas et al., 2009, Shapiro et al., 2009, Hnisz et al., 2010). CLA was 
effective at inhibiting hyphal growth in most hypha-inducing media (Figure 2.1). However, 
its inhibitory activity was significantly reduced in media containing FBS or N-
acetylglucosamine, in RPMI 1640, or upon embedding of cells in YP medium (data not 
shown). The medium-dependent inhibitory effect of CLA on hyphal growth may be due to 
the nature or robustness of hypha-inducing signals, to the enhanced growth capacity of 
nutritionally rich media (Nantel et al., 2002, Toenjes et al., 2005), to the nonspecific lipid-
binding capacity of serum albumin in FBS (Langford et al., 2009), or to the poor solubility 
of CLA in aqueous media (Ramirez & Lorenz, 2009).  
 
Is CLA directly inhibiting filamentation or is this effect mediated by one of its 
metabolites? Fatty acids are nonfermentable carbon sources metabolized by C. albicans to 
acetyl-CoA and to glucose via β-oxidation, the glyoxylate cycle, and gluconeogenesis 
(Lorenz et al., 2004). Hallmark genes of these three biochemical pathways were 
upregulated in CLA-treated cells (see Table S2 to S4 in the supplemental material), 
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suggesting CLA was possibly being converted to glucose. We ruled out that fatty acid 
metabolism was involved in the CLA-mediated hyphal growth inhibition by confirming 
that CLA blocked filamentation of the fox2/fox2, icl1/icl1, and ctf1/ctf1 mutant strains, 
which are unable to metabolize fatty acids (Ramirez & Lorenz, 2007, Ramirez & Lorenz, 
2009) (data not shown). However, fatty acids are not only metabolized via β-oxidation, 
they can also be derived into oxygenated lipid metabolites. In C. albicans, arachidonic acid 
was shown to be a precursor for the production of 3,18-dihydroxy-5,8,11,14-
eicosatetraenoic acid (3,18-diHETE), an eicosanoid found exclusively in hyphae which was 
suggested to play a role in morphogenesis (Deva et al., 2000). Fatty acids such as linoleic 
and arachidonic acids are also derived into prostaglandins and leukotrienes which 
reportedly affect hyphal development (Noverr et al., 2003, Erb-Downward & Noverr, 
2007). Indeed, prostaglandin E2 and thromboxane B2 were shown to enhance the yeast-to-
hypha transition (Kalo-Klein & Witkin, 1990, Noverr et al., 2001, Noverr & Huffnagle, 
2004). Thus, while our results demonstrate that molecules derived from CLA’s metabolism 
played no role in the CLA-mediated hyphal growth inhibition, we cannot exclude the 
possibility that oxygenated CLA derivatives may be involved in the effect. 
 
We used global gene expression profiling as a means to investigate the 
transcriptional profile of cells induced to filament in presence of CLA. Temperature shift in 
Spider medium promotes a hyphal growth program similar to the one induced upon 
filamentation in Lee’s medium (see Table S1 in the supplemental material) (Goyard et al., 
2008). Both Spider and Lee’s media have similar compositions, containing a source of 
fermentable carbon (mannitol or glucose), various amino acids, and salts, which may 
explain why both transcriptional profiles were similar. Transcript levels of hypha-specific 
genes, such as ECE1, ALS3, and HYR1 and of several key regulators of hyphal growth, 
including CPH1, CPH2, TEC1, BCR1, UME6, GAT2, RAS1, and CYR1, increased during 
filamentation in Spider (Tables III and S1). However, the induction levels of several of 
these genes were lower than in other studies (Nantel et al., 2002, Goyard et al., 2008). This 
discrepancy may have been due to hypha-inducing signals being weaker in Spider medium 
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or to filamentation being somewhat induced in our control condition (Figure 2.3A). 
Nonetheless, the transcriptional data indicated roles for the Ras1p-cAMP-PKA, the MAP 
kinase, the CPH2-TEC1 and the Tup1p-Nrg1p signaling pathways. These results confirmed 
that hyphal growth in Spider medium is regulated by a network of known signaling 
pathways which are activated simultaneously and converge (or do not converge) onto many 
of the same target transcription factors (Braun & Johnson, 2000, Biswas et al., 2007, 
Brown et al., 2007b). 
 
Comparing the transcriptional profiles of untreated and CLA-treated cells revealed 
that CLA affected the expression of genes encoding signal transducers and transcription 
factors, including RAS1, TEC1, UME6, and RFG1 (Figure 2.3C). We examined CLA’s 
effect on hyphal growth in strains deleted for each of these genes and showed that UME6 
and RFG1 were dispensable for CLA-mediated inhibition of filamentation (Figure 2.4). 
Similar conclusions for RAS1 and TEC1 could not be drawn, as both genes are required for 
hyphal growth in Spider medium (our observations and references (Leberer et al., 2001, 
Homann et al., 2009, Zhu et al., 2009). Given that TEC1 lies downstream of the Ras1p-
cAMP-PKA signaling pathway, we showed that CLA decreased TEC1 expression levels in 
a mostly Ras1p-dependent manner (Figure 2.5B and C). Unexpectedly, while TEC1 
induction was partially Efg1p-dependent, CLA downregulated TEC1 mRNA levels 
independently of EFG1 (Figure 2.5B). These results demonstrated that CLA inhibited 
filamentation by affecting the Efg1p-independent branch of the Ras1p signaling pathway. 
Likewise, the Hsp90p inhibitor geldanamycin was shown to modulate hyphal growth by 
affecting the Ras1p-cAMP-PKA signaling pathway independently of Efg1p (Shapiro et al., 
2009). 
 
Transcriptional profiling further revealed that CLA affected RAS1 expression 
(Figure 2.3C). Indeed, CLA blocked the increase in RAS1 transcript levels which occurred 
upon the yeast-to-hypha transition (Figure 2.6A). Quite unexpectedly, while RAS1 mRNA 
levels remained constant in CLA-treated cells, GFP-Ras1p levels declined gradually 
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(Figure 2.6B). CLA also affected localization of GFP-Ras1p to the plasma membrane 
(Figure 2.6C). Decreased GFP-Ras1p levels could be due to a decrease in its mRNA 
translation or to its degradation. However, several lines of evidence indicate that Ras 
delocalization results in its degradation and ultimately reduces its cellular levels. For 
instance, in Saccharomyces cerevisiae, a mutant Ras2p protein that could not be targeted to 
the membrane had lower cellular levels compared to the wild-type protein (Deschenes & 
Broach, 1987). Furthermore, farnesylthiosalicylic acid treatment was shown to dislodge 
Ras from the membrane and induce its degradation, resulting in lower Ras levels (Haklai et 
al., 1998). In light of our findings, we can only speculate that reduced GFP-Ras1p steady-
state levels seen in CLA-treated cells stem from the protein being delocalized from the 
plasma membrane. 
 
Several reasons may account for CLA’s effect on GFP-Ras1p localization. First, the 
fatty acid may interfere with the posttranslational modifications of GFP-Ras1p. Ras 
proteins are modified by the addition of C-terminal lipids, such as farnesyl and palmitoyl 
moieties (Wennerberg et al., 2005). Such modifications are involved in membrane 
association and subcellular localization which are critical for Ras biological activities. 
Posttranslational modifications of Ras also play a role in filamentation in C. albicans, as 
compounds that prevent Ras prenylation were shown to inhibit hyphal growth (McGeady et 
al., 2002). Second, CLA may also affect GFP-Ras1p localization by modifying the lipid 
composition of membranes. By being incorporated into membrane phospholipids, 
unsaturated fatty acids such as CLA may alter membrane structure and function, 
influencing the interaction of resident proteins with the plasma membrane (Chapkin et al., 
2008). For instance, the polyunsaturated fatty acid docosahexaenoic acid (DHA) was 
shown to decrease membrane association of Ras by weakening its interactions with 
phospholipid acyl chains (Collett et al., 2001, Seo et al., 2006). Interestingly, DHA also 
affected GFP-Ras1p localization to the plasma membrane in C. albicans (data not shown). 
The upregulation of RTA3 transcript levels in CLA-treated cells may be genetic evidence 
that the fatty acid is modifying membrane lipid composition (see Table S2 to S4 in the 
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supplemental material). Indeed, the S. cerevisiae RTA3 homologue (RSB1) was shown to be 
induced when plasma membrane glycerophospholipid asymmetry was altered (Ikeda et al., 
2008). Nonetheless, further studies are warranted to address the underlying mechanism by 
which CLA exerts its effect on GFP-Ras1p membrane localization. 
 
The biological activity of Ras is dictated by its subcellular localization. In S. 
cerevisiae, the farnesylated, membrane-bound form of Ras2p is approximately 100-times 
more effective in activating adenylate cyclase than its cytoplasmic form (Kuroda et al., 
1993). Thus, it is tempting to suggest that CLA modulates the Ras1p signaling pathway by 
affecting the localization of Ras1p to the plasma membrane (Figure 2.6C) and by 
abrogating the increases in RAS1 mRNA and protein levels (Figure 2.6A and B). CLA 
would prevent the activation of the Ras1p pathway, resulting in the downregulation of 
TEC1 expression levels and inhibiting hyphal growth in C. albicans (Figure 2.8). 
Additionally, CLA may also inhibit hyphal growth by preventing the relief of repression 
exerted by the Tup1p-Nrg1p pathway (Figure 2.7B). Because the hyphal growth program is 
controlled by a network of signaling pathways, we expect the effect of CLA, like that of 
farnesol, to be multifactorial, in that the fatty acid could affect more than one signaling 
pathway (Langford et al., 2009). Nonetheless, our findings that CLA modulates RAS1 
mRNA and protein levels in C. albicans demonstrate the broad spectrum therapeutic 
properties of CLA, as the Ras pathway regulates filamentous growth and virulence in other 
fungi (D'Souza & Heitman, 2001). 
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Figure 2. 8 Proposed model underlying the mechanism by which CLA inhibits hyphal growth in 
Candida albicans.  
CLA inhibits the increase in RAS1 mRNA and protein levels and affects Ras1p membrane 
localization. Combined, these CLA-mediated effects impede the activation of the Ras1 signaling 
pathway and ultimately downregulate TEC1 expression and inhibit hyphal growth. In addition, CLA 
inhibits hyphal growth by preventing the relief of repression exerted by the Tup1p-Nrg1p complex. 
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Figure S 1 Transcriptional profiles of CLA-treated cells.  
(A) Scatter plots comparing pairs of transcriptional profiles. Genes with a statistically-significant 
change in transcript abundance are colored as indicated in the Venn diagram. (B) Hierarchical 
clustering of 689 genes with a statistically-significant change in transcript abundance (fold change > 
2, p-value < 0.05) in cells grown at 37°C, or cells treated with CLA at 30°C or 37°C compared with 
control cells grown in Spider medium at 30°C. Also included are an additional 25 genes that show 
significant differences when pairs of profiles are directly compared to each other. Upregulated 
genes are colored in red while downregulated genes are colored in green.   
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albicans by various small molecules 
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The yeast-to-hypha transition is a virulence factor in Candida albicans, and thus 
may constitute a target for the development of antifungal agents. A number of small 
molecules have been reported to modulate morphogenesis. These molecules are believed to 
harbor a therapeutic potential as they target a virulence trait of the pathogenic yeast. In this 
chapter, the literature pertaining to the modulation of morphogenesis by small molecules is 
reviewed; experimental findings regarding the modes of action and therapeutic properties 
of several small molecules are also addressed. After collating and examining data from 
relevant studies, we discuss whether or not modulating the yeast-to-hypha transition 
constitutes a strategy to treat Candida infections. The content of this chapter has been 
published in an article entitled “Modulation of morphogenesis in Candida albicans by 
various small molecules” in the scientific journal Eukaryotic Cell in 2011 (Shareck J. & 
Belhumeur P.). 
 
 
 
Contribution: I chose to write a short review on this topic. I researched the literature, 
collated the data, and wrote the manuscript, which Belhumeur corrected. I estimate my 
contribution to being close to 95%.  
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3.1 Abstract 
The pathogenic yeast Candida albicans, a member of the mucosal microbiota, is 
responsible for a large spectrum of infections, ranging from benign thrush and 
vulvovaginitis in both healthy and immunocompromised individuals to severe, life-
threatening infections in immunocompromised patients. A striking feature of C. albicans is 
its ability to grow as budding yeast and as filamentous forms, including hyphae and 
pseudohyphae. The yeast-to-hypha transition contributes to the overall virulence of C. 
albicans and may even constitute a target for the development of antifungal drugs. Indeed, 
impairing morphogenesis in C. albicans has been shown to be a means to treat candidiasis. 
Additionally, a large number of small molecules such as farnesol, fatty acids, rapamycin, 
geldanamycin, histone deacetylase inhibitors, and cell cycle inhibitors have been reported 
to modulate the yeast-to-hypha transition in C. albicans. In this review, we take a look at 
molecules that modulate morphogenesis in this pathogenic yeast. When possible, we 
address experimental findings regarding their mechanisms of action and their therapeutic 
potential. We discuss whether or not modulating morphogenesis constitutes a strategy to 
treat Candida infections. 
 
 
3.2 Introduction 
Candida albicans, a member of the endogenous human microflora, is the most 
common human fungal pathogen. In healthy individuals, outgrowth of C. albicans results in 
superficial mycoses of the skin, nails, and mucous membranes (thrush and vulvovaginitis). 
However, in individuals with immune deficiencies caused by underlying disease, 
chemotherapy treatment, or immunosuppression following a transplantation, C. albicans 
can cause severe, life-threatening invasive candidiasis. C. albicans now ranks as the fourth 
leading cause of nosocomial infections and is the most common fungal species causing 
bloodstream infections, with associated mortality rates of 38 to 49% (Horn et al., 2009; 
Miceli et al., 2011; Pfaller & Diekema, 2007; Wisplinghoff et al., 2004). Antifungal drugs 
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currently used for the treatment of Candida infections include polyenes, azoles, 
echinocandins, allyamines, and flucytosine. These drugs exert either fungicidal or 
fungistatic activities by interfering with essential processes (Odds et al., 2003). Intensive 
prophylactic and therapeutic uses of antifungals have selected for drug-resistant strains 
(Anderson, 2005; Cowen et al., 2002; Sanglard & White, 2007). Moreover, the limited 
arsenal of antifungal drugs is further compromised by severe side effects in patients and the 
emergence of species refractory to conventionally used agents (Miceli et al., 2011). There 
is a need to develop new antifungals and to explore novel therapeutic approaches to treat 
Candida infections. 
 
C. albicans has the ability to grow in a variety of morphological forms, including as 
budding yeast, pseudohyphae, and true hyphae (Sudbery et al., 2004). The transition from 
yeast growth to hyphal growth is induced by a variety of environmental cues reflecting host 
conditions (temperature of 37°C, neutral or alkaline pH, or presence of serum) which 
activate a complex network of signaling pathways (Biswas et al., 2007; Brown et al., 2007; 
Ernst, 2000; Whiteway & Bachewich, 2007). Although recent findings have demonstrated 
that the yeast-to-hypha (Y-H) transition is not always required for virulence in systemic 
candidiasis (Noble et al., 2010), morphogenesis still belongs to the realm of C. albicans 
virulence factors as demonstrated by several lines of evidence, the first being that strains 
defective in morphogenesis are attenuated in virulence in systemic candidiasis (Lo et al., 
1997; Saville et al., 2003; Zheng & Wang, 2004). In addition, hyphal development is 
necessary for C. albicans to evade phagocytes (Lorenz et al., 2004), to escape from blood 
vessels (Phan et al., 2000), and to colonize medical devices by forming biofilms (Nobile & 
Mitchell, 2005; Nobile et al., 2006). Moreover, both yeast and hyphal cells are found in C. 
albicans-infected organs (Odds, 1988). Thus, morphogenesis contributes to the overall 
virulence of C. albicans. 
 
To widen the repertoire of antifungal drugs, targets that differ from those of 
conventional drugs have to be identified. Recently, targeting virulence rather than essential 
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processes has been postulated as a new paradigm for the development of antifungal agents, 
following the successful development of drugs targeting bacterial virulence in antimicrobial 
therapy (Alksne & Projan, 2000; Calugi et al., 2011; Gauwerky et al., 2009). Thus, instead 
of being killed, a pathogen is maintained in a harmless form by blocking virulence 
attributes that contribute to its pathogenicity. Moreover, resistance to drugs that target 
virulence instead of growth is less likely to develop, given that selective pressure is reduced 
on non-essential targets that are required only to colonize host environments (Jiang et al., 
2002). In C. albicans, virulence factors that are eligible as targets for the development of 
new antifungal drugs have been reviewed recently and include secreted aspartic proteases, 
phospholipases, calcineurin, inositol phosphoryl ceramide synthase, and elastase (Calugi et 
al., 2011; Gauwerky et al., 2009).  
 
Given that morphogenesis is a virulence factor of C. albicans, it may also constitute 
a target for the development of antifungal drugs. Indeed, impairing morphogenesis has been 
shown to be a means to treat candidiasis. Using the tet-NRG1 strain, which can be induced 
to filament when doxycycline is added to the drinking water of animals, studies have 
demonstrated that inhibiting filamentation attenuated virulence in a model of systemic 
candidiasis and served as an effective therapeutic intervention (Saville et al., 2003; Saville 
et al., 2006). Concurrently, numerous molecules have been reported to modulate the Y-H 
transition in C. albicans. These molecules may harbor interesting therapeutic properties, 
given that they target a virulence factor. In addition, they are in line with the current trend 
in antifungal drug development and may constitute novel antifungal agents, which are 
required to remedy antifungal drug resistance problems and to enhance the arnesal of 
antifungal agents. In this review, we research the literature in an attempt to list the 
molecules reported to influence morphogenesis in C. albicans, while focusing on studies 
that have addressed the modes of action of specific molecules. When possible, we review 
experimental findings regarding their effects on C. albicans infections. We discuss whether 
or not modulating morphogenesis constitutes a strategy to treat Candida infections. 
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3.3 Farnesol 
Farnesol, a 15-carbon oxygenated lipid made up of isoprene moieties, was the first 
quorum sensing (QS) molecule to be identified in eukaryotes (Hornby et al., 2001). 
Secreted by a number of Candida laboratory strains and clinical isolates, farnesol inhibits 
the Y-H transition in C. albicans (Hornby et al., 2001; Hornby & Nickerson, 2004). The 
QS molecule is active at blocking hyphal growth induced by a variety of morphogenetic 
cues such as serum and N-acetylglucosamine (Mosel et al., 2005). Moreover, farnesol 
affects various developmental processes in other Candida spp. and in pathogenic fungi 
including Aspergillus spp., Fusarium graminearum, and Paracoccidiodes brasiliensis 
(reviewed in Langford et al. 2009). 
 
Findings regarding farnesol’s repressive effects on filamentation and its mode of 
action have been reviewed extensively (Cottier & Muhlschlegel, 2009; Hogan, 2006; 
Kruppa, 2009; Langford et al., 2009; Nickerson et al., 2006). To gain insight into the 
response of C. albicans to farnesol, global gene expression analyses were performed (Cao 
et al., 2005; Cho et al., 2007; Enjalbert & Whiteway, 2005; Sato et al., 2004). Although 
experimental approaches varied from one study to another, farnesol commonly affected the 
expression of genes that belonged to functional categories such as stress response, heat 
shock, drug resistance, amino acid and carbon metabolism, iron transport, cell wall, and cell 
cycle. One study suggested that farnesol affected the MAP kinase pathway, as transcript 
levels of the HST7 kinase and the CPH1 transcription factor were reduced in the presence 
of the molecule (Sato et al., 2004). However, farnesol inhibited the Y-H transition in a 
cph1/cph1 mutant, suggesting that CPH1 is not a primary, but rather a secondary target of 
farnesol (Davis-Hanna et al., 2008). While gene expression analyses generated a wealth of 
data pertaining to farnesol’s transcriptional effects on C. albicans, specific cellular targets 
were not identified. 
 
Other morphogenetic regulators may play a role in the C. albicans response to 
farnesol. CHK1, a two-component signal transduction pathway histidine kinase, appeared 
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to be required for the farnesol-mediated inhibition of hyphal growth (Kruppa et al., 2004). 
Chk1p may act either as a sensor or downstream of the sensor for farnesol (Kruppa, 2009). 
The histidine kinase may function via the Hog1p MAP kinase, which was shown to be 
phosphorylated in the presence of farnesol (Smith et al., 2004). Like CHK1, the negative 
regulators of filamentation TUP1 and NRG1 were shown to be involved in the response of 
cells to farnesol (Kebaara et al., 2008). Indeed, tup1/tup1 and nrg1/nrg1 mutants remained 
filamentous in the presence of farnesol. Farnesol treatment also resulted in an increase in 
TUP1 mRNA and protein levels and corrected the haploinsufficient phenotype of a 
TUP1/tup1 mutant strain (Kebaara et al., 2008). Concurrently, the Ras1p-cyclic AMP 
(cAMP)-protein kinase A (PKA) signaling pathway was identified as an important target of 
farnesol (Davis-Hanna et al., 2008). Several lines of evidence suggest that farnesol inhibits 
the Y-H transition by downregulating Ras1p signaling. Farnesol repressed hypha formation 
in a strain that expressed the hyperactive Ras1pG13V variant. Moreover, the addition of 
dibutyryl cAMP, a cAMP analogue, restored filamentation to farnesol-treated cells. 
Farnesol treatment also increased mRNA levels of cAMP-repressed genes, suggesting that 
cAMP levels were reduced in the presence of farnesol. 
 
There are several ways by which farnesol could modulate the Ras1p signaling 
pathway as well as other factors involved in the Y-H transition. Membrane-bound, Ras1p 
interacts with the adenylate cyclase Cyr1p in the vicinity of the plasma membrane, thus 
promoting cAMP synthesis (Fang & Wang, 2006; Wennerberg et al., 2005). Because 
farnesol is a highly hydrophobic molecule that localizes to the plasma membrane, it may 
disrupt the membrane, causing the release of farnesylated Ras1p or affecting the Ras1p-
Cyr1p complex, thus impairing cAMP production and the Y-H transition (Davis-Hanna et 
al., 2008; Langford et al., 2009; Shchepin et al., 2005). Farnesol may also impede 
posttranslational modifications of Ras1p, which are required for the protein’s localization to 
the plasma membrane and its biological activity as well as for hyphal development in C. 
albicans (Hancock, 2003; Langford et al., 2009; McGeady et al., 2002). Another possibility 
is that farnesol binds directly to Ras1p or to Cyr1p, thus interfering with cAMP synthesis. 
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The effect of farnesol on HST7 and CPH1 expression levels (Sato et al., 2004) is likely to 
be mediated by Ras1p, given that the GTPase is a regulator of the MAP kinase signaling 
pathway (Leberer et al., 2001). Additionally, Tup1p/Nrg1p and Chk1p may also be 
downstream targets of Ras1p, as regulators of these factors have yet to be identified 
(Langford et al., 2009). With the current state of knowledge regarding the molecular 
networks regulating the Y-H transition, it is impossible to determine whether farnesol has 
one specific target or modulates simultaneously different targets that vary according to 
hypha-inducing conditions. Furthermore, a receptor or a binding protein for farnesol has not 
been identified. 
 
Given its hypha-inhibiting properties, farnesol was purported to harbor a therapeutic 
potential (Nickerson et al., 2006) and its effects on various types of Candida infections 
were examined. C. albicans cells cocultured with human gingival fibroblasts and epithelial 
cells were exposed to farnesol. At concentrations tolerated by gingival cells, farnesol 
blocked the Y-H transition of C. albicans (Saidi et al., 2006). In a follow-up study that used 
a human oral mucosa model, farnesol was shown to promote epithelial cell defense against 
C. albicans by increasing Toll-like receptor 2 (TLR2) expression levels, promoting 
interleukin-6 (IL-6) secretion, and increasing antimicrobial peptide human beta-defensin 2 
(hBD2) levels (Decanis et al., 2009). Likewise, using a mouse model of mucosal 
candidiasis, farnesol administered orally to infected animals suppressed hyphal 
development and had an overall protective effect against oral candidiasis (Hisajima et al., 
2008). Farnesol had contrasting effects in a mouse model of systemic candidiasis. Whether 
administered intraperitoneally, intravenously, or orally to infected mice, farnesol treatment 
accelerated the demise of infected animals (Navarathna et al., 2007a). Moreover, farnesol 
interfered with the normal progression of cytokine induction by decreasing IL-12 levels, 
which increased the susceptibility of mice to systemic candidiasis (Navarathna et al., 
2007b). Administered on its own, farnesol was harmless, indicating it specifically enhanced 
virulence in systemic candidiasis. Taken together, these findings suggest that farnesol has 
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therapeutic potential in the context of oral mucosal infections but cannot be used to treat 
systemic candidiasis. 
 
 
3.4 Bacterial and fungal autoregulatory molecules 
In addition to farnesol, C. albicans secretes other autoregulatory molecules which 
influence the Y-H transition (Hogan, 2006; Kruppa, 2009). The fusel alcohols 2-
phenylethanol and tryptophol were the first molecules reported to inhibit hyphal growth 
(Lingappa et al., 1969). Yet, these molecules are not QS molecules, given that they are 
inhibitory at concentrations the yeast cannot produce naturally (Hazen & Cutler, 1979). An 
unknown substance termed MARS (morphogenic autoregulatory substance), isoamyl 
alcohol, and E-nerolidol have also been shown to possess hypha-inhibiting activities 
(Hazen & Cutler, 1979; Hazen & Cutler, 1983; Martins et al., 2007). Farnesoic acid, which 
is structurally related to farnesol, also blocked the Y-H transition (Oh et al., 2001). 
However, it only possessed 3% of farnesol’s inhibitory activity when germ tube formation 
was induced in N-acetylglucosamine-containing medium (Shchepin et al., 2003). PHO81, 
which encodes a phosphatase, was recently shown to be required for farnesoic acid to 
inhibit the Y-H transition (Chung et al., 2005; Chung et al., 2010). Additionally, PHO81 
was proposed to be a negative regulator of Ras1p activity, as it appears to act upstream of 
Ras1p signaling (Chung et al., 2010). In contrast to these hypha-inhibiting molecules, 
tyrosol was described as a QS molecule that stimulated germ tube formation (Chen et al., 
2004) and promoted hyphal development in the early stages of biofilm formation (Alem et 
al., 2006). Tyrosol also reduced the lag phase of growth in a diluted culture, which may 
account for its hypha-stimulating properties (Chen et al., 2004). 
 
As a commensal of the mucosal microbiota and a pathogen in different host niches, 
C. albicans encounters microorganisms of the endogenous microflora as well as several 
opportunistic pathogens. A number of bacteria and yeast have been reported to secrete 
molecules that influence the Y-H transition. Pseudomonas aeruginosa secretes the 3-oxo-
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C12-acyl homoserine lactone (3OC12HSL), a 12-carbon backbone molecule structurally 
related to farnesol, which inhibited the Y-H transition induced in N-acetylglucosamine-
containing medium and caused filaments to revert to the yeast morphology (Hogan et al., 
2004). Similar in structure to farnesol and farnesoic acid, dodecanol and three other QS 
molecules produced by Xanthomonas campestris, Burkholderia cenocepacia, and 
Streptococcus mutans also exerted hypha-inhibiting activities (Boon et al., 2008; Vilchez et 
al., 2010; Wang et al., 2004). Like farnesol, these molecules may block the Y-H transition 
by inhibiting the Ras1p-cAMP-PKA signaling pathway, potentially through similar 
mechanisms (Hogan, 2006; Hogan & Sundstrom, 2009). Additionally, P. aeruginosa also 
had an inhibitory effect on C. albicans growth in vitro, in burn wounds, and in the lungs of 
patients with cystic fibrosis (Gupta et al., 2005; Kerr, 1994). Pyocyanin, phospholipase C, 
and phenazines were the molecules responsible for this inhibitory effect (Hogan & Kolter, 
2002; Kerr et al., 1999). Interestingly, the antifungal activity of P. aeruginosa was 
specifically targeted towards hyphal cells, as bacteria were shown to attach to and kill 
fungal filaments only (Hogan & Kolter, 2002). 
 
Other microorganisms, including oral and gut residents, have also been reported to 
exert morphogenesis-modulating activities. S. mutans secreted a 22-amino acid-containing 
peptide which inhibited the Y-H transition induced using saliva-coated culture plates 
containing YNB medium (Jarosz et al., 2009). In contrast, cell-free S. gordonii supernatants 
enhanced hyphal development and biofilm formation induced in presence of human saliva 
at 37°C and affected the activation of several MAP kinases, including that of Cek1p, 
Mkc1p, and Hog1p (Bamford et al., 2009). Although the active compound was not 
identified, H2O2 and autoinducer 2 were proposed to promote filamentation by impacting 
the oxidative stress response. Culture supernatants from Lactobacillus rhamnosus GG and 
the probiotic yeast Saccharomyces boulardii blocked germ tube formation induced in 
serum-containing and in RPMI media at 37°C (Krasowska et al., 2009; Murzyn et al., 
2010; Noverr & Huffnagle, 2004). Butyric acid was shown to mimic the effect of L. 
rhamnosus GG spent medium, at concentrations well within the physiological range 
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observed in the colon (Noverr & Huffnagle, 2004; Saemann et al., 2002). The hypha-
inhibiting activities of butyric acid had previously been reported (Braun et al., 1987; 
Hoberg et al., 1983). In the case of S. boulardii, capric acid was identified as the active 
molecule: it inhibited the Y-H transition as well as adhesion and biofilm formation 
(Murzyn et al., 2010). Two other compounds produced by Acinetobacter baumannii and 
Salmonella enterica serovar Typhimurium also inhibited filamentation and biofilm 
formation but have yet to be identified (Peleg et al., 2008; Tampakakis et al., 2009). 
 
In complex microbial communities, molecules mediate interspecies interactions 
(Hogan, 2006; Hogan & Kolter, 2007; Wargo & Hogan, 2006). With respect to 
morphogenesis-modulating molecules, these secreted products may be a mechanism by 
which microbes compete with C. albicans by inhibiting hypha formation, limiting 
attachment, and preventing invasion. It may also be a way for C. albicans to respond to the 
presence of microorganisms. For instance, in presence of 3OC12HSL, C. albicans may 
block hyphal development as a means to escape being killed by P. aeruginosa. Conversely, 
hypha-inducing molecules may mediate synergistic interactions between bacteria and C. 
albicans by promoting biofilm formation and invasion (Bamford et al., 2009). 
 
 
3.5 Fatty acids, eicosanoids, and cyclooxygenase inhibitors 
Lipids are involved in fungal development and pathogenicity (Erb-Downward & 
Huffnagle, 2006; Noverr et al., 2003; Rhome & Del Poeta, 2009; Shea & Del Poeta, 2006). 
In C. albicans, lipid molecules such as fatty acids and eicosanoids have been reported to 
modulate the Y-H transition. Fatty acids, including butyric, capric, lauric, palmitoleic, 
oleic, linoleic, conjugated linoleic, and arachidonic acids, inhibited the Y-H transition 
induced in various conditions (Clement et al., 2007; McLain et al., 2000; Murzyn et al., 
2010; Noverr & Huffnagle, 2004). The hypha-inhibiting activities of fatty acids were 
dependent on the medium. For instance, linoleic and oleic acids were shown to have no 
effect on germ tube formation induced in serum or to block the Y-H transition induced in 
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other conditions, such as Spider medium (Clement et al., 2007; Noverr & Huffnagle, 2004). 
Such discrepancies may be due to the lipid-binding capacity of serum albumins, which 
sequester lipidic molecules and reduce their effective concentrations (Langford et al., 
2009). Moreover, although the effects of fatty acids on the Y-H transition have been 
described, their modes of action have not been studied extensively. Conjugated linoleic acid 
(CLA) was reported to block the Y-H transition induced in Spider medium by affecting the 
subcellular localization of Ras1p and reducing its levels, thereby impeding the activation of 
Ras1p signaling and blocking the induction of the TEC1 transcription factor (Shareck et al., 
2011). In addition, while the antifungal properties and cytotoxicity of several fatty acids 
have been reported (Bergsson et al., 2001; Carballeira, 2008; Deva et al., 2000), fatty acids 
inhibited hyphal growth at concentrations that did not affect cellular growth (Shareck et al., 
2011). 
 
In contrast to fatty acids, eicosanoids such as prostaglandin E2 (Erb-Downward & 
Noverr, 2007; Kalo-Klein & Witkin, 1990; Noverr et al., 2001) and thromboxane B2 
(Noverr & Huffnagle, 2004) enhanced the Y-H transition. Eicosanoids are oxygenated 
lipids derived from 20-carbon polyunsaturated fatty acid precursors such as arachidonic 
acid. In mammalian cells, cyclooxygenases (COX) catalyze the conversion of arachidonic 
acid into prostaglandins. While C. albicans does not possess a COX homolog, the fatty acid 
desaturase OLE2 and the multicopper oxidase FET3 were found to play a role in 
prostaglandin synthesis (Erb-Downward & Noverr, 2007). Concurrently, several COX 
inhibitors, including diclofenac sodium, indomethacin, ibuprofen, resveratrol, and 
eicosatetraynoic acid (ETYA), were shown to block the Y-H transition induced in serum-
containing, Lee’s or Spider media at 37°C (Alem & Douglas, 2004; Ghalehnoo et al., 2010; 
Okamoto-Shibayama et al., 2010; Toenjes et al., 2009). It is not clear whether or not COX 
inhibitors affected filamentation by blocking prostaglandin synthesis, given that a direct 
association between reduced prostaglandin levels and reduced hypha formation was not 
shown and that C. albicans does not encode a COX homolog. Moreover, COX inhibitors 
appeared to reduce viability of C. albicans cells, which may account for their hypha-
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inhibiting activities (Alem & Douglas, 2004; Deva et al., 2001; Noverr et al., 2001). For 
instance, diclofenac sodium and resveratrol blocked hyphal development but also affected 
cellular growth (Ghalehnoo et al., 2010; Okamoto-Shibayama et al., 2010). 
 
 
3.6 Peptides and proteins 
Various peptides and proteins were shown to modulate the Y-H transition in C. 
albicans. At concentrations of 25 μg ml-1, nisin Z, an antimicrobial peptide of the 
lantibiotic family, reduced germ tube formation induced in serum-containing medium and 
decreased adhesion of C. albicans cells to gingival monolayer cultures (Akerey et al., 
2009). However, a previous study had shown that at slightly higher concentrations (100 μg 
ml-1), nisin Z reduced cellular growth rates and caused ultrastructural disturbances in C. 
albicans cells, casting doubt on the mechanism by which the antimicrobial peptide 
inhibited filamentation (Le Lay et al., 2008). Salivary components statherin and mucin also 
affected morphogenesis. Hyphae grown overnight in RPMI medium switched to yeast 
growth in presence of statherin (Leito et al., 2009), while mucin inhibited hypha formation 
induced in RPMI medium at 37°C and blocked RAS1 induction without affecting cellular 
growth (Ogasawara et al., 2007). Cdc42/Rac interactive binding (CRIB) fusion 
polypeptides containing the CRIB consensus sequence were designed to disrupt the binding 
of the Rho GTPase Cdc42p to its effectors Cst20p and Cla4p, interactions that are required 
for hyphal development (Leberer et al., 1996; Leberer et al., 1997). CRIB polypeptides, 
which have high-affinity binding to Cdc42p, blocked the Y-H transition induced in Lee’s 
medium in time- and dose-dependent fashions, without impairing cellular growth (Su et al., 
2007). Additionally, hyphal cells grown overnight in Lee’s medium switched to yeast-like 
forms when they were incubated in fresh medium in the presence of either of the CRIB 
polypeptides, indicating the peptides can convert hyphal cells back into the yeast-like form. 
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3.7 Rapamycin 
Rapamycin, a hydrophobic macrolide produced as a secondary metabolite by the 
soil bacterium Streptomyces hygroscopicus, was initially discovered as an antifungal agent 
against C. albicans (Vezina et al., 1975). Rapamycin inhibits the function of the Tor (target 
of rapamycin) kinases (Heitman et al., 1991), of which one homolog was identified in C. 
albicans (Tor1p) (Cruz et al., 2001). Tor1p has contrasting roles in regulating 
morphogenesis which vary according to hypha-inducing conditions. For instance, on solid 
synthetic low ammonium dextrose (SLAD) medium, alkaline M199 medium (pH 8.0), and 
Spider medium at 37°C, sublethal concentrations of rapamycin blocked hyphal growth, 
indicating that Tor1p is a positive regulator of filamentation under nitrogen or nutrient 
starvation conditions and in response to alkaline growth conditions (Bastidas et al., 2009; 
Cutler et al., 2001; Martins et al., 2008). In contrast, in most liquid hypha-inducing media, 
rapamycin had no effect on the Y-H transition, indicating that Tor1p does not regulate 
hyphal development under these conditions (Bastidas et al., 2009). 
 
Interestingly, in liquid Spider medium, rapamycin promoted cellular aggregation 
and flocculation (Bastidas et al., 2009). These findings demonstrate that Tor1p negatively 
regulates cellular adhesion under such growth conditions. Gene expression analysis showed 
that rapamycin treatment strongly induced the hyphal growth program in C. albicans, 
resulting in the induction of hypha-specific genes (ALS1, ALS3, HWP1, and ECE1) and 
hyphal growth regulators (TEC1 and RFG1). Additionally, rapamycin decreased transcript 
levels of filamentation repressors TUP1 and NRG1. The transcription factors Efg1p and 
Bcr1p were required for the rapamycin-mediated cellular aggregation as well as for 
expression of adhesins. Thus, in liquid Spider medium, rapamycin promotes cellular 
aggregation by compromising Tor1p function, which results in the activation of Efg1p and 
Bcr1p and the downregulation of TUP1 and NRG1. 
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3.8 Geldanamycin 
Geldanamycin (GdA) is a microbial metabolite that inhibits the function of Hsp90p, 
a molecular chaperone and heat-shock protein (Roe et al., 1999). Hsp90p regulates the form 
and function of various client proteins, several of which regulate morphogenesis in C. 
albicans (Pearl & Prodromou, 2006; Pratt & Toft, 2003; Shapiro et al., 2009). GdA 
treatment induced filamentation in C. albicans cells grown in noninducing conditions 
(Shapiro et al., 2009). The genetic depletion of HSP90 was also shown to phenocopy the 
GdA-induced filamentation. Combined, these results suggest that Hsp90p is a negative 
regulator of morphogenesis. Upstream inputs from the cAMP-PKA signaling pathway were 
required for cells to filament in presence of GdA, while the transcription factor Efg1p was 
not required. These results suggest that the GdA-induced filamentation may be regulated by 
transcription factors that function downstream of PKA, such as Tec1p, Flo8p, and Sfl1p 
(Shapiro et al., 2009; Shapiro & Cowen, 2010). Hsp90p has been proposed to repress 
cAMP-PKA signaling, either by (i) interacting with a positive regulator of the pathway, and 
maintaining it in an inactive form (e.g., Tpk1p or Tpk2p, the catalytic subunits of PKA), 
(ii) stabilizing a negative regulator of the pathway (e.g., Bcy1p, the regulatory subunit of 
PKA), or (iii) interacting indirectly with the cAMP-PKA pathway via an unknown protein 
(Shapiro & Cowen, 2010). Other models involving different Hsp90p client proteins are also 
possible. Interestingly, the genetic depletion of HSP90 attenuated virulence in a mouse 
model of systemic candidiasis, resulting in clearance of the infection (Shapiro et al., 2009). 
While these findings suggest that modulating morphogenesis by compromising Hsp90p 
function is a means to treat candidiasis, reduced virulence may have been due to reduced 
cellular growth rates associated with reduced HSP90 cellular levels. Nonetheless, a study 
has shown that harnessing Hsp90p function, either with the use of clinically relevant GdA 
derivatives or by genetically compromising HSP90, improved the therapeutic efficacy of an 
azole in two animal models of infection (Cowen et al., 2009). Because they enhance the 
efficacy of existing antifungal drugs, Hsp90p inhibitors such as GdA and structurally 
related compounds are good candidates for the development of effective combination 
therapy strategies. 
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3.9 Histone deacetylase inhibitors 
Histone deacetylases (HDACs) are chromatin-remodeling proteins usually involved 
in transcriptional repression (Grozinger & Schreiber, 2002). HDACs deacetylate histones 
globally or at specific promoters, directed by transcription factors or other DNA-binding 
proteins (Kadosh & Struhl, 1998). The HDACs Hda1p, Hos2p, Set3p, and Hst3p have been 
reported to regulate morphogenesis, yet they have contrasting roles (Hnisz et al., 2010; 
Wurtele et al., 2010; Zacchi et al., 2010). Moreover, several HDAC inhibitors have been 
shown to modulate hyphal development and virulence (Hnisz et al., 2010; Simonetti et al., 
2007; Smith & Edlind, 2002; Wurtele et al., 2010). For instance, suberoylanilide 
hydroxamic acid (SAHA) inhibited the serum-induced Y-H transition, which correlated 
with a minor reduction in EFG1 transcript levels (Simonetti et al., 2007). In contrast, 
nicotinamide, an inhibitor of Hst3p, induced filamentation of C. albicans cells in 
noninducing conditions (Wurtele et al., 2010). Hst3p, a member of a family of NAD+-
dependent histone deacetylases known as sirtuins, is inhibited by nicotinamide, a product of 
the NAD+-dependent deacetylation reaction. The pharmacological inhibition of Hst3p using 
nicotinamide or the genetic depletion of HST3 not only induced filamentation but also 
attenuated virulence in a model of systemic candidiasis. Yet, reduced virulence in vivo was 
likely due to reduced growth rates rather than to the modulation of morphology, as 
nicotinamide treatment or the repression of HST3 resulted in cell death. 
 
Trichostatin A (TSA), a well-characterized HDAC inhibitor (Yoshida et al., 1995), 
had contrasting effects on morphogenesis that depended on experimental settings, including 
strains, growth conditions, and TSA concentrations used. Clinical isolates of C. albicans 
pretreated for 48 h with 4 μg ml-1 of TSA were unable to form germ tubes when induced to 
filament in yeast extract-peptone-dextrose (YPD) medium supplemented with 20% serum 
(Simonetti et al., 2007). In addition, EFG1 transcript levels were reduced in TSA-treated 
cells. These results suggest that TSA inhibited a histone deacetylase required for the Y-H 
transition and downregulated EFG1 expression. The Hda1p HDAC was proposed to 
potentially mediate the effects of TSA on hyphal development. In contrast, similar TSA 
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concentrations had no effect on the serum-induced Y-H transition (Smith & Edlind, 2002). 
In these experiments, TSA treatment may have been insufficient to affect morphogenesis, 
given that the HDAC inhibitor was added at the onset of hyphal induction. Another study 
showed that TSA treatment promoted hyphal development under noninducing conditions 
(Hnisz et al., 2010). Indeed, on solid YPD medium supplemented with 10 μg ml-1 of TSA, 
colonies displayed filamentous growth after 3 days of incubation at 37°C. The TSA-
induced filamentation was phenocopied by the deletion of the SET3 and HOS2 histone 
deacetylase genes. Additionally, both histone deacetylases were shown to be involved in 
repressing morphogenesis at the level of the Efg1p transcription factor. Thus, the TSA-
induced filamentation appears to be caused by TSA inhibiting the Set3p and Hos2p HDACs 
and relieving the repression of filamentation (Hnisz et al., 2010). Interestingly, despite the 
fact the set3/set3 mutant strain filamented in vivo, it was still attenuated in virulence in a 
model of systemic candidiasis. Moreover, reduced growth rates did not account for reduced 
virulence, as generation times of wild-type and set3/set3 strains did not differ significantly 
(Hnisz et al., 2010). Given that TSA inhibits Set3p, the HDAC inhibitor may reduce 
virulence in vivo, but this has yet to be demonstrated. 
 
 
3.10 Cell cycle inhibitors 
Hydroxyurea (HU) and nocodazole (NZ) are cell cycle-perturbing agents. While HU 
inhibits ribonucleotide reductase, depleting ribonucleotides and inhibiting DNA synthesis, 
NZ disrupts microtubules and locks cells in mitosis. In addition to causing cell cycle arrest, 
both drugs also trigger hyperpolarized growth of C. albicans cells grown in noninducing 
conditions (Bachewich et al., 2003; Bachewich et al., 2005; Bai et al., 2002; Whiteway & 
Bachewich, 2007). Upon exposure to HU or to NZ, yeast cells developed hyperpolarized 
buds, which continued to elongate despite DNA replication being blocked (Bachewich et 
al., 2003; Bachewich et al., 2005; Bai et al., 2002). HU- and NZ-induced elongated buds 
displayed pseudohyphal morphological features (constrictions at the neck and width of >2 
μm) as well as hyphal-like features, in that they maintained polarized growth, demonstrated 
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nuclear movement out of the mother cell and into the elongating filament, and expressed 
several hypha-specific genes (HSGs) (Bachewich et al., 2003; Bachewich et al., 2005). 
HU-induced elongated buds eventually died after 24 h. However, sublethal concentrations 
of the inhibitor have also been reported to induce hyperpolarized growth without impacting 
cellular growth (Shi et al., 2007). The development of hyperpolarized buds involves 
different proteins, several of which are cell cycle checkpoints. For instance, the Rad53p 
effector kinase of the DNA replication checkpoint and the Mad2p spindle assembly 
checkpoint were required for hyperpolarization of buds induced by HU and NZ treatments, 
respectively (Bai et al., 2002; Shi et al., 2007). Interestingly, bud elongation appears to be 
caused by the activation of cell cycle checkpoints by cell cycle inhibitors rather than by cell 
cycle arrest (Shi et al., 2007). Moreover, several components of Ras1p signaling, including 
the GTPase Ras1p and adenylate cyclase Cyr1p, were required for HU-induced elongated 
buds (Bachewich et al., 2003; Bachewich et al., 2005). Given that hyperpolarized growth 
has been observed only in response to cell cycle-inhibiting agents or in strains in which cell 
cycle genes are inactivated or overexpressed (reviewed in Berman, 2006; Whiteway & 
Bachewich, 2007), it is not clear whether or not this growth mode is physiologically 
relevant. Yet, it remains that hyperpolarized buds may be important for pathogenicity 
and/or survival in the host, as they eventually express hypha- and virulence-specific factors 
(Whiteway & Bachewich, 2007). 
 
 
3.11 Other small molecules 
Many other small molecules have been reported to affect morphogenesis in C. 
albicans (Toenjes et al., 2005; Toenjes et al., 2009). Propranolol, a calmodulin inhibitor 
(Volpi et al., 1981), was shown to inhibit serum-induced hypha formation by reducing 
EFG1 expression levels (Baker et al., 2002; Ueno et al., 2009). Various inhibitors of actin 
dynamics, including latrunculin, jasplakinolide, and cytochalasin A, also blocked the Y-H 
transition induced in serum-containing, Spider or M199 media at 37°C (Akashi et al., 1994; 
Hazan & Liu, 2002; Toenjes et al., 2005; Wolyniak & Sundstrom, 2007). 1,4-Diamino-2-
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butanone (DAB) blocked the Y-H transition induced in RPMI medium at 37°C by reducing 
polyamine levels, decreasing CYR1 mRNA levels, and reducing cAMP cellular levels 
(Ueno et al., 2004). Sublethal concentrations of azoles inhibited hypha formation induced 
in M199 medium at 37°C (Ha & White, 1999; Odds et al., 1985). Azoles’ hypha-inhibiting 
activities may be due to increased farnesol production reported in azole-treated cells 
(Hornby & Nickerson, 2004). Two derivatives of propanol from a chemical library reduced 
C. albicans-induced endothelial injury, most likely by preventing hypha formation (Toenjes 
et al., 2005). The cellular targets of these structurally different molecules are not known. In 
contrast, hydrogen peroxide and the iron chelator bathophenanthrolene disulfonic acid 
(BPS) both induced hyphal development in noninducing conditions (Hameed et al., 2008; 
Nasution et al., 2008). BPS promoted filamentation by increasing EFG1 mRNA levels. 
 
Additionally, several cytostatic or cytotoxic molecules have been reported to inhibit 
the Y-H transition in C. albicans, including garlic extracts (Low et al., 2008), a Mannich 
ketone compound (Kocsis et al., 2009), the monoterpene thymol (Braga et al., 2007), 
riccardin D, a macrocyclic bisbibenzyl compound isolated from Chinese liverwort 
Dumortia hirsute (Cheng et al., 2009), and ECC145 and ECC188, two compounds that 
impair the fatty acid Δ9 desaturase Ole1p and block the biosynthesis of unsaturated fatty 
acids (Xu et al., 2009). Lithium affected filamentation on solid galactose- and serum-
containing media, but also reduced cellular growth in presence of galactose (Martins et al., 
2008). However, it is unclear whether or not lithium impacted growth rates in the presence 
of serum. It remains possible that molecules that are toxic to cells cannot be considered to 
have hypha-inhibiting properties, given that they might impede the Y-H transition merely 
by impairing cellular growth. 
 
 
3.12 Conclusion 
Many small molecules have been reported to modulate morphogenesis in C. 
albicans. Yet, an overview of the literature revealed that the mechanisms of few of these 
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compounds have been investigated. Interestingly, studies that have addressed the modes of 
action of small molecules have shown that many of these compounds target components of 
the Ras1p signaling pathway (Figure 3.1). It is surprising that several structurally different 
molecules commonly affect RAS1, CYR1, EFG1, HST7 and CPH1 mRNA levels, modulate 
cAMP levels or Efg1p-dependent transcription, or require components of the pathway to 
exert their morphogenesis-modulating activities (Table V). On one hand, despite being 
structurally different, it may be expected that these molecules modulate hyphal growth by 
targeting components of the Ras1p signaling pathway, given the major role this signaling 
pathway plays in morphogenesis. On the other hand, it is also possible that these common 
components are not primary targets, but rather secondary targets of various molecules. For 
instance, while farnesol was reported to downregulate CPH1 transcript levels (Sato et al., 
2004), the transcription factor was not required for the QS molecule to block the Y-H 
transition (Davis-Hanna et al., 2008). These results suggest that farnesol’s effect on CPH1 
expression levels was a consequence of farnesol affecting its primary target, i.e. the Ras1p-
cAMP-PKA signaling pathway. Likewise, components of the Ras1p signaling pathway that 
have been identified as primary targets of morphogenesis-modulating molecules may well 
be secondary targets. 
 
Proof-of-concept experiments have shown that interfering with the morphogenetic 
plasticity of C. albicans and promoting its growth in a form that does not damage the host 
attenuates virulence in vivo (Saville et al., 2003; Saville et al., 2006). Therefore, does 
modulating morphogenesis constitute a sound approach to treat candidiasis? First, it is 
noteworthy to mention that there is an overall lack of evidence demonstrating that 
impairing the developmental process can be used to treat candidiasis. While many small 
molecules have been reported to modulate the Y-H transition in vitro, very few compounds 
have been evaluated for their effects on virulence using in vitro or in vivo infection models. 
Second, the therapeutic potential of some molecules, including nicotinamide, ECC145, 
ECC188, and geldanamycin, may stem in part from their cytotoxicity toward C. albicans 
rather than from their capacity to modulate the Y-H transition, as they target essential gene 
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products. Indeed, the genetic depletion of HST3, OLE1, and HSP90 modulated 
morphogenesis in C. albicans and attenuated virulence in a model of systemic candidiasis 
but also reduced cellular growth rates (Shapiro et al., 2009; Wurtele et al., 2010; Xu et al., 
2009). Third, the studies that have evaluated the effects of small molecules on virulence in 
various infection models have yielded mixed results. Farnesol and nisin Z were both shown 
to have a protective effect in mucosal candidiasis (Akerey et al., 2009; Hisajima et al., 
2008; Saidi et al., 2006), while in a model of systemic candidiasis, farnesol enhanced 
pathogenicity (Navarathna et al., 2007a; Navarathna et al., 2007b). 
 
On the basis of current findings, it appears that modulating morphogenesis is a 
means to treat mucosal/superficial Candida infections. As for systemic candidiasis, the lack 
of literature renders it difficult to reach similar conclusions. To circumvent this 
impediment, small molecules that modulate the Y-H transition in C. albicans without 
affecting cellular growth should be evaluated for their therapeutic potential in various 
infection models. More data are needed to determine whether or not targeting the Y-H 
transition constitutes a sound therapeutic strategy to treat Candida infections. 
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Figure 3. 1 Summary of the modes of action of selected small molecules which modulate 
morphogenesis in Candida albicans.  
(A) Several small molecules, including farnesol (FOH), conjugated linoleic acid (CLA), rapamycin 
(Rapa), geldanamycin (GdA), mucin, diclofenac sodium, 1,4-diamino-2-butanone (DAB), 
hydroxyurea (HU), propranolol, and bathophenanthrolene disulfonic acid (BPS), modulate 
morphogenesis by targeting the Ras1p-cAMP-PKA signaling pathway and its downstream 
effectors. Notably, both CLA and GdA modulate morphogenesis independently of Efg1p. Extended 
CRIB (eCRIB) peptides interrupt the binding of the GTPase Cdc42p to its effectors Cst20p and 
Cla4p, and thus prevent the activation of the MAP kinase (MAPK) pathway. (B) Farnesol and CLA 
block the downregulation of TUP1 and NRG1 expression. In contrast, rapamycin induces the 
downregulation of both repressors by inhibiting TOR. (C) Trichostatin A (TSA) induces 
filamentation by relieving the Set3C-mediated repression of Efg1p-dependent transcription. TSA 
may also reduce EFG1 transcript levels (see text for details). HSGs, hypha-specific genes. 
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Table V Small molecules that modulate morphogenesis in C. albicans by affecting the Ras1p-cAMP-PKA signaling pathway 
Molecule Description/Target Effects on C. albicans References 
farnesol Candida albicans-produced QS molecule; 
downregulates Ras1p-cAMP-PKA pathway; 
increases TUP1 mRNA levels 
inhibits Y-H transition (Davis-Hanna et al., 2008; 
Hornby et al., 2001; Kebaara et 
al., 2008; Martins et al., 2007; 
Sato et al., 2004) 
dodecanol downregulates Ras1p-cAMP-PKA pathway  inhibits Y-H transition (Davis-Hanna et al., 2008; 
Hogan et al., 2004; Martins et 
al., 2007) 
farnesoic acid represses EFG1/CPH1 expression levels in a 
PHO81-dependent manner  
inhibits Y-H transition (Chung et al., 2005; Chung et 
al., 2010; Oh et al., 2001) 
3-oxo-C12-acyl homoserine lactone 
(3OC12HSL) 
Pseudomonas aeruginosa-produced QS 
molecule; targets Ras1p signaling 
inhibits Y-H transition (Hogan et al., 2004) 
cis-11-methyl-2-dodecenoic acid Xanthomonas campestris-produced QS 
molecule; targets Ras1p signaling 
inhibits Y-H transition (Wang et al., 2004) 
cis-2-dodecenoic acid Burkholderia cenocepacia-produced QS 
molecule; targets Ras1p signaling 
inhibits Y-H transition (Boon et al., 2008) 
unknown, found in supernatant secreted by Streptococcus gordonii; affects 
activation of Cek1p, Mkc1p, Hog1p kinases 
enhances hyphal development (Bamford et al., 2009) 
conjugated linoleic acid isolated from whey cream; affects Ras1p 
localization and reduces its cellular levels 
inhibits Y-H transition (Clement et al., 2007) 
diclofenac sodium reduces RAS1/EFG1 expression levels inhibits Y-H transition; mildly 
affects growth rate 
(Alem & Douglas, 2004; 
Ghalehnoo et al., 2010) 
salivary mucin glycoprotein; downregulates RAS1 
expression levels 
inhibits hyphal development (Ogasawara et al., 2007) 
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eCRIB peptides impair the binding of the Rho GTPase 
Cdc42p to Cst20p and Cla4p 
inhibit Y-H transition and 
hyphal elongation  
(Su et al., 2007) 
trichostatin A histone deacetylase inhibitor; reduces EFG1 
expression levels; relieves Set3C-mediated 
repression of Efg1-dependent transcription 
inhibits Y-H transition in liquid 
medium; induces filamentation 
on solid medium  
(Hnisz et al., 2010; Simonetti et 
al., 2007) 
propranolol calmodulin inhibitor; reduces EFG1 mRNA 
levels 
inhibits Y-H transition (Baker et al., 2002; Ueno et al., 
2009; Wolyniak & Sundstrom, 
2007) 
rapamycin Tor1p inhibitor; affects Efg1p and Bcr1p; 
downregulates TUP1 and NRG1 expression 
levels 
blocks filamentation on solid 
media ; induces cellular 
aggregation in Spider medium 
(Bastidas et al., 2009; Cutler et 
al., 2001; Martins et al., 2008) 
geldanamycin Hsp90p inhibitor; relieves Hsp90p-mediated 
repression of Ras1p-cAMP-PKA pathway 
induces filamentation; toxic at 
high concentrations 
(Shapiro et al., 2009; Toenjes et 
al., 2009) 
bathophenanthrolene disulfonic acid iron chelator; increases EFG1 transcription induces hyphal development (Hameed et al., 2008) 
A-3 PKA inhibitor inhibits Y-H transition (Toenjes et al., 2009) 
1,4-diamino-2-butanone (DAB) ornithine decarboxylase inhibitor; reduces 
CYR1 expression 
inhibits Y-H transition (Ueno et al., 2004) 
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4.1 Fatty acids inhibit hyphal growth in Candida albicans 
An important component of C. albicans’s pathogenicity is its ability to switch from 
yeast growth to hyphal growth (Kumamoto & Vinces, 2005; Lo et al., 1997; Saville et al., 
2003; Zheng & Wang, 2004). Lipidic compounds, such as farnesol and structurally related 
quorum sensing molecules have been reported to block the morphogenetic transition 
(Chapter 3). Similarly, various fatty acids, including butyric, capric, undecylenic, lauric, 
palmitoleic, conjugated linoleic, and arachidonic acids, have been shown to inhibit 
filamentation in C. albicans (Clement et al., 2007; McLain et al., 2000; Murzyn et al., 
2010; Noverr & Huffnagle, 2004; Shareck et al., 2011). Conjugated linoleic acid (CLA), an 
18-carbon long chain polyunsaturated fatty acid (PUFA), was chosen to characterize the 
effect of fatty acids on hyphal growth and explore their putative mode of action (Shareck et 
al., 2011). Other PUFAs, such as oleic, linoleic, α- and γ-linolenic acids, exhibited hypha-
inhibiting properties in C. albicans (Figure 4.1), in Aspergillus fumigatus (Clement et al., 
2008), and in Fusarium graminearum (data not shown). Additionally, CLA also abrogated 
filamentous growth in C. tropicalis and in C. dubliniensis (Figure 4.2). These results 
suggest that the response to fatty acids may be conserved among various Candida species 
and other fungi. Accordingly, farnesol blocked filamentation in C. dubliniensis (Martins et 
al., 2007), inhibited growth and induced apoptosis in Aspergillus nidulans (Semighini et 
al., 2006), inhibited conidiation in Aspergillus niger (Lorek et al., 2008), and altered spore 
germination in Fusarium graminearum (Semighini et al., 2008).  
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Figure 4. 1 Unsaturated fatty acids inhibit hyphal growth in Candida albicans.  
(A) The effect of polyunsaturated fatty acids (PUFAs) on C. albicans hyphal growth was measured 
by using the C. albicans reporter strain HWP1p-lacZ. Cells were grown in Spider medium in 
absence or presence of PUFAs for 4 h at 37°C. Filamentation in PUFA-treated cultures was 
assessed by quantifying β-galactosidase activity, which was normalized to that of ethanol-
supplemented cultures. Data are means and standard deviations of duplicate assays performed on 
three independent days. (B) Cells grown as in (A) were visualized by DIC microscopy at ×100 
magnification. Bar = 10 μm. (C) C. albicans cells were grown on Spider and Lee’s solid media 
supplemented with ethanol or PUFAs (100 μM) for 3-4 days at 37°C. oleic acid (OA); conjugated 
linoleic acid (CLA); linoleic acid (LA); α-linolenic acid (ALA); γ-linolenic acid (GLA).
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Several fatty acids have been reported to exert cytotoxic properties towards C. 
albicans cells (Bergsson et al., 2001; Carballeira, 2008; Deva et al., 2000). Molecules that 
inhibit cellular growth are bound to impede hyphal growth, which questions whether fatty 
acids blocked filamentation merely by inhibiting overall growth. It was important to clearly 
demonstrate that while CLA interfered with hyphal growth, effective concentrations did not 
affect cellular growth. Toxicity and hypha-inhibiting properties of fatty acids in C. albicans 
depend on several factors, including concentration, growth medium, and inoculum. For 
instance, capric acid was toxic to C. albicans cells at 10 mM, causing disruption and 
disintegration of the plasma membrane, resulting in disorganization of the cytoplasm 
(Bergsson et al., 2001). In contrast, subinhibitory concentrations (10-300 μM) of capric 
acid inhibited hypha formation, but not cellular growth (Clement et al., 2007; Murzyn et 
al., 2010). Likewise, arachidonic acid inhibited growth of C. albicans cells at 
concentrations higher than 20 μM and blocked the yeast-to-hypha transition without 
affecting cell growth at 50 μM (Clement et al., 2007; Deva et al., 2000). In these 
experiments, different growth conditions and inocula accounted for the discrepancies. 
Similarly, several fatty acids used at 0.1 nM did not affect the yeast-to-hypha transition 
(Noverr & Huffnagle, 2004), while the same molecules interfered with hyphal growth at 
100 μM (data not shown). Additionally, fatty acid susceptibility assays showed that the 
MIC50 of capric acid was medium-dependent (Clement et al., 2008). Taken together, these 
results indicate that growth conditions, fatty acid concentrations, and inocula dictate 
whether fatty acids affect general growth or hyphal development in C. albicans.  
 
CLA did not block morphogenesis by inhibiting growth, which is why its mode of 
action was addressed. In addition, it was chosen to probe the mechanism by which fatty 
acids interfered with filamentation, given that it was the most effective of the molecules 
assayed (Figure 4.1A). However, it can only be assumed that CLA and other structurally 
similar PUFAs inhibit hyphal growth through the same mechanism.  
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Figure 4. 2 Other Candida species respond to CLA.  
CLA blocked filamentous growth in C. tropicalis and C. dubliniensis, suggesting that CLA 
modulates filamentous growth in other Candida species. Cells were visualized by DIC microscopy 
at ×100 magnification. Bar = 10 μm. 
 
 
4.2 Using transcriptional profiling to address the mode of action 
of CLA 
CLA, as well as other fatty acids, were deemed to be bioactive molecules on the 
basis that they inhibited hyphal growth in C. albicans. In contrast to molecules that target 
specific gene products or signaling pathways, e.g. rapamycin, geldanamycin, and histone 
deacetylase inhibitors (reviewed in Chapter 3), CLA does not have a known cellular target, 
even less so a target mediating its effect on filamentation. In this respect, CLA is similar to 
farnesol: receptors or binding proteins for farnesol still remain to be identified, although the 
GTPase Ras1p and/or the adenylate cyclase Cyr1p may be potential targets (Davis-Hanna 
et al., 2008). Thus, gene expression profiling was conducted to address the mechanism by 
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which CLA inhibited the yeast-to-hypha transition in C. albicans. This approach was 
chosen to gain insight into the transcriptional response of cells to CLA on a genome-wide 
scale. Although not novel, this type of experimental approach has been proposed as a 
means to elucidate the mechanisms of small molecules (Butcher & Schreiber, 2005). 
Additionally, transcriptional profiling has been used to examine the response of C. albicans 
to farnesol (Cao et al., 2005; Cho et al., 2007; Enjalbert & Whiteway, 2005; Uppuluri et 
al., 2007) and to rapamycin (Bastidas et al., 2009), which are two molecules that modulate 
morphogenesis.  
 
Gene expression analysis generates a wealth of data, from which genes or signaling 
pathways involved in a specific phenotype/response can be identified, thus constituting a 
starting point to direct further studies. The transcriptional profiles of cells undergoing the 
yeast-to-hypha transition treated or not with CLA were obtained independently by using a 
common control condition, and were then compared to one another. The microarray 
experiments were designed as such in order to (i) characterize independently the 
transcriptional program regulating hyphal growth in Spider medium and the transcriptional 
changes elicited by CLA and (ii) identify the genes or signaling pathways potentially 
mediating CLA’s hypha-inhibiting effects. 
 
4.2.1 Hyphal growth program in Spider medium 
The yeast-to-hypha transition is induced in cells transferred from YPD at 30°C to 
Spider at 37°C (Figure 2.2A). The transcriptional profile of cells undergoing the yeast-to-
hypha transition in Spider medium revealed that 520 genes were modulated upon growth at 
37°C (Table S1). Of those genes, 198 were upregulated while 322 were downregulated. 
Most of the downregulated transcripts encoded gene products involved in RNA metabolic 
processes, ribosome biogenesis, translation, and transcription, which reflects a repression of 
the translational machinery. Accordingly, genes involved in protein translation were also 
downregulated in cells undergoing the yeast-to-hypha transition in serum-containing YPD 
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and Lee’s media (Nantel et al., 2002). Among the subset of upregulated genes, ~30% of the 
transcripts have been described as being induced during the yeast-to-hypha transition in 
Lee’s medium (Goyard et al., 2008) (Table S1). Spider and Lee’s are hypha-inducing 
media that contain a source of fermentable carbon, various amino acids, and salts, which 
may explain the similarities between both hyphal growth programs.  
 
Transcriptional profiling of the yeast-to-hypha transition did not reveal the existence 
of a novel gene product or signaling pathway regulating specifically the Spider-induced 
hyphal growth program. Instead, several signaling pathways appeared to regulate 
filamentation concomitantly. Expression levels of key regulators of hyphal growth 
including CPH1, CPH2, TEC1, BCR1, UME6, GAT2, RAS1, CYR1, CAS4, and MSB2 were 
upregulated (Table IV). Except for BCR1, the products of these genes are required for 
filamentation in different hypha-inducing conditions (Banerjee et al., 2008; Homann et al., 
2009; Lane et al., 2001a; Lane et al., 2001b; Leberer et al., 2001; Liu et al., 1994; Rocha et 
al., 2001; Roman et al., 2009b; Schweizer et al., 2000; Song et al., 2008; Zeidler et al., 
2009). The transcriptional data suggest that each of these regulators contributes to hyphal 
growth in Spider medium. However, this was not the case, as strains deleted for CPH1, 
CPH2, and UME6 still underwent the yeast-to-hypha transition in Spider medium (Figure 
4.3). Although not verified, MSB2 may also be dispensable for filamentation, as a 
msb2/msb2 mutant strain filamented in serum-containing medium (Roman et al., 2009b). 
Among the candidate genes involved in Spider-induced filamentation, RAS1 and TEC1 
were necessary for hyphal growth (data not shown), while CYR1, CAS4, and GAT2 may 
also be required for filamentation (Fang & Wang, 2006; Homann et al., 2009; Noble et al., 
2010; Rocha et al., 2001; Song et al., 2008).  
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Figure 4. 3 Differentially expressed transcription factors dispensable for hyphal growth.  
(A) Fold-change of genes encoding transcription factors in cells undergoing the yeast-to-hypha 
transition in Spider medium at 37°C. The significantly differentially expressed genes were obtained 
by comparing growth in Spider medium at 37°C to that at 30°C (Table S1). Data are fold-change 
values. (B) cph1/cph1 (JKC19), cph2/cph2 (HLY1921), bcr1/bcr1 (CJN702), rfg1/rfg1 (DK129) 
and ume6/ume6 (DK312) strains were grown in Spider medium at 37°C for 4 h. Cells were 
visualized using DIC optics at ×100 magnification. Bar = 10 μm. 
 
 
How does one explain that genes encoding transcription factors induced during the 
yeast-to-hypha transition are dispensable for filamentation? Before presenting the concept 
of secondary effect genes, one has to bear in mind that hyphal growth is regulated by a 
complex network of signaling pathways, which lie parallel to or converge onto one another 
(Figure 1.8). In Spider medium, the yeast-to-hypha transition is controlled mainly by the 
Ras1p-cAMP-PKA signaling pathway, while other pathways, such as the MAP kinase and 
Cph2p-dependent pathways, play minor roles. CPH1 and CPH2 transcript levels are 
induced as a result of hyphal growth being driven by the Ras1p signaling pathway. Their 
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modulation is merely a consequence, a secondary effect of an induced hyphal growth 
program. Hence, secondary effect genes are genes that are differentially expressed, but that 
are not required for a specific phenotype, e.g. CPH1 and CHP2 in Spider-induced 
filamentation. The induction of UME6 also stems from a secondary effect, given that it is a 
downstream target of most signaling pathways and is induced by upstream regulators such 
as Ras1p and Tec1p (Zeidler et al., 2009). Additionally, the upregulation of Tup1-regulated 
GAT2 may be the result of Ras1p-dependent induction of hyphal growth combined to 
Tup1p-dependent derepression of filamentation (Garcia-Sanchez et al., 2005; Kadosh & 
Johnson, 2005). Thus, when analyzing transcriptional data, one has to beware of secondary 
effect genes. The combination of transcriptional profiling with other methods, i.e. 
phenotypic screening of deletion strains, enables one to eliminate such genes, an important 
step when filtering transcriptional data (discussed in 4.2.3). 
 
4.2.2 Genes upregulated by CLA  
Transcriptional profiling revealed that hallmark genes of β-oxidation, the glyoxylate 
cycle, and gluconeogenesis were upregulated in CLA-treated cells, suggesting that this fatty 
acid could be converted to glucose (Table S2-S4). C. albicans has the ability to use 
alternative carbon sources, including fatty acids such as myristic, palmitic, oleic, linoleic, 
linolenic, and arachidonic acids as sole carbon sources (Deva et al., 2000; Ramirez & 
Lorenz, 2007; Ramirez & Lorenz, 2009). Fatty acid metabolism involves β-oxidation, the 
glyoxylate cycle, and gluconeogenesis enzymes, which convert fatty acids to acetyl-CoA 
and then to sugar phosphates, while replenishing tricarboxylic acid (TCA) cycle 
intermediates to generate energy.  
 
Upon the yeast-to-hypha transition, a metabolic shift from aerobic respiration to 
fermentation occurs. Indeed, genes involved in glycolysis and fermentation were shown to 
be upregulated during filamentation, most of them being Efg1p-regulated (Bahn et al., 
2007; Doedt et al., 2004). This shift is required for hyphal growth, as glycolytic inhibitors 
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interfered with the yeast-to-hypha transition in C. albicans (Land et al., 1975a). It was ruled 
out that fatty acid metabolism interfered with metabolic specialization of cells induced to 
filament by confirming that CLA inhibited hyphal growth in mutant strains which are 
unable to metabolize fatty acids (Ramirez & Lorenz, 2007; Ramirez & Lorenz, 2009) 
(Figure 4.4). The upregulation of genes involved in fatty acid metabolism was a secondary 
effect of the response of cells to CLA. In light of these findings, similar microarray 
experiments using strains defective in fatty acid metabolism could be performed to reduce 
the amount of transcriptional data, yielding cleaner transcriptional profiles, devoid of 
differentially expressed secondary effect genes.  
 
Fatty acids are not only used as nonfermentable carbon sources, but they are also 
derived into oxygenated lipid metabolites (oxylipins) such as eicosanoids, which include 
prostaglandins and leukotrienes (Erb-Downward & Huffnagle, 2006). While eicosanoids 
are typically derived from arachidonic acid, 18-carbon PUFAs such as linoleic and α-
linolenic acids can also serve as precursors for the synthesis of oxylipins (Noverr et al., 
2003). This notion is relevant because eicosanoids PGE2 and TXB2 have been reported to 
promote filamentation in C. albicans (Kalo-Klein & Witkin, 1990; Noverr & Huffnagle, 
2004). OLE2 and FET3 appear to be involved in prostaglandin synthesis (Erb-Downward & 
Noverr, 2007). Thus, it cannot be excluded that CLA is converted into oxylipins which, in 
turn, are responsible for its hypha-inhibiting properties. Examining CLA’s effect in strains 
in which prostaglandin synthesis is defective, i.e. deleted for OLE2 and/or FET3, could 
shed light on the role of prostaglandins in the CLA-mediated hyphal growth inhibition. 
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Figure 4. 4 Inhibition of hyphal growth by CLA does not depend on its metabolism.  
Parental (SC5314) and mutant strains fox2/fox2 (MRC6), icl1/icl1 (MRC10) and ctf1/ctf1 (MRC41) 
strains were grown in Spider medium at 37°C in the absence or presence of 100 μM CLA for 4 h. 
Cells were visualized using DIC optics at ×100 magnification. Bar = 10 μm. 
 
 
4.2.3 Genes downregulated by CLA 
CLA reduced the magnitude of expression of hypha-specific genes (HSGs) and 
genes encoding morphogenesis regulators (Table S4). Expression levels of hyphal markers, 
such as HWP1, ALS3, and RBT1, were greatly reduced in CLA-treated cells compared to 
untreated cells (Table S4). However, except for HGC1, HSGs are not essential for 
morphogenesis, suggesting that they do not mediate CLA’s effect on the yeast-to-hypha 
transition (Zheng & Wang, 2004). CLA modulated the expression of several genes 
encoding transcription factors and regulators of hyphal growth (Figure 2.3C). Because they 
are involved in morphogenesis, GAT2, UME6, TEC1, RFG1 RAS1, BEM2, and MSB2 
appeared to be potential targets of CLA. Screening strains deleted for several of these genes 
revealed that UME6 and RFG1 were not required for the CLA-mediated hyphal growth 
inhibition (Figure 2.4). Thus, UME6 and RFG1 are modulated as a result of CLA affecting 
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another target and are thus secondary effect genes. The examination of deletion strains 
revealed that RAS1 and TEC1 were both required for hyphal growth in Spider medium (data 
not shown). Given that RAS1 and TEC1 function in the same pathway, these findings 
suggest that CLA may inhibit filamentation by affecting the Ras1p signaling pathway. This 
assumption was based on a phenotypic screen that was by no means exclusive. Since strains 
deleted for GAT2, MSB2, and BEM2 were not screened, it cannot be excluded that one of 
these genes encodes the target of CLA which mediates the fatty acid’s effect on hyphal 
growth.  
 
The mode of action of a small molecule can be investigated using gene expression 
profiling, which generates the global transcriptional effects exerted by a molecule in a 
given context (specific process, growth conditions, etc.). In the present study, the 
transcriptional effects of CLA on the yeast-to-hypha transition in C. albicans were 
examined. Given that such an approach generates extensive data, extrapolating a 
mechanism of action might turn out to be a laborious task. First, the target(s) of a small 
molecule may not be modulated at the transcriptional level. Second, the genes that are 
bound to be modulated tend to be downstream effectors which are not necessarily involved 
in a given effect. For instance, genes involved in fatty acid metabolism and hypha-specific 
genes are the most differentially expressed genes in response to CLA, but none play a role 
in the CLA-mediated hyphal growth inhibition. Third, not all genes have a known 
biological function.  
 
Because of these disadvantages, it is essential to use other methods in conjunction 
with transcriptional profiling in order to identify cellular targets mediating a phenotype. 
Screening collections of C. albicans mutant strains for their capacity to filament in Spider 
medium and for their response to CLA could constitute a means to identify potential CLA 
targets, i.e. genes encoding activators of Spider-induced filamentation or repressors 
mediating CLA’s effect on hyphal growth. Two sets of C. albicans deletion strains are 
available, one of 143 strains deleted for transcriptional regulators and another of 674 
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homozygous deletion strains (Homann et al., 2009; Noble et al., 2010). The screening of 
these collections has shown that GAT2, orf19.4998, and TEC1 were essential for 
filamentation induced on solid Spider medium. Since these genes regulate filamentation in 
Spider medium and they were CLA-modulated (Table S4), they may constitute CLA 
targets, as their respective deletions phenocopy CLA’s effect on hyphal growth. In fact, 
TEC1 is an indirect target of CLA because it lies downstream of Ras1p, which is the 
primary target of CLA (Figure 2.5; discussed in 4.3). By combining a phenotypic screen 
with gene expression analysis, transcriptionally-modulated targets can be validated, 
secondary effect genes can be eliminated, and genes that are not modulated 
transcriptionally or that have not been annotated can be identified.  
 
 
4.3 CLA targets Ras1p signaling  
4.3.1 CLA affects GFP-Ras1p levels and its subcellular localization  
RAS1 encodes one of the two Ras GTPases of C. albicans. Unlike its S. cerevisiae 
homologue, RAS1 is not essential for cell viability. However, it is required for hyphal 
growth under a variety of hypha-inducing conditions, including Spider medium (Leberer et 
al., 2001; Zhu et al., 2009). RAS1 mRNA and protein levels increased at the onset of the 
yeast-to-hypha transition (Figure 2.6A and B). CLA prevented RAS1 induction. Instead, 
transcript levels remained comparable to levels at the zero time point (Figure 2.6A), 
suggesting that CLA may interfere directly or indirectly with an activator of RAS1 
transcription (discussed in 4.5). Thus, based on its mRNA levels, Ras1p cellular levels 
should have remained unchanged compared to levels at the zero time point. Unexpectedly, 
GFP-Ras1p protein levels decreased in CLA-treated cells (Figure 2.6B). 
 
Why do GFP-Ras1p protein levels decrease in presence of CLA? Reduced protein 
levels can be due to a decrease in mRNA transcription or translation or to mRNA or protein 
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degradation. In presence of CLA, RAS1 transcript levels remained constant, indicating that 
a decrease in transcription or mRNA degradation did not account for reduced GFP-Ras1p 
protein levels. Additionally, transcriptional profiling revealed that 61 genes encoding 
components of the translational machinery were repressed at 37°C, whether CLA was 
present or not (Figure S1B). Thus, it is unlikely that reduced GFP-Ras1p levels were 
caused by a halt in translation, as this decrease would not have been specific to CLA-
treated cells. In fact, the downregulation of translation has been observed in C. albicans 
cells grown in presence of serum or phagocytosed (Lorenz et al., 2004; Nantel et al., 2002).  
  
Protein degradation may account for the decline in GFP-Ras1p levels. Abnormal, 
short-lived, damaged, denatured, or delocalized proteins undergo degradation (Ciechanover 
et al., 2000; Paiva et al., 2009; Roman et al., 2009a). Strikingly, GFP-Ras1p appeared 
delocalized from the plasma membrane in CLA-treated cells (at 30°C) (Figure 2.6C; 4.6). 
In these conditions, i.e. Spider 30°C, CLA also reduced RAS1 mRNA and protein levels 
(Figure 4.5). Several lines of evidence indicate that the delocalization of Ras from the 
plasma membrane influences its cellular levels. For instance, in S. cerevisiae, a Ras2p 
mutant that was not palmitoylated was delocalized from the membrane and had lower 
cellular levels compared to the wild-type protein (Deschenes & Broach, 1987). In EJ cells, 
farnesylthiosalicylic acid dislodged Ras from its membrane anchorage sites, reducing 
membrane-bound Ras levels, accelerating its degradation, and decreasing its cellular levels 
(Haklai et al., 1998). It is tempting to speculate that in CLA-treated cells, the delocalization 
of GFP-Ras1p from the plasma membrane results in its degradation, thus reducing its 
protein levels (Figure 2.6). 
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Figure 4. 5 CLA decreases RAS1 mRNA and protein levels. 
(A) SC5314 cells were grown in Spider medium at 30°C in the absence or presence of 25 μM CLA 
and harvested at the indicated time points. Transcript levels of RAS1 were measured by quantitative 
PCR and normalized to those for ACT1. Relative expression levels were obtained by normalizing 
data for each time point to data obtained at time zero. Data are means and standard deviations for 
duplicate biological samples. (B) Ras1p protein levels were analyzed using a strain expressing GFP-
Ras1p. Total protein extracts were prepared from SC5314 (mock) and GFP-Ras1p (WY-ZXD3) 
strains grown as described for panel A in the absence or presence of 100 μM CLA. Western blotting 
analysis was performed using anti-GFP antibodies. Gsp1p, shown as a loading control, was detected 
using antibodies raised against S. cerevisiae Gsp1p.   
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Alternatively, the degradation of GFP-Ras1p may be an artefact stemming from the 
nature of the protein, in that GFP-Ras1p is a fusion protein. Delocalized from the plasma 
membrane, GFP-Ras1p may be recognized as an abnormal protein and subsequently 
degraded. However, GFP fusion proteins have been used as tools to study protein 
localization, expression, and turnover. In S. cerevisiae, a GFP fusion protein was used to 
study the protein turnover of the lactate permease Jen1p in response to glucose (Paiva et al., 
2002). In C. albicans, a GFP-Ras1p-expressing strain was used to examine the subcellular 
localization and kinetics of expression of Ras1p (Zhu et al., 2009). Although it is unlikely 
that reduced GFP-Ras1p levels were caused by the degradation of the fusion protein, these 
results should be validated by examining Ras1p endogenous levels using either specific 
home-made and tested or commercial antibodies. However, commercial antibodies that 
specifically recognize the C. albicans Ras1p protein are currently unavailable.  
 
To further substantiate the findings pertaining to the delocalization of GFP-Ras1p 
from the plasma membrane and its potential degradation, several experiments could be 
performed. First, cell fractionation could provide a means to confirm the delocalization of 
GFP-Ras1p as demonstrated by microscopic observation and to assess quantitatively the 
abundance of GFP-Ras1p in membranes and in the cytosol. Second, it could be interesting 
to examine how GFP-Ras1p is degraded, either via the proteasome or the 
vacuole/lysosome. The pre1 conditional mutant strain, in which the proteasome machinery 
can be impaired, could be used to determine whether or not the proteasome is involved in 
Ras1p degradation (Roman et al., 2009a). Staining of vacuoles and colocalization studies 
could be used to determine whether or not Ras1p is targeted to the vacuole for degradation 
(Kruckeberg et al., 1999; Paiva et al., 2002). 
 
4.3.2 Causes of GFP-Ras1p delocalization 
Ras proteins undergo posttranslational modifications by lipids. Such modifications 
are important for Ras membrane targeting, subcellular localization, and effector 
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interactions. Ras proteins terminate with a CAAX tetrapeptide sequence which, once lipid-
modified, enables membrane anchorage (Wennerberg et al., 2005). Prenylation is the 
addition of a farnesyl group to the cysteine residue of the CAAX motif catalyzed by 
farnesyl transferase, while palmitoylation consists in the addition of the fatty acid palmitate 
to a cysteine residue near the carboxyl end (Figure 1.14). Prenylation is required for the 
association of Ras to ER and Golgi endomembranes, while palmitoylation allows Ras to be 
anchored stably within the plasma membrane (Hancock, 2003; Linder & Deschenes, 2007). 
Interestingly, when Ras prenylation was blocked using a protein farnesyl transferase 
inhibitor, hyphal growth was blocked in C. albicans (McGeady et al., 2002). These 
findings suggest that Ras posttranslational modifications play a role in the yeast-to-hypha 
transition in C. albicans. 
 
CLA treatment results in the delocalization of GFP-Ras1p and in the inhibition of 
hyphal growth. Both of these effects may be due to the fatty acid interfering with the 
posttranslational modifications of Ras1p. Prenylation involves two enzymes: HMG-CoA 
reductase, which produces the farnesylpyrophosphate precursor mevalonate, and farnesyl 
transferase I, which catalyzes the attachment of the farnesyl group (Collett et al., 2001; 
Nickerson et al., 2006). CLA’s effect on prenylation could be determined by quantifying 
HMG-CoA reductase transcript and/or protein levels and/or by assessing farnesyl 
transferase activity, measured by the incorporation of radiolabeled farnesylpyrophosphate 
(Collett et al., 2001). Interestingly, there is evidence that farnesol promotes the 
posttranscriptional degradation of HMG-CoA reductase in mammalian cells (Correll et al., 
1994; Meigs & Simoni, 1997). It is not known whether or not the same phenomenon occurs 
in farnesol-treated C. albicans cells. However, according to transcriptional data, HMG1 
expression levels were not differentially expressed, suggesting that CLA does not affect 
HMG-CoA reductase mRNA levels (Table S7). CLA’s effect on palmitoylation could be 
determined by measuring the incorporation of radiolabeled palmitate which reflects the 
activity of palmitoyl transferase (Collett et al., 2001; Deschenes & Broach, 1987). While it 
cannot be excluded that CLA affects GFP-Ras1p’s localization by interfering with its 
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posttranslational modifications, such a hypothesis appears rather unlikely, given that in 
mammalian cells, long-chain PUFAs modulated Ras localization without affecting its 
posttranslational processing (Collett et al., 2001; Davidson et al., 1999).  
 
Alternatively, the delocalization of GFP-Ras1p may be an indirect effect of CLA 
affecting another cellular component, e.g. the plasma membrane, which constitutes one of 
the microenvironments of Ras. The lipidated C-terminus of Ras anchors it to the inner 
leaflet of the plasma membrane (Brunsveld et al., 2009). As a peripheral protein, Ras does 
not transverse the plasma membrane, but is rather only associated to it. Peripheral proteins 
are subject to changes in their lipidic microenvironment, which can influence their 
localization (van der Rest et al., 1995). For instance, the PUFA docosahexaenoic acid 
(DHA) reduced the abundance of membrane-bound Ras in mouse colon cells by altering 
the plasma membrane structure (Collett et al., 2001; Seo et al., 2006). Indeed, DHA-
enriched membranes were suggested to have a looser packing, thereby weakening van der 
Waals interactions between anchors of lipidated proteins and phospholipid acyl chains (Seo 
et al., 2006). Based on this line of evidence, it is possible that CLA indirectly affects GFP-
Ras1p localization by altering the plasma membrane structure (discussed in 4.3.3; 4.3.4). 
 
4.3.3 A link between plasma membrane properties and hyphal growth 
n-3 PUFAs as well as CLA have been suggested to alter basic properties of cell 
membranes, including phospholipid acyl chain order, fluidity, lipid rafts, and microdomain 
organization (Chapkin et al., 2008; Ma et al., 2004; Stillwell & Wassall, 2003). In C. 
albicans, several membrane properties appear to influence hyphal development. For 
instance, the balance between unsaturated and saturated fatty acids is critical for hyphal 
growth, but membrane fluidity is not (Krishnamurthy et al., 2004; Xu et al., 2009). In 
addition, lipid rafts, which are membrane microdomains enriched in sterols and 
sphingolipids, play a role in filamentation (Martin & Konopka, 2004). Thus, the CLA- 
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mediated hyphal growth inhibition may be due to the fatty acid modulating a property of 
the plasma membrane. 
 
RTA3, which encodes an integral membrane transporter, was induced in CLA-
treated cells (Table S4). This result was initially taken as genetic evidence that the fatty 
acid was affecting the membrane. Indeed, RTA3 is homologous to the S. cerevisiae flippase 
RSB1, whose expression is induced when plasma membrane glycerophospholipid 
asymmetry is altered (Ikeda et al., 2008). In an attempt to further demonstrate that CLA 
modulated the plasma membrane, sensitivity of untreated and CLA-treated cells to various 
membrane perturbing agents, including hygromycin B, calcofluor white, and lithium 
chloride, was examined. However, CLA did not alter sensitivity of cells to the 
aforementioned agents, suggesting that CLA’s effect on the membrane may have been too 
mild to detect using this type of assay (data not shown). Alternatively, it may be more 
relevant to determine whether or not CLA modulates cellular ratios of unsaturated to 
saturated fatty acids and membrane unsaturation levels and/or interferes with the 
polarization of lipid rafts, as such properties are known to impact hyphal growth in C. 
albicans (Krishnamurthy et al., 2004; Martin & Konopka, 2004). 
 
4.3.4 Potential mechanism for the CLA-mediated delocalization of GFP-
Ras1p  
Microscopic observations showed that in C. albicans, GFP-Ras1p was already 
membrane-bound prior to hyphal induction (Figure 4.6, upper panel). In untreated cells, 
levels of GFP-Ras1p at the membrane were maintained throughout time, as reflected by the 
consistent fluorescent rim. In contrast, 30 minutes upon CLA treatment, levels of 
membrane GFP-Ras1p started to decrease (Figure 4.6), and remained low at later time 
points (Figure 2.6C; data not shown). Additionally, intracellular fluorescent clusters 
appeared, suggesting a localized accumulation of GFP-Ras1p. How may one explain 
CLA’s effect on GFP-Ras1p localization, i.e. its reduced levels at the plasma membrane 
and its relocalization to intracellular clusters? Does CLA dislodge GFP-Ras1p from the 
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membrane or does it prevent newly synthesized GFP-Ras1p from being properly anchored 
in the membrane? How can evidence pertaining to the subcellular localization and 
trafficking of Ras proteins accommodate these findings?  
 
Ras undergoes depalmitoylation/palmitoylation cycles, enabling it to traffic to and 
from the plasma membrane. This continuous cycle occurs on a time scale of minutes and 
maintains the steady-state distribution between Ras membrane and intracellular pools 
(Rocks et al., 2005). Thus, in both untreated and CLA-treated cells, the membrane-bound 
pool of GFP-Ras1p may be depalmitoylated at the membrane, relocalized to other 
membranes, repalmitoylated at the ER/Golgi complex, and retargeted to the plasma 
membrane (Figure 1.15). In untreated cells, Ras1p trafficking probably proceeds 
unperturbed, which would account for the steady-state levels of membrane-bound GFP-
Ras1p (Figure 4.6). In contrast, CLA may prevent lipidated GFP-Ras1p from being 
properly anchored in the membrane. Indeed, there is evidence that unsaturated membranes 
do not constitute an environment conducive to the attachment of lipidated proteins such as 
Ras (Seo et al., 2006). Thus, repalmitoylated GFP-Ras1p may be delivered to the plasma 
membrane via the classical secretory pathway, but may be unable to associate with it, 
resulting in decreased levels of membrane-bound GFP-Ras1p.  
 
This model remains purely speculative, as it is still unclear whether or not the Ras 
depalmitoylation/palmitoylation cycle operates in yeast (Linder & Deschenes, 2007). In S. 
cerevisiae, Ras trafficking from the ER to the plasma membrane does not seem to involve 
the secretory pathway (Linder & Deschenes, 2007; Wang & Deschenes, 2006), although in 
Cryptococcus neoformans, Ras proteins appeared to sort through the Golgi (Nichols et al., 
2009; Omerovic et al., 2007). Interestingly, the intracellular clusters in which Ras proteins 
accumulated resembled the fluorescent clusters visible in CLA-treated cells (Figure 4.6). 
Staining CLA-treated cells with a vesicle dye could help confirm the nature of these 
structures. Additionally, in S. cerevisiae, functional mitochondria appeared to be involved 
in the trafficking of Ras to the plasma membrane (Wang & Deschenes, 2006). Strikingly, 
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CLA had a strong effect on the expression of mitochondrial genes (data not shown), 
suggesting an association between the fatty acid, mitochondria, and Ras trafficking to the 
membrane. These results warrant the further examination of mitochondria, which could be 
labeled with MitoTracker, a mitochondrion-specific dye, to perform colocalization studies 
with GFP-Ras1p. 
 
Another factor that needs to be addressed is the time frame. Indeed, the proposed 
model depends on CLA altering the plasma membrane structure by increasing its 
unsaturation levels. To do so, CLA first has to be incorporated into membrane 
phospholipids. If unsaturated, CLA-enriched membranes affect the localization of GFP-
Ras1p as early as 30 minutes upon treatment with the fatty acid, then CLA must be 
incorporated into membrane phospholipids within a similar time frame. Such an issue has 
not been addressed per se in C. albicans. However, in S. cerevisiae, there is evidence that 
oleic acid treatment changes the composition of membrane phospholipids within 30 
minutes, increasing the cellular ratio of unsaturated to saturated fatty acids (Petschnigg et 
al., 2009). Moreover, in C. albicans biofilm cells, a 48-h treatment with 1 mM of 
arachidonic acid increased the unsaturation index of membrane phospholipids (Ells et al., 
2009). Thus, CLA treatment may increase unsaturation levels of membrane phospholipids, 
thus creating an environment in which lipidated GFP-Ras1p cannot be anchored properly, 
resulting in its delocalization from the plasma membrane. Examining the fatty acyl 
composition of membrane lipids in CLA-treated cells could lend support to this hypothesis. 
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Figure 4. 6 Effect of CLA on the subcellular localization of GFP-Ras1p in C. albicans. 
GFP-Ras1p-expressing cells were grown in Spider medium at 30°C in the absence or presence of 
100 μM CLA. Aliquots of cells were removed and examined directly at ×100 magnification using 
epifluorescence.  
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4.3.5 Downstream consequences of CLA-modulated Ras1p signaling 
4.3.5.1 Activation of the MAP kinase pathway 
CLA impacted GFP-Ras1p in two ways: first, by reducing its cellular levels, and 
second, by causing its delocalization from the plasma membrane (Figure 2.6). Although 
Ras has been reported to signal from various cellular locations, in S. cerevisiae, the 
cytoplasmic Ras2p was 100-times less effective than the plasma membrane-localized Ras2p 
(Hancock, 2003; Kuroda et al., 1993). Thus, suboptimal GFP-Ras1p localization and 
concentrations are bound to impede Ras1p signaling, including the activation of the MAP 
kinase and the cAMP-PKA signaling pathways (Leberer et al., 2001). The phosphorylation 
status of the ERK-like kinase Cek1p reflects the activity of Ras1p. In presence of CLA, 
Cek1p was not phosphorylated, indicating the fatty acid interfered with Ras1p signaling 
(Figure 4.7A). Likewise, the hypha-inhibiting molecule farnesol also repressed Cek1p 
phosphorylation (Roman et al., 2009a). However, CLA-mediated hyphal growth inhibition 
did not depend on CEK1 (Figure 4.7B). The apparent inactivation of the MAP kinase 
pathway is not the cause, but rather the consequence of CLA inhibiting filamentation by 
affecting another signaling pathway, i.e. the cAMP-PKA pathway.  
 
4.3.5.2 Activation of the cAMP-PKA-Efg1p pathway 
Ras1p interacts with the Ras-association domain of the adenylate cyclase Cyr1p to 
promote cAMP synthesis (Fang & Wang, 2006). cAMP binds to the regulatory subunit of 
PKA (Bcy1p), causing a conformational change and releasing the catalytic subunits Tpk1p 
and Tpk2p, which are free to activate downstream effectors. Efg1p is the potential target of 
PKA, as it harbors a potential phosphorylation site for A-type kinases at T206 (Bockmuhl 
& Ernst, 2001; Sonneborn et al., 2000). In hypha-inducing conditions, Efg1p is activated 
by PKA isoforms Tpk1p and Tpk2p. Activated Efg1p downregulates its own promoter 
activity, thereby reducing EFG1 expression levels (Tebarth et al., 2003). The transcription 
factor TEC1, partially regulated by Efg1p, is expressed in response to hypha-inducing 
conditions. Given that the activation of the cAMP-PKA-Efg1p pathway depends on Ras1p, 
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CLA’s effects on several of the aforementioned molecular events or components of the 
pathway were examined.  
 
 
 
Figure 4. 7 CLA affects the activation of the MAP kinase pathway.  
(A) CLA represses Cek1p phosphorylation. Total protein extracts were prepared from SC5314 and 
cek1/cek1 strains grown in Spider medium at 37°C for the indicated times, in the absence or 
presence of 100 μM CLA. The phosphorylated form of Cek1p was detected using anti-p44/p42 
antibodies (indicated as Cek1p-P), while total cellular levels of Cek1p were detected using a rabbit 
anti-Cek1p. (B) CEK1 is not required for CLA-mediated inhibition of hyphal growth. SC5314 and 
cek1/cek1 strains were grown as described in (A) for 4 h. Cells were visualized using DIC optics at 
×100 magnification. Bar = 10 μm.  
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Cellular cAMP concentrations increase as a result of the binding of Ras1p to Cyr1p. 
Thus, lower cAMP levels may indicate that CLA disrupts the Ras1p-Cyr1p branch of 
Ras1p signaling. Instead of measuring cAMP concentrations directly, the behavior of 
cAMP responsive genes was examined in presence of CLA. Transcriptional profiles of 
CLA-treated cells and a cyr1/cyr1 mutant strain lacking cAMP did not overlap, suggesting 
cAMP concentrations were not reduced in CLA-treated cells (data not shown). Several 
reasons may account for this result. First, CLA’s effect on cAMP levels may be more subtle 
than effects resulting from the deletion of CYR1. Indeed, cAMP-downregulated genes such 
as CSP37, BCY1, TPK2, SOD2, and HSP12 (Bahn et al., 2007; Harcus et al., 2004) were 
somewhat upregulated in CLA-treated cells (Figure 4.8A). Second, CLA may affect cAMP 
levels prior the 90-minute time point at which gene expression analyses were performed, 
given that the spike in cAMP levels is transient and rather short-lived (Jung & Stateva, 
2003; Zhu et al., 2009). Third, cAMP synthesis may simply be Ras1p-independent, and 
thus not affected by CLA. In S. cerevisiae, cAMP production is stimulated by Cyr1p 
interacting with Gpa2p (Kubler et al., 1997; Lorenz & Heitman, 1997), while in C. 
albicans, Gpr1p-Gpa2p function upstream of Cyr1p (Maidan et al., 2005a). Additionally, 
Ras1p does not signal exclusively through Cyr1p, as the deletion of RAS1 only affects a 
subset of Cyr1p-dependent genes (Harcus et al., 2004). Hence, CLA may be affecting 
Ras1p signaling independently of Cyr1p and cAMP signaling. To determine whether or not 
CLA impacts Ras1p-cAMP branch of Ras1p signaling, the levels of Ras1p interacting with 
Cyr1p in untreated and CLA-treated cells could be examined.  
 
If CLA blocked filamentation by interfering with the association of Ras1p to Cyr1p 
and the synthesis of cAMP, then the addition of exogenous cAMP should restore proper 
cAMP levels as well as hyphal growth to CLA-treated cultures. Providing exogenous 
cAMP to correct hyphal defects is a standard way to demonstrate that a mutation or a 
molecule impacts cAMP signaling in C. albicans (Davis-Hanna et al., 2008; Leberer et al., 
2001). When CLA-treated cultures were amended with 10 mM dibutyryl cAMP, 
filamentation was only restored partially (Figure 4.8B). These results, combined to the fact 
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cAMP-responsive genes were not modulated by CLA, may indicate that CLA affects Ras1p 
signaling, but not cAMP signaling. However, it seems that using exogenous cAMP to 
rescue hyphal defects may yield inconsistent results. For instance, one group showed that 
exogenous cAMP rescued the filamentation defect of a cyr1/cyr1 mutant (Leberer et al., 
2001; Rocha et al., 2001), while another group reported that no more than 5% of the 
cyr1/cyr1 cells exhibited hyphal growth (Fang & Wang, 2006).  
 
Figure 4. 8 CLA’s effect on cAMP signaling 
(A) Fold-change of several cAMP-downregulated genes in untreated and CLA-treated cells at 37°C. 
The significantly differentially expressed genes were obtained by comparing the transcriptional 
profile of cells at 37°C with that of CLA-treated cells at 37°C and are listed in Table S4. Data are 
fold-change values. (B) Effects of dibutyryl cAMP (10 mM) on SC5314 cells grown in Spider 
medium in the absence or presence of CLA for 5 h at 37°C. Cells were visualized at ×40 
magnification.  
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Upon binding cAMP, Bcy1p releases the catalytic subunits of PKA, thereby 
enabling their activity. Instead of examining CLA’s effect on PKA activity, the role played 
by Tpk1p or Tpk2p in the CLA-mediated hyphal growth inhibition was determined. In 
liquid Spider medium, filamentation depended mostly on TPK2. However, CLA inhibited 
the residual filamentous growth in the tpk2/tpk2 mutant strain, suggesting that TPK2 was 
not required for CLA’s effect on filamentation (Figure 4.9). Similar results were obtained 
using the tpk1/tpk1 mutant and the PCK1p-TPK1/tpk1/tpk2/tpk2 strain, in which both TPK2 
alleles are missing and one of the TPK1 alleles is placed under the control of the PCK1 
promoter (data not shown). The conditional mutant was reported to exhibit a severe 
filamentation defect in Spider medium (Bockmuhl et al., 2001). In our hands, it behaved 
similarly to the tpk2/tpk2 mutant, probably because the PCK1 promoter was moderately 
expressed in Spider medium. That CLA inhibited hyphal growth independently of TPK1 
and TPK2 may be due to the functional redundancy exhibited by both PKA isoforms.  
 
 
Figure 4. 9 Morphology of PKA mutant strains.  
Parental and mutant strains tpk1/tpk1 (IIHB6), tpk2/tpk2 (TPO7.4), and PCK1pTPK1/tpk1/tpk2/tpk2 
(M231) were induced to filament in Spider medium at 37°C in the absence or presence of CLA (100 
μM) for 4 h. Cells were visualized by DIC optics at ×100 magnification. Bar = 10 μm.
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The morphogenetic regulator Efg1p is necessary for hyphal growth in most hypha-
inducing conditions, including in Spider medium (data not shown). Thus, Efg1p was 
believed to be a potential downstream target of CLA. However, several lines of evidence 
clearly demonstrate the opposite, in that CLA does not affect the Efg1p branch of Ras1p 
signaling. First, CLA had no effect on EFG1 mRNA or protein levels, as both decreased in 
untreated and CLA-treated cells (Figure 4.10A and inset). Second, several glycolytic genes, 
including FBA1, PGK1, and GLK1, which are induced in an EFG1-dependent manner were 
not modulated by CLA (Figure 4.10B) (Doedt et al., 2004). Third, TEC1 expression levels 
were downregulated by CLA independently of EFG1 (Figure 4.10C). The Efg1p-
independent modulation of Ras1p signaling has rarely been reported, except in the case of 
geldanamycin-induced filamentation (discussed in section 3.8). The Hsp90p inhibitor 
geldanamycin was shown to promote filamentous growth by modulating the Ras1p-cAMP-
PKA signaling pathway independently of Efg1p (Shapiro et al., 2009).  
 
Taken together, results presented in Chapter 2 suggest that CLA reduces Ras1p 
cellular levels as well as TEC1 mRNA levels, without affecting cAMP signaling or Efg1p 
levels and activity. At first glance, it appears difficult to reconcile such results with the 
current Ras1p signaling model, which proposes that Ras1p interacts with Cyr1p to produce 
cAMP, which activates PKA and Efg1p. Fortunately, two lines of evidence concur with our 
findings, the first being that Ras1p does not only signal through Cyr1p (Harcus et al., 
2004), the second being the existence of a Ras1p-dependent pathway parallel to the Efg1p 
and MAP kinase pathways, which may include Tpk1p or Tpk2p, but not Efg1p (Bockmuhl 
et al., 2001). The latter conclusion was reached based on the fact that RAS1 overexpression 
suppressed the hyphal growth defect of an efg1/efg1 mutant, but not of tpk1/tpk1 and 
tpk2/tpk2 mutants. Thus, it is possible that CLA’s effect on Ras1p signaling may be 
mediated by Ras1p, PKA and Tec1p, independently of Cyr1p, cAMP, and Efg1p. CLA 
may affect TEC1 expression either via an unknown regulator or via PKA.  
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Figure 4. 10 CLA does not modulate the Efg1p-dependent branch of Ras1p signaling.  
(A) EFG1 expression levels in cells induced to filament in Spider medium in the absence or 
presence of CLA. Transcript levels of EFG1 were measured by quantitative PCR and normalized to 
ACT1. Relative expression levels were obtained by normalizing data for each time point to data 
obtained at time zero. Data are means and standard deviations for duplicate biological samples. 
(inset) Total protein extracts were prepared from SC5314 cells (mock) and Efg1p-3XHA (JS2284) 
cells at the zero time point or grown as in (A) for 90 minutes. Efg1p-3XHA was 
immunoprecipitated using Anti-HA Affinity Matrix. Western blotting analysis was performed using 
anti-HA antibodies (clone 12CA5). Molecular masses are indicated on the left. (B) Expression 
levels of Efg1p-regulated glycolytic genes. Data are fold-change values and were obtained by 
comparing growth in Spider medium at 37°C in absence or presence of CLA to that at 30°C. (C) 
TEC1 and HWP1 expression levels in parental and efg1/efg1 (HLC52) strains grown as described in 
(A) for 90 minutes. ACT1 is shown as the loading control.  
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4.4 CLA affects the Tup1p-Nrg1p signaling pathway  
Because the hyphal growth program is controlled by a network of signaling 
pathways, the effect of CLA can be expected to be multifactorial, in that the fatty acid may 
affect more than one signaling pathway. Other small molecules that modulate hyphal 
growth in C. albicans have been shown to have more than one target. For instance, the 
Tor1p specific inhibitor rapamycin enhanced filamentation and induced cellular 
aggregation by downregulating NRG1 and TUP1 expression and by activating 
transactivators Efg1p and Bcr1p (Bastidas et al., 2009) (discussed in section 3.7). Farnesol 
inhibited hyphal growth by affecting at least three different signaling pathways, including 
the Ras1p-cAMP-PKA pathway (Davis-Hanna et al., 2008), both the Hog1p and the Cek1p 
MAP kinase pathways (Roman et al., 2009a; Smith et al., 2004), and two regulators, 
namely the transcription factor Tup1p (Kebaara et al., 2008) and the histidine kinase Chk1p 
(Kruppa et al., 2004) (discussed in section 3.2). In addition to targeting the Ras1p signaling 
pathway, CLA appears to modulate the Tup1p- Nrg1p pathway. Indeed, transcriptional 
profiling showed that CLA downregulated several Tup1p- and/or Nrg1p-dependent genes, 
suggesting CLA may affect the Tup1p-Nrg1p signaling pathway (Figure 4.11). Both TUP1 
and NRG1 were required for CLA to inhibit filamentation (Figure 2.7A). Additionally, 
CLA prevented the downregulation of TUP1 and NRG1 transcripts, thus hindering the 
relief of TUP1 repression, which is required for filamentation to proceed (Figure 2.7B). 
Taken together, these results strongly suggest that the Tup1p-Nrg1p signaling pathway is 
involved in mediating CLA’s hypha-inhibiting properties.  
 
Although Tup1p-mediated repression plays a major role in the yeast-to-hypha 
transition in C. albicans, upstream regulators of the signaling pathway have yet to be 
identified (Hall et al., 2009; Hogan & Sundstrom, 2009). Braun & Johnson (2000) 
established that Tup1p, Cph1p, and Efg1p belonged to different signaling pathways and 
made independent contributions to the hyphal growth program. However, several lines of 
evidence argue against the rigidity of this model. First, RAS1 is induced upon the yeast-to-
hypha transition independently of Tup1p, Nrg1p, and Rfg1p (Kadosh & Johnson, 2005), 
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suggesting that RAS1 lies upstream of/parallel to Tup1p, Nrg1p, and Rfg1p. Second, the 
downregulation of NRG1 transcript levels depends on EFG1 (Braun et al., 2001). 
Moreover, EFG1, TEC1, CPH1, and CPH2 are required for the decrease in Nrg1p protein 
levels, thereby suggesting Nrg1p is a downstream effector of these transcription factors (H. 
Liu, unpublished results). Third, components of the MAP kinase and cAMP-PKA signaling 
pathways, including CST20, CEK1, CPH1, and PDE2, are either Tup1p- and/or Nrg1p-
regulated, suggesting that the relief of Tup1p repression exerts feedback on pathways that 
positively regulate the hyphal growth program (Jung & Stateva, 2003; Murad et al., 2001a; 
Murad et al., 2001b). 
 
 
 
 
Figure 4. 11 CLA affects the expression of Tup1p-Nrg1p-regulated genes.  
Fold-change of genes regulated by the Tup1p-Nrg1p repressor complex in untreated and CLA-
treated cells at 37°C. The significantly differentially expressed genes were obtained by comparing 
the transcriptional profile of cells at 37°C with that of CLA-treated cells at 37°C and are listed in 
Table S4. Data are fold-change values.  
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The relief of Tup1p-dependent repression may occur as a result of the Ras1p-
cAMP-PKA-Efg1p signaling pathway being activated. Activation of Efg1p and increased 
Tec1p levels may result in the downregulation of NRG1 mRNA and protein levels, which 
allows the Tup1p-mediated repression to be lifted. Thus, if Tup1p signaling is truly 
regulated by Ras1p signaling, then CLA’s effect on TUP1 and NRG1 expression was 
indirect, resulting instead from the fatty acid affecting Ras1p signaling. This suggestion is 
speculative, given that the upstream regulators of the Tup1p-Nrg1p pathway have not been 
identified.  
 
 
4.5 Proposed mechanism of action of CLA 
 One has to bear in mind that in addition to modulating GFP-Ras1p cellular levels, 
CLA also affected RAS1 transcript levels (Figure 2.6A), raising a question: are these events 
independent from one another? If not, which one occurs first? The precise mechanism by 
which hypha-inducing signals trigger Ras1p-mediated hyphal growth are not known yet 
(Hogan & Sundstrom, 2009). Additionally, regulators/inducers of RAS1 expression have 
not been identified in C. albicans. However, in S. cerevisiae, the regulatory subunit of 
PKA, Bcy1p, seems to be involved in the upregulation of RAS2 expression in response to 
growth at 37°C (Gasch et al., 2000; Segal et al., 2003).  
 
One may imagine that in response to hypha-inducing conditions, membrane-
associated Ras1p is GTP-loaded and activated. In turn, the cAMP-PKA and the MAP 
kinase signaling pathways are activated, inducing the hyphal growth program and 
promoting filamentation. The activated hyphal growth program may somehow engage a 
specific regulator of RAS1 (Bcy1p?), resulting in increased RAS1 mRNA and protein levels. 
A pool of newly synthesized and lipid-modified Ras1p may then be targeted to the 
membrane, thus sustaining Ras1p signaling and maintaining the hyphal growth program 
activated. Additionally, the downstream effectors of Ras1p signaling Efg1p and Tec1p may 
downregulate NRG1 expression, resulting in the relief of Tup1p repression. The control of 
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RAS1 transcription by Ras1p signaling would generate a positive feedback loop, thereby 
ensuring an increased pool of membrane-associated Ras1p molecules and driving Ras1p 
signaling, the hyphal growth program, and filamentation.  
 
According to the aforementioned sequence of events regulating filamentation, it is 
possible to foresee at which point CLA may interfere with the hyphal growth program. 
First, it should be mentioned that CLA does not affect Ras1p signaling and the hyphal 
growth program instantaneously. Indeed, Tec1p protein levels were induced at the 30 
minute time point in CLA-treated cells, suggesting that the hyphal growth program was 
initially activated, even in presence of CLA (Figure 4.12). This result somewhat correlates 
with the finding that cAMP levels were not significantly modulated by CLA, as Ras1p-
cAMP signaling may have been initially induced, despite the presence of CLA (discussed 
in 4.3.5.2). Thus, in CLA-treated cells, Ras1p signaling is initially activated. 
Concomitantly, Ras1p depalmitoylation/palmitoylation cycles may force Ras1p to leave the 
plasma membrane, to be relocalized and repalmitoylated at other intracellular membranes, 
and to be retargeted to the membrane. Meanwhile, CLA may be incorporated into 
membrane phospholipids, thus altering the membrane’s unsaturation levels and structure. 
CLA may affect Ras1p signaling at this point: repalmitoylated Ras1p may not be able to 
associate stably with the unsaturated membrane due to the weakening of van der Waals 
interactions between anchors of lipidated proteins and phospholipid acyl chains (Seo et al., 
2006) (discussed in sections 4.3.3; 4.3.4 ) 
 
Consequently, reduced membrane-bound Ras1p levels may downregulate Ras1p 
signaling, which impairs the activation of the MAP kinase pathway, downregulates TEC1 
expression (mRNA and protein levels), and the overall hyphal growth program. 
Additionally, decreased Tec1p levels may prevent the downregulation of NRG1 and the 
relief of Tup1p-mediated repression. In turn, the RAS1 regulator (Bcy1p?) may no longer 
be actively engaged in the hyphal growth program, preventing the increase in RAS1 mRNA 
and protein levels, and abrogating the positive feedback exerted on Ras1p signaling. In 
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turn, levels of membrane-bound Ras1p continue to decrease, which further enhances the 
impairment of Ras1p signaling and the downregulation of the hyphal growth program. This 
unifying model takes into account all results pertaining to the effect of CLA on molecular 
events that regulate the yeast-to-hypha transition in C. albicans. However, it holds true 
until the regulators of RAS1 and the mechanism by which Ras1p signaling is induced are 
identified. 
 
 
 
Figure 4. 12 Tec1p-3XHA protein levels are reduced in presence of CLA. 
Tec1p protein levels were analyzed using a strain expressing Tec1p-3XHA. Total protein extracts 
were prepared from SC5314 (mock) and Tec1p-3XHA strains induced to filament in Spider 
medium at 37°C supplemented or not with CLA. Western blotting analysis was performed using 
anti-HA antibodies. Gsp1p, shown as a loading control, was detected using antibodies raised against 
S. cerevisiae Gsp1p. Molecular weights (kDa) are shown on the left.   
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4.6 Therapeutic potential of molecules that modulate 
morphogenesis in C. albicans  
4.6.1 Modulating morphogenesis as a means to treat candidiasis 
Impairing morphogenesis of C. albicans has been proposed as a means to treat 
candidiasis. Indeed, using engineered strains in which the yeast-to-hypha transition was 
manipulated externally, blocking the morphogenetic transition reduced virulence in a model 
of systemic candidiasis (Saville et al., 2003; Saville et al., 2006). These findings reinforced 
the view that the ability to switch from one growth form to another is an important 
virulence attribute of the pathogenic yeast and constitutes a target for the development of 
antifungal drugs (Lo et al., 1997; Zheng & Wang, 2004). In parallel, many small molecules 
have been reported to modulate morphogenesis in C. albicans, but very few have been 
evaluated for their therapeutic properties in the context of infection (reviewed in Chapter 
3). So far, farnesol appears to be the only morphogenesis-modulating molecule used 
successfully to treat Candida infections. However, it was effective only against mucosal 
candidiasis, as it increased virulence in a model of systemic candidiasis (Hisajima et al., 
2008; Navarathna et al., 2007). The histone deacetylase inhibitor trichostatin A (TSA) is 
another morphogenesis-modulating molecule that may have therapeutic potential, although 
it has yet to be evaluated in vivo. TSA may prove useful for treating systemic candidiasis, 
as the deletion of its target (SET3) attenuated virulence in a mouse model of systemic 
candidiasis (Hnisz et al., 2010). 
 
Interfering with the morphogenetic transition of C. albicans to treat candidiasis is in 
line with the current trend in antifungal drug development, which favors targeting virulence 
processes instead of essential processes (Gauwerky et al., 2009; Jiang et al., 2002). 
Theoretically, such a strategy does constitute a sound therapeutic approach. Additionally, 
many small molecules that impair the yeast-to-hypha transition have been identified and 
characterized. However, as discussed in Chapter 3, an overview of the literature revealed 
that few of these molecules have been tested in vivo. Due to an important lack of clinical 
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evidence, modulating morphogenesis in C. albicans as a means to treat candidiasis remains 
a questionable therapeutic approach. Until the therapeutic potential of small molecules is 
evaluated in the context of different Candida infections, it can only be speculated that such 
compounds can be used to treat candidiasis. 
 
4.6.2 Putative therapeutic applications of CLA and fatty acids  
CLA’s effect on hyphal growth and virulence has not been tested in the context of 
candidiasis. However, based on previous evidence, on the nature of fatty acids, and on the 
type of Candida infection, several therapeutic applications of CLA and fatty acids may be 
suggested. One application of fatty acids could be to incorporate them into materials used 
to produce medical implants. Indwelling medical devices such as catheters, pacemakers, 
and prosthetic joints often become colonized with C. albicans biofilms, resulting in failure 
of the implant and a localized infection that can disseminate (Nobile & Mitchell, 2006; 
Ramage et al., 2009). Medical devices made of materials containing and/or surface-coated 
with fatty acids may thwart the development of C. albicans biofilms by preventing 
filamentation. There is a precedent to this type of application. Undecylenic acid present in 
denture liners inhibited the yeast-to-hypha switch in vitro (McLain et al., 2000). Although 
its presence in denture liners stemmed from serendipity rather than from scientific 
evidence, undecylenic acid was proposed to inhibit hyphal growth of C. albicans and 
prevent denture stomatitis, a condition often associated with Candida infections. CLA and 
other fatty acids may be expected to perform similarly. 
 
Topical formulations containing fatty acids could also be developed to treat 
superficial candidiasis such as oral thrush or VVC, as has been proposed for acetylenic 
acids and farnesol (Li et al., 2008; Navarathna et al., 2007). For instance, vaginal gels 
containing glycerol monolaurate, a 12-carbon fatty acid monoester, were shown to inhibit 
C. albicans and were well tolerated in patients (Strandberg et al., 2010).  
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Dairy-based, fatty acid-enriched probiotic products containing CLA and/or other 
fatty acids could be developed to prevent and/or GI candidiasis and VVC. GI candidiasis 
and VVC are due to the overgrowth of C. albicans. Probiotic microorganisms produce fatty 
acids, such as butyric and capric acids, which exert hypha-inhibiting properties (Krasowska 
et al., 2009; Murzyn et al., 2010; Noverr & Huffnagle, 2004). Additionally, fatty acids are 
present in milk (German & Dillard, 2006). However, the therapeutic potential of such a 
product would not only stem from the hypha-inhibiting fatty acids present in milk or 
produced by probiotic microorganisms, but also from the microorganisms themselves, 
which compete with C. albicans for nutrients and for attachment sites on host cells, and 
inhibit growth of the pathogenic yeast (Hogan & Kolter, 2007). Probiotic formulations have 
been used successfully to protect from Candida infections (Elahi et al., 2005; Hilton et al., 
1992; Martinez et al., 2009).  
 
Fatty acids could also be administered as adjuncts to conventional antifungal drugs. 
Indeed, an ongoing trend in antifungal therapy is the use of new combination therapies to 
enhance the efficacy of currently used drugs and to limit the evolution of antifungal 
resistance (Cowen & Steinbach, 2008; Steinbach et al., 2007). For instance, Hsp90p or 
calcineurin inhibitors used in combination with classical antifungals enhanced the activity 
of conventional antifungal agents and improved the treatment of various fungal diseases 
(Cowen et al., 2009; Steinbach et al., 2007). Similarly, arachidonic acid increased the 
antifungal susceptibility of C. albicans to amphotericin B and clotrimazole (Ells et al., 
2009). Thus, it is possible to imagine a similar application for CLA and other fatty acids. 
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4.7 Ecological role of fatty acids and other quorum sensing 
molecules in C. albicans morphogenesis 
Hypha-inhibiting fatty acids, including CLA, were initially isolated from bovine 
whey (Clement et al., 2007). Although interesting, these findings do not quite fit with the 
ecology of C. albicans, whose primary environmental niche is generally considered to be 
the intestinal tract of warm-blooded animals (Odds, 1988a). Additionally, it is rather 
unlikely to find C. albicans in milk or in dairy products (i.e. whey). So, is there a natural 
environment in which C. albicans is exposed to fatty acids, thus underpinning their effect 
on the morphogenetic transition of the pathogenic yeast? Or were these findings merely 
anecdotal? In the following section, the ecological significance of the hypha-inhibiting 
properties of fatty acids and other quorum sensing molecules is discussed. 
 
C. albicans inhabits the mucocutaneous surfaces of the oral cavity, the GI tract, and 
the vaginal cavity. In these host niches, the pathogenic yeast is bound to encounter 
microorganisms of the endogenous microflora. Interestingly, several lines of evidence show 
that many bacteria and yeast interact with C. albicans via fatty acid-like signaling 
molecules. For instance, the oral pathogen Streptococcus mutans was shown to secrete a 
fatty acid signaling molecule, trans-2-decenoic acid, which inhibited the yeast-to-hypha 
transition (Vilchez et al., 2010). This compound is structurally similar to the bacterially-
secreted diffusible signal factor (DSF) and to farnesoic acid, and has been termed 
Streptococcus DSF (SDSF) (Oh et al., 2001; Wang et al., 2004). Culture supernatants of 
lactic acid bacteria (LAB), important inhabitants of the gut and female reproductive tract, 
were shown to block germ tube formation (Noverr & Huffnagle, 2004). This effect was 
mimicked by the presence of 25 mM butyric acid, a concentration well within the 
physiological range observed in the colon (Noverr & Huffnagle, 2004; Saemann et al., 
2002). LAB produce biologically active short chain fatty acids as by-products of anaerobic 
fermentation, which may affect C. albicans morphogenesis (Saemann et al., 2002). 
Similarly, the probiotic yeast Saccharomyces boulardii inhibited the yeast-to-hypha 
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transition, adhesion, and biofilm formation of C. albicans by secreting capric acid 
(Krasowska et al., 2009; Murzyn et al., 2010). P. aeruginosa secretes the 3-oxo-C12 acyl 
homoserine lactone, while B. cenocepacia produces cis-2-dodecenoic acid (BDSF), two 
molecules that inhibit the yeast-to-hypha transition (Boon et al., 2008; Hogan et al., 2004). 
These quorum sensing molecules are structurally similar to the hypha-inhibiting molecules 
farnesoic acid and cis-11-methyl-2-dodecenoic acid (DSF) secreted by C. albicans and 
Xanthomonas campestris, respectively (Oh et al., 2001; Wang et al., 2004).  
 
C. albicans is also bound to encounter fatty acids derived from host cells, e.g. in 
macrophages and at the surface of the skin. Gene expression analysis demonstrated that 
upon phagocytosis, C. albicans cells underwent drastic metabolic changes, switching to an 
alternative carbon metabolism (Lorenz et al., 2004). These results suggested that cells were 
exposed to fatty acids, such as arachidonic acid (AA), derived either from Candida itself or 
from the internal milieu of the macrophage. Phagocytosed cells eventually formed hyphae, 
despite the presence of AA whose concentration may have been too low to block 
morphogenesis. Conditions found on the skin, which produces surface oils, promoted germ 
tube formation, white-opaque switching, and mating in C. albicans (Lachke et al., 2003). 
While conditions of the skin were not examined per se, oxylipins were suggested to play a 
role in these developmental processes (Erb-Downward & Huffnagle, 2006; Noverr & 
Huffnagle, 2004). In addition, opaque cells are known to have an oxidative metabolism, 
which may be indirect evidence that opaque cells present at the surface of the skin are 
exposed to fatty acids (Lan et al., 2002). 
  
In several of its preferred niches, C. albicans encounters fatty acids or fatty acid-like 
molecules, either produced by members of the host microbiota or derived from host cells, 
which generally inhibit its hyphal development. The secretion of hypha-inhibiting 
compounds may be a means by which antagonistic microorganisms maintain C. albicans in 
the yeast form and reduce its attachment to host surfaces, providing them with a 
competitive edge over the pathogenic yeast. Interactions between C. albicans and other 
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microorganisms mediated by fatty acid-like molecules appear to be ubiquitous. Given that 
milk is not a natural habitat of C. albicans, the discovery that whey-derived fatty acids 
inhibited hyphal growth was serendipitous. Yet, bacteria, yeast, and host cells interact with 
C. albicans in its natural niches by secreting fatty acids and lipidic quorum sensing 
molecules. Thus, the inhibitory effects of fatty acids and fatty acid derivatives on hyphal 
growth in C. albicans appear to be ecologically significant. 
 
 
 
  
Conclusion 
This study has allowed the hypha-inhibiting effects of several fatty acids to be 
characterized and the mechanism by which CLA blocked the yeast-to-hypha transition to be 
deciphered. Inhibition of hyphal growth stemmed from CLA (i) reducing levels of 
membrane-bound Ras1p and impairing Ras1p signaling, possibly by altering the plasma 
membrane structure, (ii) preventing the activation of the MAP kinase pathway, (iii) 
downregulating the PKA-TEC1 branch of Ras1p signaling, (iv) inhibiting the increase in 
RAS1 mRNA and protein levels, (v) possibly blocking the positive feedback loop on Ras1p 
signaling, and (vi) preventing the relief of the Tup1-mediated repression of filamentation. 
While it is possible to speculate that all fatty acids have the capacity to affect Ras1p 
signaling, it remains that the findings presented in this work are specific to CLA. Ras1p 
signaling controls aspects of filamentation and virulence in other fungi. Moreover, CLA 
inhibited hyphal growth in other Candida species, as well as in other filamentous fungi. 
Thus, it is tempting to suggest that CLA possesses a broad spectrum of anti-filamentation 
activity, given that its target is ubiquitous. However, the effect of CLA on Ras1p signaling 
in other fungi should also be demonstrated.  
 
Elucidating the mechanism of action of CLA had another purpose, namely to 
identify CLA’s target(s) and predict whether or not the fatty acid would have deleterious 
effects in humans, if it were to ever be used clinically. CLA affects Ras1p, a protein found 
in humans, and is thus bound to affect mammalian Ras proteins. However, this effect is 
unlikely to be a harmful one. Indeed, other PUFAs have been reported to modulate 
mammalian Ras proteins, and have had beneficial effects, namely by reducing 
tumorigenesis (Chapkin et al., 2008; Collett et al., 2001).  
 
This work may constitute the rationale to evaluate CLA’s therapeutic potential in 
the context of Candida infections. The therapeutic properties of CLA and other small 
morphogenesis-modulating molecules should be assessed to remedy the lack of clinical 
evidence demonstrating that impairing the yeast-to-hypha transition in C. albicans is a 
means to treat candidiasis. In addition, because such molecules target a virulence 
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determinant rather than an essential process, they are in line with the current trend in 
antifungal drug development. Studies evaluating the therapeutic potential of small 
molecules such as CLA to treat Candida infections are warranted, and may lead to the 
identification of new antifungal agents. 
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Supplementary Table S1. The significantly differentially expressed obtained by comparing 
"Experiment 37°C" with itself. Differentially expressed genes were defined by a fold 
difference > 2 and a P-value < 0.05. Only upregulated genes are shown. 
 
Systematic P-value Norm Norm Norm Name  
 
37
°C
 
30
°C
 +
 
CL
A
 
37
°C
 +
 
CL
A
 
520 genes Y→H (Lee) 
orf19.3374 4,14E-04 22,6 0,4 0,7 ECE1 √ 
orf19.1327 2,04E-03 21,4 0,3 1,1 RBT1 √ 
orf19.5760 1,22E-04 12,6 0,2 1,3 IHD1 √ 
orf19.2060 5,46E-04 10,9 0,2 0,2 SOD5 √ 
orf19.2020 1,71E-03 8,8 1,0 2,8 HGT6  
orf19.2210 1,94E-03 8,2 1,1 1,5   
orf19.1321 5,76E-03 7,8 0,4 0,9 HWP1 √ 
orf19.815 4,86E-03 6,4 0,9 1,2 DCK1 √ 
orf19.7668 4,31E-03 5,9 1,4 3,3 MAL2  
orf19.3384 1,41E-02 5,7 0,3 0,5   
orf19.1816 3,91E-03 5,6 0,3 0,5 ALS3 √ 
orf19.701 9,68E-04 5,6 0,6 0,6 CFL11 √ 
orf19.2877 1,12E-04 5,0 0,7 3,7 PDC11 √ 
orf19.5585 1,88E-03 5,0 1,4 1,6 SAP5  
orf19.675 4,50E-02 4,9 2,1 1,8   
orf19.6387 1,65E-02 4,8 1,4 3,6 HSP104  
orf19.1354 3,13E-02 4,7 0,7 2,1 UCF1  
orf19.6028 6,89E-05 4,6 0,7 0,8 HGC1 √ 
orf19.3707 2,22E-03 4,2 1,1 2,7 YHB1  
orf19.5114.1 6,68E-03 4,0 0,6 2,6   
orf19.4980 8,95E-03 4,0 1,2 3,6 HSP70  
orf19.918 4,78E-03 3,7 1,2 3,2 CDR11 √ 
orf19.7323 5,04E-03 3,6 1,2 2,8 CBP1 √ 
orf19.7085 2,30E-02 3,6 1,0 2,4   
orf19.2737 3,13E-04 3,6 2,5 3,3   
orf19.2770.1 2,99E-05 3,6 1,7 4,6 SOD1 √ 
orf19.4450.1 3,58E-02 3,6 0,5 1,5   
orf19.2355 7,66E-03 3,5 0,5 0,6 ALS10  
orf19.5102 6,68E-03 3,5 1,6 1,9 PLB5 √ 
xxi 
 
 
orf19.3981 3,94E-06 3,5 0,7 0,6 MAL31  
orf19.7350 4,15E-03 3,5 2,3 2,8   
orf19.1715 1,92E-04 3,4 1,2 1,3 IRO1  
orf19.6169 1,50E-02 3,4 0,6 0,8   
orf19.1490 1,27E-03 3,4 1,1 1,4 MSB2 √ 
orf19.5636 6,91E-03 3,4 1,3 1,7 RBT5 √ 
orf19.3997 7,13E-03 3,3 0,9 3,1 ADH1 √ 
orf19.7676 6,78E-03 3,3 1,6 2,4 XYL2  
orf19.2292 3,28E-08 3,3 0,8 0,8   
orf19.1161 1,52E-03 3,3 1,3 1,8 PLD1  
orf19.4527 3,95E-02 3,3 1,1 1,4 HGT1 √ 
orf19.2833 6,14E-03 3,3 0,8 1,2 PGA34  
orf19.638 3,32E-04 3,3 1,7 1,8 FDH1  
orf19.1847 2,51E-04 3,2 1,7 3,0 ARO10 √ 
orf19.3823 1,14E-02 3,2 1,1 1,5 ZDS1 √ 
orf19.6928 3,80E-02 3,2 2,2 2,1 SAP9  
orf19.3746 1,31E-02 3,2 1,0 1,1 IFC1  
orf19.6229 1,34E-02 3,2 8,7 9,4 CAT1  
orf19.1799 8,31E-05 3,1 1,1 1,2   
orf19.14 3,10E-02 3,1 1,7 1,7   
orf19.2151 6,22E-03 3,1 1,4 2,3 NAG6 √ 
orf19.6202 2,09E-02 3,1 2,4 2,2 RBT4 √ 
orf19.1407 3,24E-02 3,1 1,9 1,7   
orf19.3718 3,63E-03 3,1 0,9 0,9   
orf19.1585 7,26E-03 3,1 1,5 1,6 ZRT2  
orf19.1187 1,78E-03 3,0 1,3 2,5 CPH2  
orf19.2685 8,19E-03 2,9 0,8 1,4 PGA54  
orf19.6844 4,25E-02 2,9 5,2 3,6 ICL1  
orf19.4732 5,73E-04 2,9 2,0 3,0 SEC24 √ 
orf19.6408 1,71E-02 2,9 1,9 1,9   
orf19.6705 2,57E-02 2,9 0,9 1,0   
orf19.6114 1,83E-02 2,9 1,4 2,4   
orf19.7021 1,17E-05 2,8 1,0 1,6 GPH1  
orf19.4056 4,57E-02 2,8 0,8 1,0 GAT2 √ 
orf19.449 1,52E-02 2,8 1,8 2,1   
orf19.2170 1,24E-02 2,8 0,9 1,2 PHM7  
orf19.2777 6,82E-03 2,8 1,3 1,4   
orf19.6745 1,33E-04 2,7 1,7 2,8 TPI1  
orf19.6287 9,49E-03 2,7 2,1 1,5 AAT21 √ 
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orf19.5447 1,02E-02 2,7 0,8 1,1 HGT19  
orf19.6178 5,40E-03 2,7 2,6 2,7 FBP1 √ 
orf19.5908 2,47E-02 2,7 0,4 0,8 TEC1 √ 
orf19.4449 2,38E-04 2,7 1,5 2,1   
orf19.1822 3,82E-04 2,7 0,7 0,8 UME6 √ 
orf19.2457 2,60E-05 2,7 1,0 1,1   
orf19.176 1,34E-02 2,6 1,0 0,8 OPT4  
orf19.5015 1,35E-02 2,6 1,5 1,9 MYO2 √ 
orf19.921 3,46E-03 2,5 0,9 2,5   
orf19.5691 4,86E-03 2,5 1,3 1,9 CDC11  
orf19.4450 6,43E-06 2,5 1,3 1,9   
orf19.347 3,13E-05 2,5 1,2 2,2 RSN1  
orf19.467 9,55E-03 2,5 0,9 1,3   
orf19.1693 1,67E-02 2,5 1,3 1,5 CAS4 √ 
orf19.7531 3,81E-02 2,5 1,0 2,0   
orf19.7612 4,08E-04 2,5 1,4 2,3 CTM1 √ 
orf19.682 3,45E-04 2,5 1,5 2,1   
orf19.3642 4,86E-03 2,5 1,3 1,6 SUN41  
orf19.3438 1,58E-02 2,5 1,4 1,9   
orf19.4618 1,01E-02 2,5 1,5 2,1 FBA1  
orf19.4591 3,48E-03 2,5 9,0 8,7 CAT2  
orf19.395 1,44E-02 2,5 1,4 1,7 ENO1  
orf19.4109 8,25E-04 2,5 1,8 2,5 PMT4 √ 
orf19.4477 2,10E-02 2,5 2,1 4,8 CSH1 √ 
orf19.1690 3,75E-02 2,5 1,3 1,5 TOS1  
orf19.4590 5,52E-03 2,4 0,7 0,6 RFX2 √ 
orf19.5446 4,19E-02 2,4 0,8 0,9   
orf19.3070.1 8,32E-03 2,4 9,0 9,3   
orf19.4631 8,12E-05 2,4 0,6 1,7 ERG251  
orf19.1562 1,32E-02 2,4 1,4 1,3   
orf19.2333 9,82E-06 2,4 1,4 2,7   
orf19.7328 2,81E-04 2,4 1,8 2,7   
orf19.6573 1,90E-02 2,4 1,1 1,1 BEM2 √ 
orf19.5995 9,03E-04 2,4 1,2 1,9 MCA1  
orf19.2050 1,29E-02 2,4 1,4 2,0   
orf19.3448 2,05E-05 2,4 0,8 1,8   
orf19.730 5,60E-03 2,4 1,4 1,7   
orf19.1409.2 1,79E-05 2,4 0,6 0,7   
orf19.2803 1,95E-03 2,4 1,3 1,9 HEM13  
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orf19.2626 1,17E-02 2,4 1,5 2,1 RGD2  
orf19.4998 6,57E-03 2,4 0,8 0,9   
orf19.999 2,58E-02 2,3 1,7 1,9 GCA2  
orf19.1401 4,17E-03 2,3 0,8 0,7 EAP1  
orf19.723 1,68E-02 2,3 1,1 1,3 BCR1 √ 
orf19.2699 2,38E-03 2,3 1,6 2,1 ABP1 √ 
orf19.3651 2,23E-03 2,3 2,0 2,4 PGK1  
orf19.2574 1,68E-02 2,3 1,5 1,9   
orf19.4975 2,34E-03 2,3 1,0 0,9 HYR1 √ 
orf19.5686 2,02E-02 2,3 1,7 2,4   
orf19.4035 2,21E-04 2,3 1,2 1,5 PGA4  
orf19.85 3,65E-03 2,3 0,5 0,5 GPX2 √ 
orf19.5495 3,11E-02 2,3 1,4 1,5   
orf19.4655 1,03E-04 2,3 1,2 1,2 OPT6  
orf19.6491 3,57E-02 2,3 5,9 6,1   
orf19.2157 8,23E-03 2,3 1,0 1,5 DAC1 √ 
orf19.6882 2,19E-02 2,3 1,0 2,6 OSM1  
orf19.374 3,80E-02 2,3 1,3 1,5   
orf19.1189 7,85E-04 2,3 1,1 1,8   
orf19.7654 2,53E-03 2,3 1,1 2,4 CPR6  
orf19.6176 4,01E-05 2,2 1,4 1,9 SEC61 √ 
orf19.2340 3,66E-02 2,2 1,5 2,3 CDC48  
orf19.1478 2,77E-02 2,2 1,6 2,0   
orf19.399 1,07E-02 2,2 1,5 1,7   
orf19.4936.1 2,04E-02 2,2 0,2 0,5   
orf19.473 4,53E-02 2,2 14,0 20,4 TPO4  
orf19.6327 6,62E-04 2,2 1,5 2,0 HET1  
orf19.5459 1,07E-02 2,2 1,4 1,5   
orf19.4735 1,25E-03 2,2 2,2 2,6   
orf19.13 6,00E-03 2,2 1,7 2,5   
orf19.5445 1,79E-02 2,2 1,1 1,6 GLO3  
orf19.7304 6,62E-04 2,2 0,6 1,1   
orf19.7297 5,54E-06 2,2 1,4 1,9   
orf19.2947 4,06E-02 2,2 1,0 1,0 SNZ1 √ 
orf19.2098 1,13E-02 2,2 1,8 1,9 ARO8 √ 
orf19.7308 5,39E-03 2,2 1,3 1,7 TUB1  
orf19.6842 7,72E-04 2,2 1,4 1,5   
orf19.1408 1,12E-04 2,2 1,5 1,9   
orf19.3038 1,34E-03 2,1 1,2 1,6 TPS2  
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orf19.316 6,73E-04 2,1 1,7 2,4 SEC13  
orf19.1180 1,58E-04 2,1 1,5 1,9   
orf19.1254 4,37E-04 2,1 1,8 2,4 SEC23 √ 
orf19.1949 1,52E-02 2,1 1,5 1,8 VPS1  
orf19.3944 1,21E-02 2,1 1,3 1,6 GRR1  
orf19.3409 6,61E-03 2,1 1,2 1,8 SEC12  
orf19.3744 1,50E-03 2,1 1,4 1,6   
orf19.4082 1,28E-02 2,1 2,1 2,7 DDR48  
orf19.3969 3,57E-02 2,1 0,9 1,1   
orf19.7258 6,35E-03 2,1 1,0 1,5 DDI1  
orf19.3941 2,71E-02 2,1 1,3 1,0 URA7  
orf19.4183 3,44E-03 2,1 1,3 1,7 MUC1  
orf19.4451 3,73E-02 2,1 1,3 1,8 RIA1  
orf19.6763 7,99E-03 2,1 2,0 2,2 SLK19  
orf19.4433 1,11E-03 2,1 1,0 1,5 CPH1  
orf19.7242 5,98E-03 2,1 1,6 2,0 NCR1  
orf19.1191 4,02E-05 2,1 1,3 2,0   
orf19.3166 1,64E-02 2,1 1,4 1,8   
orf19.7053 3,04E-02 2,1 1,0 1,3 GAC1  
orf19.1760 3,40E-03 2,1 0,9 1,0 RAS1  
orf19.7538 1,99E-02 2,1 1,0 1,2   
orf19.6112 1,24E-02 2,0 0,8 1,4 CTA2  
orf19.4024 1,65E-05 2,0 1,5 1,9 RIB5  
orf19.734 1,50E-03 2,0 1,8 2,4 GLK1  
orf19.7600 1,87E-04 2,0 0,9 2,2 FDH3  
orf19.5823 1,36E-02 2,0 1,4 1,9 SGT2  
orf19.1964 1,45E-05 2,0 0,9 1,0   
orf19.92 8,93E-05 2,0 1,6 1,8   
orf19.6249 3,69E-02 2,0 1,1 1,5 HAK1  
orf19.979 3,49E-02 2,0 1,4 2,0 FAS1  
orf19.1120 2,37E-02 2,0 0,9 0,9 FAV2 √ 
orf19.5171 3,61E-02 2,0 1,6 2,1 PMT1  
orf19.4255 1,55E-03 2,0 2,2 2,6 ECM331  
orf19.3811 1,24E-02 2,0 1,6 1,9 GYP1  
orf19.1193 1,59E-02 2,0 1,0 1,8 GNP1  
orf19.6527 2,06E-02 2,0 1,3 1,6   
orf19.1979 4,12E-02 2,0 1,0 1,4 GIT1  
orf19.6165 3,10E-02 2,0 1,3 1,7 KGD1  
orf19.6155 3,15E-02 2,0 1,0 1,0   
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orf19.4054 3,21E-04 2,0 0,9 1,5 CTA24  
orf19.7329 7,39E-04 2,0 1,2 1,7   
orf19.2296 3,39E-02 2,0 1,0 1,7   
orf19.3419 2,90E-02 2,0 0,4 0,6 MAE1  
orf19.1203 1,95E-04 2,0 1,6 1,9 SRO77  
orf19.6448 2,56E-02 2,0 1,1 1,4   
orf19.1871 2,31E-02 2,0 1,3 1,8   
orf19.69 3,02E-02 2,0 1,2 1,4   
orf19.5148 7,96E-03 2,0 1,4 1,5 CYR1  
orf19.281 1,78E-02 2,0 1,0 1,2   
orf19.5463 7,74E-03 2,0 1,1 1,3   
orf19.2163 2,58E-02 2,0 1,0 1,3   
orf19.1288 4,56E-03 2,0 4,1 7,5 FOX2  
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Supplementary Table S4. The significantly differentially expressed genes were obtained by 
comparing "Experiment 37°C" with "Experiment CLA 37°C ". Differentially expressed 
genes were defined by a fold difference > 2 and a P-value <0.05 
 
Systematic P-value Norm Norm Norm FC ratio Name 
  
37
°C
 
30
°C
 +
 C
LA
 
37
°C
 +
 C
LA
 
37
°C
 +
 C
LA
 v
s 
37
°C
 
150 genes 
orf19.272 4,58E-04 1,8 16,3 16,9 9,3 FAA21 
orf19.3442 1,02E-03 0,4 4,8 3,7 9,2  
orf19.473 1,59E-03 2,2 14,0 20,4 9,2 TPO4 
orf19.3684 3,37E-03 1,4 12,4 12,4 9,0  
orf19.3040 4,79E-05 1,5 11,5 12,8 8,6 EHT1 
orf19.1652 2,76E-03 1,8 14,4 11,8 6,5 POX1-3 
orf19.7520 1,83E-03 1,6 12,1 10,2 6,4 POT1 
orf19.344 9,81E-04 1,2 4,1 6,8 5,8  
orf19.3548.1 1,24E-03 0,8 3,9 4,4 5,7 WH11 
orf19.1704 3,01E-04 1,1 10,9 5,9 5,3 FOX3 
orf19.1655 1,78E-04 1,2 8,3 5,9 4,9 PXP2 
orf19.1809 2,34E-03 1,9 8,0 8,4 4,4  
orf19.164 6,45E-05 1,0 3,0 4,1 4,3  
orf19.1709 5,05E-06 1,1 6,1 4,5 4,0  
orf19.5215 8,53E-04 1,9 5,9 7,4 4,0 TES15 
orf19.4807 3,14E-04 0,9 3,2 3,3 3,9  
orf19.3070.1 1,54E-03 2,4 9,0 9,3 3,8  
orf19.23 1,01E-02 0,8 2,9 3,0 3,7 RTA3 
orf19.6254 8,47E-05 1,1 4,7 3,8 3,6 ANT1 
orf19.1027 1,12E-02 1,2 2,9 4,1 3,6 PDR16 
orf19.4591 3,49E-03 2,5 9,0 8,7 3,5 CAT2 
orf19.7111.1 2,72E-02 0,2 1,0 0,6 3,0 SOD3 
orf19.6007 1,71E-03 0,6 2,2 1,9 3,0  
orf19.6229 1,55E-02 3,2 8,7 9,4 2,9 CAT1 
orf19.7371 2,13E-02 0,9 1,8 2,6 2,9  
orf19.2531 9,92E-03 0,5 1,6 1,6 2,9 CSP37 
orf19.5218 1,35E-03 1,0 4,2 2,9 2,8  
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orf19.5217 7,12E-05 1,3 4,5 3,7 2,8 TES1 
orf19.4211 1,85E-02 0,1 2,0 0,4 2,7 FET3 
orf19.6838 2,70E-03 1,3 7,8 3,7 2,7  
orf19.1089 3,27E-03 0,3 1,4 0,9 2,7 PEX11 
orf19.1473 1,54E-03 0,5 1,4 1,3 2,7  
orf19.2175 1,70E-02 1,6 2,0 4,3 2,7  
orf19.86 2,68E-03 1,4 3,7 3,8 2,7  
orf19.6491 1,65E-02 2,3 5,9 6,1 2,7  
orf19.4121 7,12E-03 1,6 5,7 4,3 2,7  
orf19.4122 1,87E-05 1,0 3,9 2,5 2,7  
orf19.6830 1,38E-03 0,9 2,5 2,3 2,6  
orf19.7513 2,22E-03 1,1 2,7 2,9 2,6  
orf19.5267 1,40E-03 0,4 1,0 1,1 2,5  
orf19.1890 1,73E-03 1,3 2,5 3,1 2,5  
orf19.7306 1,36E-03 0,9 1,6 2,3 2,4  
orf19.5753 7,51E-03 0,4 1,5 0,9 2,4 HGT10 
orf19.909 7,13E-03 0,6 1,5 1,5 2,4 STP4 
orf19.7569 1,76E-02 0,3 0,6 0,8 2,4 SIK1 
orf19.54 1,73E-02 0,2 1,1 0,5 2,4 RHD1 
orf19.6577 6,39E-03 1,0 2,3 2,5 2,4 FLU1 
orf19.4763 2,68E-03 0,9 1,5 2,0 2,4  
orf19.5078 8,98E-03 0,6 1,4 1,4 2,4  
orf19.3133 3,47E-02 1,4 3,1 3,3 2,3 GUT2 
orf19.5286 9,48E-03 1,2 1,8 2,7 2,3 YCP4 
orf19.5193 7,16E-04 1,1 1,8 2,5 2,3  
orf19.2599 2,78E-03 1,3 3,1 2,9 2,3  
orf19.7288 2,88E-03 1,1 3,4 2,5 2,3  
orf19.4216 3,19E-02 1,4 2,4 3,1 2,3  
orf19.6627 4,74E-03 1,0 2,1 2,2 2,2  
orf19.6058 7,32E-03 0,9 1,4 1,9 2,2 GLO1 
orf19.3488 1,22E-02 1,3 3,4 2,9 2,2  
orf19.5285 5,36E-04 1,2 1,9 2,6 2,2 PST3 
orf19.3139 2,50E-03 1,1 2,2 2,4 2,2  
orf19.4157 1,76E-04 1,1 3,7 2,3 2,2 SPS20 
orf19.4041 9,70E-03 1,4 2,3 3,1 2,2 PEX4 
orf19.6445 3,21E-02 1,2 3,4 2,5 2,2 ECI1 
orf19.163 1,02E-03 0,6 1,2 1,2 2,1  
orf19.7 7,29E-03 0,9 2,8 1,9 2,1  
orf19.5921 1,39E-03 1,2 3,5 2,5 2,1  
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orf19.2881 7,21E-04 0,8 1,4 1,6 2,1 MNN4 
orf19.3668 9,12E-03 0,3 1,5 0,7 2,0 HGT2 
orf19.2883 6,63E-04 0,9 2,1 1,9 2,0 CSO99 
orf19.926 2,22E-02 0,5 1,1 1,0 2,0 EXO1 
orf19.1300 1,54E-02 0,4 0,8 0,9 2,0  
orf19.2726 2,22E-02 0,8 2,1 1,6 2,0  
orf19.3364 1,49E-02 1,0 1,0 2,0 2,0  
orf19.3710 4,84E-03 1,4 0,5 0,7 0,5 YHB5 
orf19.2823 1,53E-02 1,7 0,9 0,8 0,5 RFG1 
orf19.2061 1,49E-02 1,3 0,9 0,6 0,5  
orf19.3941 2,10E-02 2,1 1,3 1,0 0,5 URA7 
orf19.7304 7,80E-03 2,2 0,6 1,1 0,5  
orf19.6155 2,71E-02 2,0 1,0 1,0 0,5  
orf19.2947 4,32E-02 2,2 1,0 1,0 0,5 SNZ1 
orf19.1760 2,51E-03 2,1 0,9 1,0 0,5 RAS1 
orf19.5741 2,13E-02 1,4 0,7 0,7 0,5 ALS1 
orf19.2685 4,73E-02 2,9 0,8 1,4 0,5 PGA54 
orf19.2721 1,99E-02 1,5 0,7 0,7 0,5  
orf19.1996 3,28E-02 1,6 0,5 0,7 0,5 CHA1 
orf19.3641 2,03E-02 1,5 0,7 0,7 0,5  
orf19.5455 1,42E-04 1,1 0,6 0,5 0,5  
orf19.3823 4,27E-02 3,2 1,1 1,5 0,5 ZDS1 
orf19.2179 2,79E-02 1,1 0,7 0,5 0,5 SIT1 
orf19.5431 2,47E-02 1,2 0,7 0,5 0,4  
orf19.1120 1,46E-02 2,0 0,9 0,9 0,4 FAV2 
orf19.3219 3,71E-03 1,7 0,6 0,7 0,4  
orf19.6573 1,93E-02 2,4 1,1 1,1 0,4 BEM2 
orf19.3232 1,47E-02 1,4 0,9 0,6 0,4  
orf19.4716 4,77E-02 1,0 0,9 0,4 0,4 GDH3 
orf19.1490 3,28E-03 3,4 1,1 1,4 0,4 MSB2 
orf19.2457 7,00E-03 2,7 1,0 1,1 0,4  
orf19.5308 2,28E-02 0,6 0,3 0,3 0,4  
orf19.2170 2,86E-02 2,8 0,9 1,2 0,4 PHM7 
orf19.5094 9,66E-03 1,5 0,8 0,6 0,4 BUL1 
orf19.4682 4,65E-03 1,1 0,8 0,5 0,4 HGT17 
orf19.6459 1,32E-02 0,9 0,5 0,4 0,4 DPP3 
orf19.5447 1,46E-02 2,7 0,8 1,1 0,4 HGT19 
orf19.4975 7,27E-03 2,3 1,0 0,9 0,4 HYR1 
orf19.5170 3,89E-02 1,5 0,8 0,6 0,4 ENA21 
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orf19.4998 1,63E-03 2,4 0,8 0,9 0,4  
orf19.1995 1,23E-02 0,8 0,4 0,3 0,4  
orf19.1715 2,53E-04 3,4 1,2 1,3 0,4 IRO1 
orf19.4749 9,50E-03 1,0 0,5 0,4 0,4  
orf19.84 3,35E-03 1,5 0,6 0,6 0,4 CAN3 
orf19.2833 6,36E-03 3,3 0,8 1,2 0,4 PGA34 
orf19.6556 5,09E-03 1,6 0,7 0,6 0,4  
orf19.1799 1,84E-03 3,1 1,1 1,2 0,4  
orf19.5446 2,17E-02 2,4 0,8 0,9 0,4  
orf19.4056 4,00E-02 2,8 0,8 1,0 0,4 GAT2 
orf19.6705 2,14E-02 2,9 0,9 1,0 0,3  
orf19.3746 1,23E-02 3,2 1,0 1,1 0,3 IFC1 
orf19.7610 5,30E-04 1,3 0,5 0,4 0,3 PTP3 
orf19.1822 9,88E-04 2,7 0,7 0,8 0,3 UME6 
orf19.5585 3,92E-03 5,0 1,4 1,6 0,3 SAP5 
orf19.1401 6,12E-03 2,3 0,8 0,7 0,3 EAP1 
orf19.3718 2,25E-03 3,1 0,9 0,9 0,3  
orf19.5908 1,50E-02 2,7 0,4 0,8 0,3 TEC1 
orf19.3419 7,08E-03 2,0 0,4 0,6 0,3 MAE1 
orf19.176 2,70E-03 2,6 1,0 0,8 0,3 OPT4 
orf19.1409.2 2,83E-05 2,4 0,6 0,7 0,3  
orf19.3475 1,29E-04 1,5 0,4 0,4 0,3  
orf19.4590 1,07E-03 2,4 0,7 0,6 0,3 RFX2 
orf19.4936.1 3,63E-03 2,2 0,2 0,5 0,2  
orf19.2292 2,66E-03 3,3 0,8 0,8 0,2  
orf19.6169 4,83E-03 3,4 0,6 0,8 0,2  
orf19.85 1,04E-03 2,3 0,5 0,5 0,2 GPX2 
orf19.5307 1,45E-02 1,1 0,3 0,2 0,2 JEN2 
orf19.4555 6,28E-03 1,7 0,5 0,4 0,2 ALS4 
orf19.2121 8,25E-03 1,6 0,5 0,4 0,2  
orf19.1097 1,70E-02 1,7 0,5 0,4 0,2 ALS2 
orf19.4900 2,25E-05 1,2 0,4 0,2 0,2  
orf19.815 4,80E-03 6,4 0,9 1,2 0,2 DCK1 
orf19.2210 1,39E-03 8,2 1,1 1,5 0,2  
orf19.6028 2,00E-05 4,6 0,7 0,8 0,2 HGC1 
orf19.3981 9,28E-06 3,5 0,7 0,6 0,2 MAL31 
orf19.2355 9,55E-04 3,5 0,5 0,6 0,2 ALS10 
orf19.1321 1,30E-03 7,8 0,4 0,9 0,1 HWP1 
orf19.701 1,56E-04 5,6 0,6 0,6 0,1 CFL11 
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orf19.5760 4,95E-05 12,6 0,2 1,3 0,1 IHD1 
orf19.3384 1,98E-03 5,7 0,3 0,5 0,1  
orf19.1816 1,45E-03 5,6 0,3 0,5 0,1 ALS3 
orf19.1327 3,33E-04 21,4 0,3 1,1 0,0 RBT1 
orf19.3374 3,07E-03 22,6 0,4 0,7 0,0 ECE1 
orf19.2060 5,94E-04 10,9 0,2 0,2 0,0 SOD5 
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